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ABSTRACT
Methylation controlled J protein (MCJ) is a negative regulator of
mitochondrial metabolism that has a substantial impact on overall cell metabolism
and function. MCJ is highly expressed by naïve CD8+ T cells, however its role in
their immune effector functions was unknown. In this dissertation, it will be
demonstrated that MCJ restricts the mitochondrial metabolism of CD8+ T cells, in
part by reducing respiratory supercomplex formation. MCJ deficiency enhances
the immune effector functions and memory responses of CD8+ T cells in a
mitochondrial ATP dependent manner. As a consequence, protection to influenza
virus infection is substantially improved. Reduced expression of MCJ therefore
promotes viral immunity, however the loss of MCJ is not always beneficial. In
cancer, decreased MCJ expression is correlated with ATP binding cassette (ABC)
transporter mediated chemotherapy resistance and poor patient responses. This
dissertation will also address the role of MCJ in chemoresistance. Increased
mitochondrial ATP production due to MCJ deficiency is sufficient to fuel ABC
transporter activity, thereby directly promoting chemoresistance. This can be
reversed by restoration of MCJ function in chemoresistant cells. Overall, the
results presented in this dissertation identify MCJ as a potential therapeutic target,
as modulating MCJ expression can significantly affect the severity of viral
infections and the responses to chemotherapy.
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CHAPTER 1. Comprehensive Literature Review
1. Introduction to metabolism
One of the major characteristics that has been proposed to delineate life
from nonlife is metabolism (Koshland, 2002; McKay, 2004), which is the ability to
perform the chemical reactions necessary for the production and breakdown of
biomolecules, the conversion of nutrients and food sources into usable energy, and
the elimination of waste byproducts. In order for an organism to maintain
homeostasis, regulatory mechanisms must exist to control the flow of metabolites
through the catabolic and anabolic reactions that are performed by cells. To
facilitate these metabolic reactions, all mammalian cells ultimately depend on the
production of the energy carrier adenosine triphosphate (ATP), of which the
majority is synthesized via glycolysis, the tricarboxylic acid cycle (TCA), and
oxidative phosphorylation.
1.1. Glycolysis
Glycolysis occurs in the cytosol and functions to break down carbohydrates
for the production of ATP and the reducing equivalent NADH (Berg et al., 2002;
Voet and Voet, 2011). The most common carbohydrate utilized by cells is glucose,
a six-carbon simple sugar that is ubiquitously used as a fuel source and molecular
building block. Glucose enters cells through one of 14 known glucose transporters
that are differentially expressed throughout the body (Thorens and Mueckler,
2010). Once inside the cell, glucose is readily phosphorylated by the enzyme
1

hexokinase to glucose 6-phosphate. The negatively charged phosphate group
prevents glucose from exiting the cell and also facilitates entry into glycolysis.
The reactions of glycolysis are broadly characterized into two groups, the
preparatory and the payoff phases (Figure 1-1) (Berg et al., 2002; Voet and Voet,
2011). The preparatory phase reactions break down the carbons of glucose into two
molecules of glyceraldehyde 3-phosphate and require the hydrolysis of two
preformed molecules ATP. In the payoff phase, glyceraldehyde 3-phosphate is
ultimately converted into pyruvate. In the process four ATP and two NADH
molecules are produced, therefore the overall yield of glycolysis per molecule of
glucose metabolized is two molecules each of ATP, NADH, and pyruvate.

DHAP
ATP
glucose

HK

ATP
G6P

PI

F6P

PFK-1

TPI
F-1,6-BP

F-BA

G3P
GAPDH

ATP
1,3-BP

PGK

ATP
3PG

PGM

2GP

PPH

PEP

PK

NADH
pyruvate

Figure 1-1. The reactions of glycolysis
Preparatory phase reactions, red; payoff phase reactions, blue. G6P, glucose
6-phosphate; F6P, fructose 6-phosphate; F-1,6-BP, fructose 1,6-bisphosphate;
DHAP, dihydroxyacetone phosphate; G3P, glyceraldehyde 3-phosphate; 1,3-BP,
1,3-bisphosphoglycerate; 3PG, 3-phosphogycerate; 2PG, 2-phosphoglycerate; PEP,
phosphoenolpyruvate; HK, hexokinase; PI, phosphoglucose isomerase; PFK-1,
phosphofructose kinase 1; F-BA, fructose-bisphosphate aldolase; TPI, triose
phosphate isomerase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase;
PGK, phosphoglycerate kinase; PGM, phosphoglycerate mutase; PPH,
phosphopyruvate hydratase (enolase); PK, pyruvate kinase.
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The activity of glycolysis is regulated by several mechanisms (Berg et al.,
2002; Voet and Voet, 2011). The amount of glucose entering cells, and thereby the
overall cytosolic concentration, is controlled by the expression and activity of
glucose transporters (GLUT) at the cell surface (Thorens and Mueckler, 2010).
Reactions that are highly thermodynamically favorable are essentially irreversible,
and the enzymes catalyzing them are under reversible allosteric regulation. This
is generally due to downstream metabolic intermediates that serve as feedback
inhibitors or activators. The rate limiting step of glycolysis is catalyzed by
phosphofructokinase (Bosca and Corredor, 1984). Metabolic enzymes are also
regulated by posttranslational modifications such that signals from other
metabolic pathways or extracellular cues can alter the flux through glycolysis
(Wiese and Hitosugi, 2018).
Additionally, transcriptional regulation can limit or increase enzyme
abundance in response to major changes that substantially alter metabolic needs
(e.g., cell growth and division). In addition, GAPDH can bind the 3’ UTR of some
RNAs, thereby regulating protein translation (White and Garcin, 2016). The time
required for each of these regulatory mechanisms varies significantly from
milliseconds to hours, however all play roles in controlling the flux of
intermediates through glycolysis.
While glycolysis is not substantially efficient in terms of net ATP
production as the yield is only two ATP per glucose molecule entering the
pathway, it is carbon sparing and produces intermediates that can be shuttled to
3

other metabolic pathways (Berg et al., 2002; Voet and Voet, 2011). The pentose
phosphate pathway uses glucose 6-phosphate to generate NADPH and five
carbon sugars needed for nucleotide synthesis. Glucose 6-phosphate is also used
for the production of glycogen, which predominantly occurs in the liver and
skeletal muscle. Glyceraldehyde 3-phosphate is a substrate used for triglyceride
and lipid synthesis. The glucose dependent production of the amino acid serine
requires 3-phosphoglycerate. In addition, pyruvate serves as a metabolic
branchpoint as it can be transaminated to alanine for amino acid synthesis,
carboxylated to oxaloacetate for use in the TCA cycle or gluconeogenesis, reduced
to lactate (with the corresponding oxidation of NADH) to maintain cellular redox
balance, or further oxidized in the mitochondria.
1.2. Mitochondrial respiration
In organisms that can perform aerobic respiration, the complete oxidation
of carbon substrates and the production of ATP ultimately occurs via the reactions
of the tricarboxylic acid (TCA) cycle and oxidative phosphorylation (OXPHOS) in
the mitochondria.
1.2.1. Tricarboxylic acid cycle
The TCA cycle is a set of cyclic reactions that integrates intermediates from
a number of metabolic pathways including the breakdown products of
carbohydrates, amino acids, and fatty acids (Figure 1-2) (Berg et al., 2002; Voet and

4

Voet, 2011). The net yield of one round of the TCA cycle is one GTP (equivalent to
one ATP), three NADH, one FADH2, and two CO2 molecules.

cytosol
intermembrane space
matrix

acetyl-CoA
citrate

oxaloacetate

CS

NADH

acconitase

MDH

isocitrate
CO2

malate

IDH

fumarase

NADH
α-ketoglutarate
CO2

fumarate
FADH2

α-KGDH

NADH
succinyl-CoA

SDH
SCS

succinate
GTP

Figure 1-2. The reactions of the tricarboxylic acid cycle

CS, citrate synthase; IDH, isocitrate dehydrogenase; α-KGDH, α-ketoglutarate
dehydrogenase; SCS, succinyl-CoA synthetase; SDH, succinate dehydrogenase;
MDH, malate dehydrogenase.

Carbons derived from glucose enter the TCA cycle in the form of acetylCoA, which is also the final break down product of fatty acid oxidation (Berg et al.,
2002; Voet and Voet, 2011). Fatty acids are a significant source of energy and
consist of an aliphatic chain of varying length bound to a fully oxidized carbon in
5

the form of a carboxylic acid. Saturated fatty acids contain no double bonds
between the carbon atoms of the chain (i.e., they are saturated with hydrogen
atoms), while unsaturated fatty acids contain one or more double bonds in either
a cis or trans configuration.
The breakdown of fatty acids occurs mainly in the mitochondrial matrix via
the process of b-oxidation. Fatty acids are also metabolized to a lesser degree in
peroxisomes (Poirier et al., 2006). Similar to glycolysis, b-oxidation is tightly
regulated by different mechanisms (Eaton, 2002; Schulz, 1994). The majority of
fatty acids in the body are stored in adipocytes, which, along with the liver, control
their availability to other cells. Skeletal muscle also serves as a depot for fatty acid
storage (Berg et al., 2002; Voet and Voet, 2011). Allosteric regulation plays a major
role in regulating b-oxidation, with a notable example being the potent inhibition
of the carnitine shuttle by malonyl-CoA (Foster, 2012). Additionally, the overall
abundance of mitochondria varies between cell types based on metabolic needs,
which limits the overall capacity for b-oxidation (and mitochondrial respiration in
general) (D'Erchia et al., 2015).
Amino acids are also a significant fuel source used by mammalian cells
(Berg et al., 2002; Voet and Voet, 2011). These biomolecules consist of a central
carbon atom bound to an amine (-NH2), a carboxylic acid (-COOH), and a variable
side chain (R group). The side chains found in eukaryotes differ in length, charge,
and polarity, all of which provide different chemical properties that are exploited

6

by cells. In addition, the amine functional group is a weak base that can be
protonated at cytosolic pH to produce a positively charged ammonium group (NH3+). Likewise, the carboxylic acid group can be deprotonated to become a
negatively charged carboxylate (-COO-). Amino acids are therefore zwitterions
that exist in a pH-dependent equilibrium between all three possible charge states
(neutral, negative, and positive). The functional groups of some side chains can
also be neutral or charged, which adds further chemical complexity.
Excess amino acids that are not used for protein synthesis or other
biological processes (e.g., neurotransmitter synthesis) are metabolized into
intermediates that can directly enter the TCA cycle (Figure 1-3). While most amino
acid catalysis pathways result in the formation of acetyl-CoA, succinyl-CoA,
fumarate, oxaloacetate, and a-ketoglutarate are also produced. In rapidly dividing
cells (e.g., cancer cells and proliferating lymphocytes), the breakdown of the amino
acid glutamine via glutaminolysis is a major energy production pathway (Figure
1-4) (Newsholme, 2001; Yang et al., 2017). In addition, several amino acids can be
readily converted to others through the action of transaminases such as the
conversion of glutamate to alanine or aspartate (Figure 1-4).
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Figure 1-3. Amino acid catalysis
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pyruvate

alanine

GPT
NH4+
glutamine

glutaminase

NH4+
glutamate

α-ketoglutarate

GDH

NADH
GOT
oxaloacetate

aspartate

Figure 1-4. The reactions of glutaminolysis

GDH, glutamate dehydrogenase; GPT, glutamate pyruvate transaminase; GOT,
glutamate oxaloacetate transaminase.

Like glycolysis, the TCA cycle integrates metabolites from other metabolic
pathways and as such, functions as a metabolic hub within the cell (Berg et al.,
2002; Voet and Voet, 2011). A notable export is citrate, which can be shuttled out
of mitochondria for fatty acid synthesis. Additionally, oxaloacetate can be used in
a number of pathways including amino acid and fatty acid synthesis. Imports
include fumarate, which is produced by the urea cycle, and as noted above, the
final products of amino acid catabolism.
The TCA cycle is regulated by allosteric regulation in response to cellular
energy charge (Berg et al., 2002; Voet and Voet, 2011). As such, ATP and NADH
are negative regulators, while ADP is a positive regulator. In addition, NAD+ and
FAD are key substrates for several reactions that are readily available during times
of low energy charge. The production of a-ketoglutarate is the irreversible rate
9

limiting step of the TCA cycle. Unlike glycolysis, the TCA cycle is not carbon
sparing as two carbons are lost as CO2 during each cycle, however the NADH and
FADH2 produced are used in the synthesis of substantial amounts of ATP via
oxidative phosphorylation.
1.2.2. Oxidative phosphorylation
Oxidative phosphorylation (OXPHOS) is facilitated by the large, multisubunit protein complexes of electron transport chain (ETC), which are integrated
into the inner mitochondrial membrane (Berg et al., 2002; Voet and Voet, 2011).
Through a series of coordinated redox reactions, the ETC ultimately transfers
electrons from NADH and FADH2 to oxygen, which is the final electron acceptor
in mammals. In the process, protons are pumped across in the inner mitochondrial
membrane into the inner membrane space (IMS) to facilitate the synthesis of ATP.

Figure 1-5. Reactions and complexes of the electron transport chain
Adapted from Sazanov (2015).
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Complex I (NADH : ubiquinone oxidoreductase) is the largest of the ETC
complexes at ~970 kDa and transfers the electrons from NADH to Coenzyme Q10
(CoQ). In the process, four protons are translocated from the matrix to the IMS.
The quaternary structure of Complex I is L-shaped and consists of 45 individual
subunits in mammals (Sazanov, 2015). It is organized as a core of 14 subunits that
are conserved from bacteria surrounded by a shell of 31 supernumerary subunits.
A notable example is NDUFv1, which serves as the NADH binding site (Deng et
al., 1990).
While the structure of Complex I has been studied for decades, it generally
the least understood as only partial structures were known until the recent
publication of the nearly complete ovine Complex I at high resolution (3.9 Å)
(Fiedorczuk et al., 2016). Complex I has been shown to exist in two distinct
conformations – the catalytically active (A) form and the inactive dormant (D)
form (Babot et al., 2014). It is still unclear, however, what regulates the transition
between the A and D forms as well as the specific mechanism(s) connecting proton
translocation and electron transfer.
Since Complex I catalyzes the first set of ETC reactions, deficiencies can lead
to severe dysfunction in mitochondrial metabolism and cause significant
pathology (Scheffler, 2015). Tissues that are most sensitive to Complex I
dysregulation are the liver, kidney, muscle (both skeletal and cardiac), and those
of the nervous system. As such, patients experience a myriad of symptoms such
as lactic acidosis, myalgia, ataxia, epilepsy, and vision problems (Scheffler, 2015).
11

In addition to overall deficiencies in mitochondrial respiration, defects in or
dysregulation of Complex I activity result in increased levels of mitochondrial
reactive oxygen species (ROS) (Vinogradov and Grivennikova, 2016; Wirth et al.,
2016). Excess ROS production can lead to a breakdown in cellular redox potential
and is a major source of oxidative stress (Schieber and Chandel, 2014). In disease
states such as ischemia reperfusion injury, Complex I plays a predominant role in
ROS production via reverse electron transport (RET) (Chouchani et al., 2014; Scialo
et al., 2017).
Complex II (succinate dehydrogenase) is the smallest ETC complex at ~120
kDa and is comprised of four subunits (Sun et al., 2005). Complex II reduces CoQ
via the oxidation of FADH2. Unlike the other members of the ETC, Complex II
does not translocate protons into the IMS. Additionally, it catalyzes the conversion
of succinate to fumarate and thus plays a direct role in the TCA cycle. Deficiencies
in Complex II can also lead to mitochondrial disorders and have been implicated
in disease pathology (Jain-Ghai et al., 2013).
The lipid soluble CoQ formed by Complexes I and II travels through the
inner mitochondrial membrane to Complex III (Coenzyme Q : cytochrome c
oxidoreductase). Complex III is an ~240 kDa dimer of two identical monomers that
are each comprised of 11 subunits each and catalyzes the transfer of electrons from
CoQ to cytochrome c (Iwata et al., 1998). Each electron transferred to cytochrome
c results in one proton being translocated into the IMS. Complex III is also a major
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site of mitochondrial ROS production, and deficiencies are common causes of
mitochondrial disorders (Benit et al., 2009).
Reduced cytochrome c migrates to Complex IV (cytochrome c oxidase),
which catalyzes the final redox reactions of the ETC. Complex IV is a homodimer
and is ~400 kDa in size (Tsukihara et al., 1996). There are 13 subunits in each
monomer. Complex IV transfers two electrons from cytochrome c to oxygen,
producing water. In the process, two protons are translocated into the IMS. Similar
to the other complexes, deficiencies in Complex IV activity can result in ROS
production and mitochondrial disorders (Rak et al., 2016).
The protons transferred to the IMS cannot freely diffuse back into the
matrix. As such, an electrochemical gradient is produced across the inner
membrane as the IMS and matrix become positively and negatively charged,
respectively. According to the chemiosmotic theory (Mitchell, 1961), the potential
energy of this gradient – known as the proton motive force – is used by ATP
Synthase (also known as Complex V) to facilitate the oxidative phosphorylation of
ADP to ATP.
1.2.3. Respiratory supercomplexes
The macromolecular organization of the electron transport chain has been
an intense area of research for decades. Two models of the supramolecular
organization have been proposed that are effectively direct opposites of one
another – the solid and fluid state models (Figure 1-6). The solid state model posits
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that the respiratory complexes associate to form large aggregates that coordinate
the reactions of the ETC (Keilin and Hartree, 1947). The aggregates are proposed
to contain pathways that direct the movement of CoQ and cytochrome c between
the individual complexes. In contrast, the fluid state model posits that individual
complexes freely diffuse throughout the inner mitochondrial membrane and that
CoQ and cytochrome c are not restrained to specific paths (Hackenbrock et al.,
1986).
The fluid model was generally accepted until analyses of mitochondrial
extracts using blue native gel electrophoresis (BNE) showed that the complexes of
the ETC can organize into supramolecular structures known as respiratory
supercomplexes (Schagger and Pfeiffer, 2000). It was originally thought that
supercomplexes were simply artifacts of the mild detergent solubilization
employed by BNE, however their presence has been confirmed using other
experimental methods (Acin-Perez et al., 2008; Dudkina et al., 2005). In addition,
crystal structures of mammalian respiratory supercomplexes were recently solved
(Gu et al., 2016; Letts et al., 2016).
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Figure 1-6. Structural models of the electron transport chain
Adapted from Schon and Dencher (2009).

There is still debate in the literature over the specific purpose(s) served by
supercomplexes (Milenkovic et al., 2017). Several proposed benefits to cells have
been suggested including decreased production of ROS, regulation of ETC
activity, and prevention of protein aggregation in the mitochondrial matrix
(Milenkovic et al., 2017). Despite a lack of definitive evidence for these proposals,
there have been several reports showing a significant correlation between
supercomplex abundance and increased mitochondrial respiration. Additionally,
increased ROS production has been detected after chemical disruption of
supercomplexes containing Complexes I and III (Maranzana et al., 2013). Future
studies are needed to elucidate the mechanistic role of respiratory supercomplexes
in the regulation of mitochondrial metabolism.
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1.3. Urea cycle
In addition to the production of usable energy, mitochondria are vital to the
removal of ammonia from cells (Berg et al., 2002; Voet and Voet, 2011). Ammonia
is a toxic byproduct of amino acid breakdown that is ultimately excreted as urea
in ureotelic organisms. The conversion of ammonia to urea is facilitated by the
urea cycle, which primarily occurs in the liver and kidneys and is regulated by
substrate availability. The urea cycle is a highly energy demanding process as it
requires the hydrolysis of three ATP molecules, one of which is fully hydrolyzed
to AMP. This cyclic set of five reactions starts in the mitochondria and also has
cytosolic components (Figure 1-7).
Like other pathways, the urea cycle produces intermediates that can be
shuttled to other pathways (Berg et al., 2002; Voet and Voet, 2011). Citrulline is
used in the synthesis of polyamines, while arginine has multiple fates including
protein synthesis, production of the signaling and immune effector molecule nitric
oxide (NO), and the synthesis of other amino acids. Additionally, fumarate can be
oxidized in the TCA cycle. The final step of the cycle yields urea, which is
ultimately excreted in urine.
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Figure 1-7. The reactions of the urea cycle

CPS1, carbamoyl phosphate synthetase 1; OTC, ornithine transcarbamylase; AS,
argininosuccinate synthetase; ASL, argininosuccinate lyase.

2. Introduction to cancer biology
Cancer is a disease characterized by abnormal cell growth that can disrupt
the normal functions of the healthy tissues and cells of the body. In addition, the
process of metastasis induces the spread of these altered cells from their site of
development to other regions of the body. Cancer is currently the second leading
cause of death in the U.S., and approximately of 40 % of Americans will experience
a cancer diagnosis during their lifetime according to the National Cancer Institute.
While nearly all tissues and cells of the body can become cancerous, certain tissues
are more susceptible to transformation (Table 1-1).
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Table 1-1. Incidence and death rates of the most common cancers in the
U.S.
Cancer
Breast
Prostate
Lung
Colorectal
Uterine

Incidence
123.6
114.9
61.5
39.8
25.9

Deaths
20.9
19.5
43.4
14.5
4.6

Rates are per 100,000 individuals according to the American Cancer Society.

Cancer diagnoses are graded based on disease progression and are staged
according to criteria defined by the American Joint Committee on Cancer. The
scale used varies by cancer type, however they are all based on the extent to which
healthy tissue has been affected. The breast cancer system starts with Stage 0,
where a benign growth is localized and not yet considered cancerous. Tumors that
have invaded healthy breast tissue or local lymph nodes are considered cancerous
and graded as Stage I, II, or III depending on the extent of spread. Stage IV breast
cancer has metastasized to other parts of the body, represents the most progressed
form of the disease, and is often the most difficult to treat. Other examples of
grading schemes are the Ann Arbor staging system for lymphomas and the
Gleason Score for prostate cancer.
While treatment of the initial manifestation of low grade cancer is often
effective, patients can relapse as the treatment may not clear all cancerous cells.
While all cancer cells generally have an increased ability to proliferate compared
to their nontransformed counterparts, certain cells within a tumor have an
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enhanced self-renewal capacity. These are known as cancer stem cells and have
the ability to differentiate into all of the cells that comprise a tumor. Cancer stem
cells are often highly resistant to treatment and can be left behind while the bulk
of the tumor is eliminated. As such, they are thought to be a major cause of relapse
and are also implicated in metastasis (Carnero et al., 2016; Li et al., 2015; Owens
and Naylor, 2013; Schwarz-Cruz et al., 2016).
2.1. Cancer treatment strategies
Several treatments for cancer have been devised, however the specific
regimen used varies for each patient due to numerous factors. These include the
type of cancer, location within the body, size of the tumor(s), and the age and
medical history of the patient. The most commonly used treatment is
chemotherapy. This treatment consists of the administration of one or more
chemotherapeutic agents, many of which are natural products originally
discovered in bacteria and plants. While these drugs are toxic to all cells of the
body, their mechanisms of action are designed to target rapidly dividing cells. As
such, several classes of chemotherapy agents are used in the clinic that effectively
target different mechanisms that regulate the cell cycle.
The most effective overall in terms of the number of cancers that respond
are the anthracyclines, which are derivatives of compounds discovered in
Streptomyces bacteria (e.g., daunorubicin, doxorubicin). Anthracyclines work by
intercalating into DNA, thereby inhibiting the activity of topoisomerase II and the
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synthesis of new DNA molecules. Nucleotide analogs (e.g., fluorouracil) also
inhibit DNA synthesis either directly or by interfering with nucleotide production.
Platinum based drugs (e.g., cisplatin) covalently crosslink DNA to prevent
synthesis and repair of DNA damage. Chemotherapeutic agents can also interfere
with the cytoskeletal machinery, thereby restricting cell division. Examples are the
vinca alkaloids (e.g., vincristine) that were originally discovered in the rosy
periwinkle (Catharanthus roseus) and interact with tubulin to inhibit microtubule
polymerization. In contrast, taxanes (e.g., paclitaxel) prevent depolymerization by
stabilizing microtubules. Taxanes originate from trees of the Taxus genus (yews).
Other classes of chemotherapeutic agents include inhibitors of kinases (e.g.,
erlotinib), histone deacetylases (e.g., vorinostat), and transcription (e.g.,
actinomycin D).
While many cancers initially respond to treatment, the development of
chemoresistance is a major cause of poor patient outcomes. There are several
mechanisms of chemoresistance including modifications to the drug target,
changes in the metabolism or cellular distribution of the drug, and increased DNA
repair capacity, however the most common mechanism is through activity of ATP
binding cassette (ABC) transporters (Fodale et al., 2011; Kathawala et al., 2015).
These efflux pumps normally function to export xenobiotics from cells,
however in the case of cancer cells they remove chemotherapeutic agents. While
ABC transporters came into existence well before the use of chemotherapy as they
are found in all domains of life, chemotherapeutic agents are often biological
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products and consequently are substrates for multiple ABC transporters (Dlugosz
and Janecka, 2016; Pan et al., 2016; Ween et al., 2015). Due to this, chemoresistance
often manifests as multidrug resistance, a phenomenon that is characterized by
resistance to multiple drugs simultaneously (Gillet and Gottesman, 2010).
Multidrug resistance often renders several classes of chemotherapeutic agents
ineffective, thereby significantly limiting treatment options.
ABC transporters comprise a large family of diverse membrane bound
efflux pumps that use the energy of ATP hydrolysis to actively transport
substrates across membranes (Ambudkar et al., 2003). There are currently 48
known in humans, and the family is subdivided into seven groups based on
structure (ABCA, B, C, D, E, F, and G) (Dean et al., 2001). ABC transporters are
generally dimers that consist of two nucleotide binding domains and several
membrane spanning regions that form a channel in the membrane (Figure 1-8)
(Linton and Higgins, 2007). Up to two ATP molecules are needed for efflux of one
substrate molecule, therefore the activity of ABC transporters is highly energy
demanding (Linton and Higgins, 2007; Patzlaff et al., 2003; Poolman et al., 2005).
The role of metabolism in the function of ABC transporters is a later focus of this
dissertation (CHAPTER 3).
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Figure 1-8. Structure of the murine ABC transporter ABCB1
Protein Data Bank ID: 3G5U (Aller et al., 2009).

The first family member discovered was ABCB1, which is also known as
P-glycoprotein 1 (P-gp) and multidrug resistance protein 1 (MRP1), while other
notable examples commonly involved in chemoresistance are ABCG2 and ABCC1
(Allikmets et al., 1998; Cole et al., 1992; Doyle et al., 1998; Miyake et al., 1999;
Roninson et al., 1984; Ueda et al., 1987). Despite the correlation of ABC transporter
expression and the development of chemoresistance, there are currently no
approved therapies directly targeting these efflux pumps. All three generations of
inhibitors that have been tested in clinical trials have failed to show efficacy, with
the majority of failures due to off target effects and toxicity (Robey et al., 2018). In
addition to these pharmacological effects, it has been shown that genetic variation
in ABC transporters, specifically shown for ABCB1, can affect the outcome of
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treatment (Chaturvedi et al., 2013; Reed and Parissenti, 2011; Tulsyan et al., 2016).
Therefore, novel therapies for inhibiting ABC transporter function represent a
significant medical need in the treatment of chemoresistance. Later in this
dissertation it will be shown that reducing mitochondrial respiration in cancer
cells can effectively reverse ABC transporter mediated chemoresistance, a finding
that may lead to the development of novel metabolism-based therapies
(CHAPTER 3).
Surgery is also used in the treatment of cancer. While many solid tumors
can be physically removed, not all cancers are treatable by this method due to the
extensive normal tissue damage that would occur during their removal (e.g., brain
cancers). Surgery can also be combined with chemotherapy to increase efficacy.
Chemotherapy administered prior to surgery is known as neoadjuvant therapy
and has the goal of shrinking a tumor for more efficient removal and to allow for
less normal tissue damage. Administration after surgery is known as adjuvant
therapy and targets cancer cells that were not removed or those that may have not
been detected during screening assays. The primary goal of adjuvant therapy is to
lessen the risk of relapse.
Radiation therapy (also known as radiotherapy) is also used to treat cancer
and has the goal of inducing sufficient DNA damage such that cell death occurs.
Rapidly dividing cells are the most sensitive to radiation treatment, however
normal tissue is also affected. External beam radiation is used for many types of
cancer and is a localized treatment that directs high energy beams of photons,
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protons, or electrons to the site of a tumor. In contrast, internal radiation is the
administration of radioactive nuclides into the body. This can occur via systemic
administration or as brachytherapy where a sealed radiation source is implanted
near the tumor.
While chemotherapy, radiotherapy, and surgery have been used and
refined for decades, there is still a need for new types of therapy as many patients
do not respond to these treatments. The latest advances in cancer treatment are
based on immunotherapy, which employs the tools of the immune system to treat
cancer. One strategy is through the use of monoclonal antibodies that target cells
of the immune system (Apetoh et al., 2015; Wargo et al., 2015). As described later
(§3.2), mechanisms exist that negatively regulate immune responses. These can be
exploited by cancer cells, thereby downmodulating immune responses and
protecting tumor cells from clearance. These regulatory mechanisms are known as
checkpoint inhibitors, and a notable example is programmed cell death protein 1
(PD-1) ligand (PD-1L), which blocks T cell immunity by engaging PD-1 on T cells
(Sharpe and Pauken, 2018). Blocking antibodies (e.g., pembrolizumab) can
effectively prevent this interaction and have been shown to effectively improve
treatment outcomes. In addition, bispecific antibodies have been generated that
target antigens on cancer cells and immune cells simultaneously, increasing the
likelihood of their interaction (e.g., catumaxomab) (Brinkmann and Kontermann,
2017; Kontermann and Brinkmann, 2015).
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In addition, immune cells from patients can be genetically altered ex vivo to
improve their cancer immunity function and then administered back to the
patient. A notable example is the addition of a chimeric antigen receptor to T cells,
which was recently approved for the treatment of certain types of leukemia. The
engineered cells, known as CAR-T cells, are induced to express a TCR/antibody
chimera that allows for specific targeting of cancer cells (Kochenderfer et al., 2010).
Cellular immunotherapy is currently an intense area of research and numerous
clinical trials are ongoing.
2.2. Tumor metabolism
There are six acquired capabilities of cancer that have been described as the
“hallmarks” of cancer (Hanahan and Weinberg, 2000). These characteristics are
common to all cancers, and their acquisition is facilitated by the inherent genomic
instability and genetic diversity of cancer cells (Figure 1-9). As such, these
hallmarks have been targets of intense research for decades. This paradigm was
recently revisited, and alterations to cellular energetics was proposed as an
“emerging hallmark” of cancer (Hanahan and Weinberg, 2011). It has since been
demonstrated that dysregulated metabolism is not just a hallmark of cancer, but it
is a key driver of development and progression.
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Figure 1-9. Biological hallmarks of cancer cells
Adapted from Hanahan and Weinberg (2011).

The metabolism of cells has been studied for over a century, and discoveries
of its role in cancer were pioneered by Otto Warburg in the early 1920s (Warburg
et al., 1927). Under normal oxygen conditions (normoxia), mammalian cells
typically convert pyruvate derived from glycolysis to acetyl-CoA for further
oxidation in mitochondria. However, the reduction of pyruvate to lactate and the
corresponding oxidation of NADH to NAD+ can also occur under normoxic
conditions and is often detected in rapidly dividing cells. Warburg noted that even
in conditions where oxygen concentrations were sufficient for oxidation to occur,
glucose was still fermented to lactate (Warburg et al., 1927). This metabolic state
was later termed aerobic glycolysis and is generally known as the Warburg effect.
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The altered metabolism of cancer cells serves to promote anabolic processes
(Liberti and Locasale, 2016; Vander Heiden et al., 2009). While glycolysis is
generally considered a catabolic pathway, it produces metabolic intermediates
that support the biosynthesis needed for cell growth and proliferation. A number
of signaling and transcription factors have been shown to induce aerobic
glycolysis in cancer (Figure 1-10). A notable example is the well-known tumor
suppressor p53, which is commonly mutated in cancer cells (Ozaki and
Nakagawara, 2011). While most famous for its role in DNA repair, p53 also
negatively regulates flux through glycolysis (Zhang et al., 2014). Activation of
phosphatidylinositol-3 kinase (PI3K) also plays a major role in upregulating
glycolysis through regulation of the downstream modulators protein kinase B
(Akt) and the mammalian target of rapamycin complex (mTORC) (DeBerardinis
and Chandel, 2016). The combined effects of these and other regulators leads to an
overall change in cancer cell metabolism that supports biogenesis.
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Figure 1-10. Signaling pathways regulating cancer metabolism.
Adapted from DeBerardinis and Chandel (2016).

The abnormal accumulation of some metabolic intermediates can have a
significant effect on the metabolism and growth of tumor cells. Termed
oncometabolites, these intermediates can alter DNA and histone methylation in
ways that promote tumor growth and progression (Sciacovelli and Frezza, 2016;
Yang et al., 2013). A notable example is D-2-hydroxyglutarate, which has been
shown to have substantial impacts on the epigenetic landscape of cancer cells
(Figure 1-11). In addition, common products of mitochondrial respiration (e.g.,
acetyl-CoA, a-ketoglutarate) have also been shown to affect epigenetic markers of
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histones, thereby altering chromatin structure and gene transcription (Ward and
Thompson, 2012).

Figure 1-11. Biological changes induced by D-2-hydroxyglurate
Adapted from Yang et al. (2013).

Several changes in mitochondrial metabolism in cancer have been shown
to promote cancer progression (Wallace, 2012; Zong et al., 2016). Mutations in key
enzymes of the TCA cycle, including succinate dehydrogenase (Complex II), lead
to increased levels of intermediates (e.g., succinate, fumarate) that serve as
feedback inhibitors and promote aerobic glycolysis (Kurelac et al., 2011).
Activation of the MYC pathway promotes glutaminolysis, which provides a
supplemental carbon source to the TCA cycle (a process known as anaplerosis) in
order to produce citrate and support fatty acid synthesis (DeBerardinis et al., 2008).
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In addition, it has been shown that reduced Ca2+ flux into mitochondria occurs in
cancer, which has been proposed to play a role in preventing apoptosis (Wallace,
2012). These examples, along with others not mentioned, all promote
tumorigenesis and cancer progression via alterations to mitochondrial function.
Additionally, the metabolism of cancer cells serves not only to promote
tumor development, but it can also modulate immune responses. Due to the high
utilization of glucose, cancer cell metabolism results in “deserts” of low glucose in
the

tumor

microenvironment

that

effectively

starve

tumor

infiltrating

lymphocytes (Lyssiotis and Kimmelman, 2017). Furthermore, waste products of
cancer metabolism can alter immune responses as it has been shown that lactate
excreted by cancer cells negatively affects the glycolytic activity of T cells, which
suppresses cytotoxic T cell function (Fischer et al., 2007).
3. Overview of the immune system
An important characteristic of life is the ability to discern between what
components constitute the body and those of other organisms (self versus nonself).
The need to protect the self from nonself threats led to the evolution of the immune
system, which is a complex suite of tissues, cells, and molecules that defend an
organism from disease. The human immune system is capable of detecting and
eradicating a wide variety of pathogens, including many different types of viruses,
bacteria, parasites, and fungi. It is also capable of neutralizing internal threats,
such as eliminating cancerous cells and tumors.
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The complex responses of the immune system are heavily regulated to
prevent autoimmunity, which occurs when the immune system attacks the normal
cells and tissues of the body. In addition, allergic responses to normally harmless
substances can result in severe, life-threatening conditions (e.g., anaphylaxis).
Thus, a balance must be maintained such that immune responses occur while
damaging effects to the body are limited.
The human immune system can be broadly separated into two major arms,
the innate and adaptive immune systems. The immune system can also be further
divided into humoral immunity, which is due to the immune effector functions of
proteins and other soluble components (e.g., the complement system and
antibodies), and cell mediated immunity, which is immunity due to the actions of
leukocytes (Figure 1-12).
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Figure 1-12. Mediators of the immune system
Adapted from Dranoff (2004).

3.1. Innate immunity
The innate immune system is comprised of physical and chemical barriers,
proteins such as the complement system and inflammatory mediators, and innate
immune cells. Innate immunity is fast-acting and is often the first to encounter and
respond to an invader. In addition to pathogens, it is also activated by endogenous
signals from damaged or stressed cells.
Several barriers exist that separate or differentiate the body into different
compartments, and innate immunity is crucial for their protection (Owen et al.,
2013). Physical barriers are present where the body encounters the environment.
These barriers are generally lined with epithelial cells that are protected by a layer
of mucus, which is a thick secretion of glycoproteins, antimicrobial peptides,

32

antibodies, and other factors. This is known as a mucosal layer and protects areas
such as the linings of the lungs and gastrointestinal tract. As living systems require
constant transport of nutrients and waste products, none of these barriers are
completely impermeable and are therefore armed with multiple defenses from
pathogens.
Chemical barriers are another line of defense against invading pathogens.
These exist in several forms including broadly acting antibiotics in the form of
antimicrobial peptides (e.g., b-defensins) and enzymes (e.g., lysozyme).
Additionally, the pH of the stomach is chemical barrier that acts against ingested
pathogens. The specific defenses present depend on the nature of the barrier and
vary by location in the body.
Innate immune responses to pathogens are generally initiated by the
engagement of pattern recognition receptors (Brubaker et al., 2015; Takeuchi and
Akira, 2010). These innate receptors recognize conserved molecular patterns
known as pathogen associated molecular patterns. A classic example from bacteria
is lipopolysaccharide (LPS), which activates Toll-like receptor 4 (TLR4) (Park and
Lee, 2013). Pattern recognition receptors also detect damage associated molecular
patterns, which are endogenous cues of cellular stress and tissue damage
(Schaefer, 2014). The release of mitochondria DNA is one such example and is
recognized by TLR9 (Kumagai et al., 2008). A major effect of signals downstream
of TLR engagement is the activation of the inflammasome, which is a multi-
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subunit protein scaffold that facilitates the production and release of inflammatory
mediators (e.g., IL-1b) (Broz and Dixit, 2016).
The induction of an acute inflammatory response is the first line of defense
when the innate immune system is activated (Owen et al., 2013). Acute
inflammation is characterized by five classic symptoms - heat, pain, redness,
swelling, and loss of function. It can be caused by responses to pathogens, but it
can also manifest after an injury that results in tissue damage. These responses are
initiated by the release of inflammatory mediators that activate downstream
signaling cascades. Proinflammatory cytokines such as IL-1, IL-6, and TNF are key
components of the inflammatory cascade. A subset of cytokines known as
chemokines are also released and function to recruit other immune cells to the site
of infection or injury. Whether from pathogens or tissue damage, the responses
initiated are facilitated by innate immune cells.
The most abundant cells of the innate immune system are macrophages,
neutrophils, natural killer cells, and dendritic cells. When a pathogen enters the
body, it is typically first engaged by tissue resident macrophages (Davies et al.,
2013). These cells serve as “vacuum cleaners” for the body as they endocytose and
break down invading microbes and debris in a process known as phagocytosis.
Macrophages also release cytokines and other mediators that direct and further
activate immune responses (e.g., IL-1b, TNF). Additionally, macrophages can
serve as antigen presenting cells to directly activate the adaptive immune system.
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Macrophages are found throughout the body and exist in two major
phenotypes – classic (M1) and alternative (M2) macrophages (ShapouriMoghaddam et al., 2018). M1 macrophages are proinflammatory cells that secrete
inflammatory cytokines (e.g., IL-1b, IFNg). These macrophages are highly
phagocytic and effectively clear bacteria and cell debris. In contrast, M2
macrophages are anti-inflammatory and serve roles in dampening immune
responses and in wound healing. Most tissue resident macrophages are of the M2
phenotype, however the molecular mechanisms that induce their differentiation
are not clear.
Neutrophils are also phagocytic cells, but they generally reside in the blood,
bone marrow, or vascular bed until activated (Kolaczkowska and Kubes, 2013).
Neutrophils enter the tissue at the site of inflammation via a process called
chemotaxis in response to chemokines released during the inflammatory response
(e.g., IL-8). In addition to phagocytosis, neutrophils eliminate pathogens by
releasing granules filled with antimicrobial peptides and enzymes (e.g., defensins,
lysozyme) in a process known as degranulation. They can also release neutrophil
extracellular traps (NETs), which are primarily composed of DNA and effectively
bind and trap pathogens (Papayannopoulos, 2018). Activation and release of NETs
occurs by NETosis, which is a specialized form of programmed cell death
(Zawrotniak and Rapala-Kozik, 2013).
Natural killer cells are cytotoxic lymphocytes that are critical for immunity
to intracellular bacteria and viruses (Vivier et al., 2008). Unlike extracellular
35

bacteria and parasites, intracellular pathogens are not easily engaged by immune
cells. Therefore, the most effective method of clearance is to induce death of the
infected cell. NK cells recognize changes induced by infection – the so called state
of “altered self” – and induce programmed cell death in the target cell. One
mechanism employed is through the detection of decreased cell surface expression
of major histocompatibility complex (MHC) molecules by infected cells, which is
often induced by viral infections. Nearly all nucleated cells express MHC
molecules, and NK cells are sensitive to differences in their expression. NK cells
are also crucial for the elimination of transformed cells and tumors. NK cells
induce cell death by releasing granules containing death mediators (e.g., perforin,
granzymes). NK cells also secrete cytokines that further direct the immune system
(e.g., recruitment of macrophages to phagocytose dead cell debris).
Dendritic cells are phagocytic antigen presenting cells that reside in tissues
along with tissue resident macrophages (Mildner and Jung, 2014; Sato and Fujita,
2007). They function to processes pathogens and present antigens to the adaptive
immune system. As such, they serve as messengers of the innate immune system
that activate adaptive immune responses. Dendritic cells migrate from the site of
infection to the lymph nodes, where they present whole and processed antigen to
the cells of the adaptive immune system. Dendritic cells also secrete cytokines that
direct and further activate immune responses (e.g., TNF, IL-10, IL-12).
Other less common cells of the innate immune system are eosinophils,
basophils, and mast cells (Rosenberg et al., 2013; Siracusa et al., 2010; Wernersson
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and Pejler, 2014). These, along with neutrophils, are known as granulocytes due
the abundance of granules containing antimicrobial factors in their cytoplasm.
Unlike neutrophils, however, eosinophils, basophils, and mast cells are involved
in allergic responses and are important for the clearance of parasites. Due to the
decreased parasite burdens found in the developed world, these cells are mainly
associated with excessive allergic responses and inflammatory diseases (e.g.,
asthma) and are the key mediators of extreme allergic response symptoms (e.g.,
anaphylaxis) (Fulkerson and Rothenberg, 2013; Sharma and Bayry, 2015;
Voehringer, 2013).
3.1.1. Complement system
In addition to the cell mediated immunity described above, the innate
immune system also has humoral components. A notable example is the
complement system, which is comprised of serum proteins that are activated in a
catalytic cascade that ultimately leads to the breakdown of the membrane integrity
of invading pathogens (Ricklin et al., 2010). Complement components can also
induce the opsonization of pathogens, thereby enhancing innate immune cell
function. Complement activation also releases proinflammatory mediators that
direct and recruit other components of the immune system. Complement
components are synthesized in the liver as inactive precursors that can be
activated by three distinct pathways, all of which lead to the formation of the
membrane attack complex (MAC) on the surface of an invading pathogen. The
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MAC leads to the release of cytosolic components and eventual death of the
invading cell.
3.2. Adaptive immunity
While the innate immune system is generally effective against most threats,
the receptors used to detect pathogens are static and limited in diversity. Due to
the constant evolution of pathogens, they can adapt such that detection by the
innate immune system is avoided or rendered less effective. To combat this, jawed
vertebrates evolved the adaptive immune system. Adaptive immune responses
are mediated by T and B cells and are highly specific due to the diverse nature of
their antigen receptors. T cell receptors (TCRs) and B cell receptors (BCRs) are
produced by a process known as V(D)J recombination that through genetic
rearrangement forms enormous numbers of unique receptors (Figure 1-13) (Schatz
and Ji, 2011). In this way, the adaptive immune system can adapt to changes in
pathogens and becomes more specific as immune responses progress.
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Figure 1-13. T cell receptor gene rearrangement
Adapted from Turner et al. (2006).

3.2.1. T cells
T cells are the facilitators of cell-mediated immunity within the adaptive
immune system. They develop from common lymphoid precursors derived from
the bone marrow, and the majority mature in the thymus (Owen et al., 2013). There
are several subsets of T cells, however all are characterized by the presence of a
T cell receptor (TCR) on the cell surface. TCRs recognize peptide antigens
presented on MHC molecules and are highly diverse in nature. There are two
major types of T cells, which are defined by the expression of the glycoproteins
CD4 or CD8. These cell surface molecules enhance the binding of the TCR to MHC
molecules and also functionally differentiate T cells into the major subsets. CD4+
T cells are generally known as helper T cells as they direct the immune responses
of other cells, and their TCR recognizes peptides presented by MHC class II
molecules. CD8+ T cells are distinguished by cytotoxic activity and are restricted
to peptides presented by MHC class I molecules.
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TCRs are heterodimers formed by the association of two peptide chains
(Reinherz et al., 1999). The most common type of T cell bears a TCR formed by the
association of a and b chains. These are known as ab T cells and can effectively
respond to all pathogens. The other type of TCR is a combination of g and d chains,
which marks the less understood gd T cells that are often found in mucosal linings
(e.g., intestinal barriers) (Chien et al., 2014; Vantourout and Hayday, 2013).
The development of T cells begins in the bone marrow and is completed in
the thymus (Figure 1-14). Common lymphoid progenitor cells destined to become
T cells migrate from the bone marrow to the thymus where they differentiate into
double negative (DN) thymocytes, defined by a lack of both CD4 and CD8
expression. During the DN stages of development thymocytes proliferate, lose the
potential to become B cells, and rearrange the TCRb chain genes. They then
transition to the double positive (DP) stage, characterized by expression of both
CD4 and CD8 and formation of the TCRa chain.
The binding of the complete TCR to self peptide expressing MHC molecules
is then tested in a process known as positive selection (Klein et al., 2009). If the TCR
does not bind any MHC molecules, the thymocyte will die by apoptosis. Proper
engagement of an MHC molecule will activate a signaling cascade through the
TCR that induces lineage commitment and the transition to the single positive (SP)
stage. Mature T cells only express CD8 or CD4, and this depends on whether their
TCR engaged MHC class I or II molecules, respectively. Thymocytes also undergo
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negative selection in the SP stage, a process which is vital to preventing
autoimmunity (Klein et al., 2014). If a TCR strongly engages the MHC molecule, it
has a high chance of being autoreactive (specific for self peptides). Therefore,
thymocytes that receive a strong signal through the TCR are eliminated by
apoptosis.

Figure 1-14. Stages of T cell development
Adapted from Owen et al. (2013).
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MHC molecules are cell surface proteins that are essential for adaptive
immunity (Owen et al., 2013). MHC molecules are broadly characterized into two
major classes. MHC class I are expressed by nearly all cells (including platelets),
however red blood cells are a notable exception. MHC class I molecules present
self-derived peptides and mainly function in immunity to intracellular pathogens
(e.g., viruses) and transformed cells. MHC class II are expressed by professional
antigen presenting cells (APCs; comprised of dendritic cells, macrophages, and B
cells) and present peptides derived from processed antigens. Professional APCs
can also present processed antigen on MHC class I via a process known as cross
presentation.
After maturation in the thymus, T cells enter the circulation as naïve cells.
In this state, they are relatively quiescent and exhibit low levels of DNA
transcription and protein translation. They can be found in the blood and in
tissues, however most are found in the secondary lymphoid organs (e.g., lymph
nodes, spleen). Due to the enormous energy demands of an immune response,
T cells remain in the naïve state until activated.
T cell activation requires engagement of the TCR with cognate peptide
presented by an MHC molecule, however the TCR itself does not contain a
signaling component. Signal transduction requires the T cell coreceptor CD3 and
the z chain (CD247) (Gaud et al., 2018; Smith-Garvin et al., 2009). Complete
activation of naïve T cells also requires signaling from co-stimulatory molecules
(Gaud et al., 2018; Smith-Garvin et al., 2009). The is primarily due to CD28, however
42

other molecules such as inducible costimulatory (ICOS) can serve this function
(Chen and Flies, 2013). In addition, there are regulatory molecules such as
cytotoxic T lymphocyte associated protein 4 (CTLA4) and programmed cell death
protein 1 (PD-1) and that negatively regulate T cell activation (Chen and Flies,
2013).

Figure 1-15. Regulation of T cell activation
Adapted from Chen and Flies (2013).

3.2.1.1. CD4+ T cells
When naïve CD4+ T cells become activated, they differentiate into helper
T cells (Owen et al., 2013). These cells direct the immune responses of other
leukocytes and play a central role in the progression, strength, restriction, and
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conclusion of immune responses. Helper T cells perform this function by
producing cytokines that act on other immune cells and by fully activating B cells
to produce antibodies and induce class switching. Helper T cells are activated by
professional antigen presenting cells, and they differentiate into several types with
specialized effector functions depending on the cytokine environment and nature
of the immune response.

Figure 1-16. Helper T cell subsets
Adapted from O'Shea and Paul (2010).

The majority of activated CD4+ T cells are classified at type 1 helper (TH1)
or TH2 effector cells (Mosmann et al., 1986; Romagnani, 1991). Immunity driven by
TH1 cells is most effective against intracellular pathogens. These cells are
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characterized by high production of IFNg and expression of the transcription
factors STAT4 and T-bet (Farrar et al., 2002; Luckheeram et al., 2012; Romagnani,
1994). In contrast, TH2 cells are most effective against extracellular pathogens
(Walker and McKenzie, 2018). They are induced by IL-4 and IL-6 signaling and
predominantly produce cytokines involved in allergic responses (e.g., IL-4, IL-5,
IL-13) (Luckheeram et al., 2012; Romagnani, 1994). TH2 cells activate a number of
innate immune cells including eosinophils, basophils, and mast cells as well as IgE
and IgG antibody producing B cells (Annunziato et al., 2015).
Follicular B helper T (TFH) cells are a subset of helper T cells that are
localized to the periphery of B cell follicles in secondary lymphoid organs (Crotty,
2014). TFH cells mediate the generation of germinal centers, in which B cells
proliferate, differentiate, and undergo antibody class switching and affinity
maturation. TFH cells are therefore crucial to the production of antibodies that
effectively target pathogens. The cytokine IL-21 and the immune checkpoint
protein ICOS induce TFH cell differentiation (Luckheeram et al., 2012).
Another subset is comprised of T helper 17 (TH17) cells, which are
proinflammatory cells that produce significant amounts of IL-17 (AcostaRodriguez et al., 2007; Annunziato et al., 2007; Harrington et al., 2005). These cells
are important mediators of immune responses at mucosal sites and are enriched
in the linings of the lungs and intestinal tract. The differentiation of TH17 cells is
induced by transforming growth factor b (TGFb) and IL-6 signaling and the
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transcription factors STAT3 and RORgt (Luckheeram et al., 2012; Yang et al., 2007).
Excessive inflammation caused by TH17 cells has been shown to exacerbate
diseases (e.g., psoriasis) (Tesmer et al., 2008), which may be due (at least in part) to
the signals that induce TH17 differentiation competing with those that induce
regulatory T (Treg) cells.
Treg cells are immunosuppressive T cells that are important for the
maintenance of tolerance and the prevention of autoimmunity. The transcription
factor forkhead box P3 (FOXP3) directs the differentiation of Treg cells, expression
of which begins in the thymus during the later stages of T cells development
(Luckheeram et al., 2012; Ohkura et al., 2013). The TCR of Treg cells is often specific
to self peptides, however activation of these cells leads to dampened immune
responses (Josefowicz et al., 2012). Treg cells restrict immune responses by
producing anti-inflammatory cytokines (e.g., IL-10, IL-35) and by releasing
cytolytic mediators (e.g., granzyme B) that induce apoptosis of effector immune
cells (Josefowicz et al., 2012). Treg cells also alter the cytokine environment by
rapidly absorbing cytokines released by other cells (Pandiyan et al., 2007). Defects
in the number and/or function of Treg cells have been implicated in the pathology
of several diseases (e.g., cancer, autoimmunity), however the exact mechanisms
involved are unclear.
In addition to these commonly known subsets, other T helper cell subsets
have been reported that are less understood. A subset characterized by high
production of IL-9 was recently described and termed T helper 9 (TH9) cells
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(Kaplan et al., 2015). This subset currently lacks specific biomarkers, but TH9 cells
are thought to be involved in allergy responses. Similarly, T helper 22 (TH22) cells
are characterized by substantial production of IL-22. Originally thought to related
to TH17 cells, TH22 cells have also been shown to produce IL-13 and granzymes
and are implicated in the pathology of asthma and atopic dermatitis (Plank et al.,
2017). In addition, functionally unique CD4+ T cells with cytotoxic activity have
been described (Takeuchi and Saito, 2017), contrasting with the dogma of
immunology that only CD8+ T cells have cytolytic activity.
3.2.1.2. CD8+ T cells
The other major class of effector T cells are cytotoxic T (TC) cells, which
develop from naïve CD8+ T cells (Owen et al., 2013). Similar to NK cells, TC cells
provide immunity to intracellular pathogens and eliminate transformed cells
through the production and release of cytolytic granules. A key difference from
NK cells, however, is that TC cells are specifically activated as their TCR is
restricted to a unique peptide presented on an MHC class I molecule.
The main function of TC cells is to induce cell death. Engagement of their
TCR with an infected or transformed cell triggers the release of the components of
cytotoxic granules (mainly perforin and granzymes), which induce programmed
cell death in the target cell. TC cells can also induce cell death through expression
of other effector proteins such as first apoptosis signal receptor (Fas) ligand (FasL),
which binds to Fas expressed on target cells (Owen et al., 2013).
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Another major function of TC is to produce cytokines, including significant
amounts of IFNg. There are currently three defined subtypes of cytotoxic T cells
based on their cytokine secretion profile (Annunziato et al., 2015; Kondo et al., 2009;
Mosmann et al., 1995). T cytotoxic 1 (TC1) cells are the most common type of
effector cytotoxic cell and produce significant amounts of IFNg (Mosmann et al.,
1995). The transcription factors T-bet and Eomes are critical for both their
production of IFNg and cytolytic activity (Glimcher et al., 2004). Similar to TH2
cells, T cytotoxic 2 (TC2) cells produce IL-4, IL-5, and IL-13 and are involved in
immunity to parasites and in allergy responses (Mosmann et al., 1995). Lastly, T
cytotoxic 17 (TC17) cells are proinflammatory cells characterized by production of
IL-17 (Kondo et al., 2009). Activation of STAT3 and signaling through RORgt are
required for their differentiation (Annunziato et al., 2015).
In addition to these subsets, a functionally unique type of TC cells was
recently described. In response to IL-6, a subset of TC cells can produce IL-21
during an influenza infection, which is sufficient to support B cell antibody
production and class switching (Yang et al., 2016). These “helper” cytotoxic T cells,
along with the “cytotoxic” helper T cells described previously (§3.2.1.1) are
examples of the immense and as yet understood complexity of the immune
system.
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3.2.2. B cells
B cells function to produce and secrete antibodies (Owen et al., 2013). B cells
mainly reside in the lymph nodes and spleen and are activated through direct
interaction with antigens from pathogens, which engage the B cell receptor on the
cell membrane. B cells also function as antigen presenting cells, and, along with
dendritic cells and activated macrophages, are known as professional antigen
presenting cells as they express MHC class II molecules and can effectively activate
CD4+ T cells. B cells also secrete cytokines and chemokines when activated. Like T
cells, B cells also develop from common lymphoid progenitor cells, however they
develop and mature in the bone marrow.
B cells are characterized by the cell surface expression of the B cell receptor
(BCR), which, like the TCR, is formed through the process of V(D)J recombination
(Schatz and Ji, 2011). Naïve B cells are activated by binding of the cognate ligand
to the BCR. This leads to endocytosis of the antigen, which is then processed and
presented to helper T cells via MHC class II molecules. B cells that receive T cell
help undergo a rapid proliferation and begin secreting antibodies, which are
soluble versions of the BCR.
There are five major types of antibodies that can be produced by B cells –
immunoglobulin M (IgM), IgD, IgA, IgG, and IgE (Owen et al., 2013). The BCR of
naïve B cells is in the form of IgM or IgD. To produce the other types of antibodies,
germinal center B cells undergo a process known as class switching (Stavnezer et
al., 2008). The specific type of antibody induced depends on the cytokine
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environment and the type of pathogen that initiated the immune response.
Additionally, antibody specificity for antigen increases over time as B cells
introduce mutations in antibody genes via somatic hypermutation (Teng and
Papavasiliou, 2007). B cells that produce higher affinity antibodies preferentially
receive help from TFH cells, which leads to their selection over time. The combined
effects of somatic hypermutation and TFH cell selection are known as affinity
maturation.
3.3. Immunologic memory
After the stimulus that initially activated the immune response is
eliminated, the cells of the immune system undergo a process known as
contraction during which the majority of the activated leukocytes die (Marrack et
al., 2010). Unlike innate immune cells, however, some activated T and B cells
differentiate into long lived memory cells (Owen et al., 2013). These cells serve as
sentinels in the event of another infection with the same pathogen and can persist
for decades. Due to the individual nature of the pathogens and other threats that
each organism experiences, the memory cell repertoire of every individual is
unique. Unlike a primary immune response, activation of memory cells occurs
quickly, is less dependent on costimulatory molecules, and leads to rapid
protection from secondary infections.
Both CD4+ and CD8+ memory T cells form and have been classified into
three subsets (Mahnke et al., 2013; Mueller et al., 2013; Sallusto et al., 1999). Central
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memory T (TCM) cells circulate between the blood and secondary lymphoid organs
(e.g., spleen, lymph nodes). TCM cells exhibit self-renewal, have a large proliferative
capacity, can differentiate into effector cells, and produce significant amounts of
IL-2. Effector memory T (TEM) cells can be found migrating between the blood and
nonlymphoid peripheral tissues. TEM cells have a lower proliferative capacity
compared to TCM cells but are potent cytotoxic cells that can rapidly produce
substantial amounts of effector cytokines (e.g., IFNg). Tissue resident memory
(TRM) cells do not circulate and therefore permanently remain in the tissue in
which they develop (Gebhardt et al., 2009; Masopust et al., 2010). These cells serve
as immediate responders to invading pathogens and are especially effective
against recurrent, localized challenges from the same pathogen.
In contrast to these “classically” derived memory cells that develop after
antigen exposure, a subset of memory cells that are antigen naïve have been
recently described. These cells, known as virtual memory T (TVM) cells (White et
al., 2017) have been shown to comprise a substantial portion of the pool of all CD8+
T cells in naïve mice (15 – 20 %) (Dobber et al., 1992; Le Campion et al., 2002).
Instead of foreign antigen, it is thought that cytokine signaling leads to their
development (Haluszczak et al., 2009). Future studies are needed to characterize
this unique memory cell subset.
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3.4. Immunometabolism
In recent years, the metabolism of immune cells has become an intense area
of research. Unlike the majority of cells in the body, those of the immune system
experience rapid and drastic changes in nutrient availability and oxygen
concentrations during the normal course of their function. Accordingly, the
metabolic state of immune cells has been shown to directly correlate with immune
effector functions (Figure 1-17).

Figure 1-17. Metabolism of T cells
Adapted from Buck et al. (2015).
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Naïve and certain memory cells (e.g., TCM cells) are commonly found in
relatively resource rich compartments such as the blood, spleen, and lymph nodes
(McNamee et al., 2013). In contrast, activated effector cells that traffic to the
nutrient and oxygen poor environments of infected and/or inflamed tissues
experience extracellular signals and cues are exceedingly different from those of
nutrient replete compartments (Eltzschig and Carmeliet, 2011). As such, the
metabolic demands of effector cells are significantly different from those of resting
cells. In order to survive and function in these vastly different niches, cells of the
immune system have the ability to substantially reprogram their metabolism
(Buck et al., 2015; Pearce et al., 2013).
Naïve and resting memory T cells are small and relatively quiescent,
however they require ATP for the cytoskeletal rearrangements necessary to
navigate the blood and lymphatic vessels. To maintain this state, they primarily
utilize oxidative phosphorylation fueled by glucose and fatty acids to produce
ATP (van der Windt and Pearce, 2012; Wang et al., 2011). In contrast, effector T
cells are large, highly proliferative, and secrete substantial amounts of cytokines
and other effector molecules. Since glycolytic pathways are more supportive of
biosynthesis, effector T cells rely on aerobic glycolysis (Figure 1-18) (Pearce et al.,
2013).
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Figure 1-18. Metabolic changes T cells over time
Adapted from Pearce et al. (2013).

Signaling pathways activated via engagement of the TCR, costimulatory
molecules, and cytokines initiate the upregulation of glucose and amino acid
transporters (Carr et al., 2010; Frauwirth et al., 2002; Sinclair et al., 2013) and
promote the metabolic switch from OXPHOS to aerobic metabolism (Frauwirth et
al., 2002). For example, CD28 ligation leads to increased PI3K activity, which
activates Akt and mTORC. The combined effect of these integrated promotes the
differentiation and proliferation of effector T cells (Buck et al., 2015; Delgoffe et al.,
2011; Pollizzi et al., 2015; Pollizzi and Powell, 2015). In addition, metabolic changes
induced by these pathways during activation have lasting effects as memory cell
development requires CD28 signaling during the initial stages of naïve T cell
activation (Klein Geltink et al., 2017).
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Consistent with the switch to aerobic glycolysis, b-oxidation of fatty acids
is downregulated during T cell activation (Wang et al., 2011). While effector cells
primarily utilize aerobic glycolysis, OXPHOS is still utilized by these cells (Wang
et al., 2011). However, the paradigm of effector T cells primarily using aerobic
glycolysis is not universal as Treg cells have been shown to depend on b-oxidation
and OXPHOS (Michalek et al., 2011). Consistent with this, mTORC signaling
represses FoxP3+ Treg cell differentiation, while the conventional effector subsets
(TH1, TH2, TH17) are promoted (Delgoffe et al., 2009; Kopf et al., 2007). In addition,
while the metabolism of TFH cells is currently unclear, the transcription factor Bcl6
(which defines the lineage) suppresses glycolysis (Oestreich et al., 2014), indicating
that these cells may also rely more on OXPHOS.
As effector cells undergo contraction and become memory T cells, their
metabolism undergoes additional reprogramming. Like naïve cells, memory T
cells primarily rely on OXPHOS for their metabolic needs. However, they have
increased mitochondrial mass, which instills these cells with a significantly higher
spare respiratory capacity (van der Windt et al., 2012). The cytokine IL-15, which
is critical to the differentiation of memory T cells, is important for the generation
of this phenotype (van der Windt et al., 2012). It has also been shown that memory
T cells heavily rely on the oxidation of fatty acids, which they produce and store
in membrane bound compartments in the cytosol (Araki et al., 2009; O'Sullivan et
al., 2014; Pearce et al., 2009; van der Windt and Pearce, 2012).
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The morphology of mitochondrial networks has also been shown to vary
between T cell activation states, and the patterns are consistent with their
metabolic phenotypes. In effector T cells, mitochondria exhibit a punctate, fissed
morphology, while those of memory T cells appear as a fused and connected
network (Buck et al., 2016). Fused mitochondrial networks are thought to promote
mitochondrial function, including the generation of respiratory supercomplexes
(Cogliati et al., 2013; Mishra et al., 2014).
Metabolic changes have also been shown to affect cells of the innate
immune system (O'Neill and Pearce, 2016). Like activated T cells, M1 macrophages
heavily rely on aerobic glycolysis. They also exhibit a “broken” TCA cycle,
whereby succinate and citrate accumulate, and this ultimately facilitates the
effective secretion of IL-1b (Mills et al., 2017). In contrast, the TCA cycle is fully
functional in M2 macrophages as they primarily utilize OXPHOS for ATP
synthesis. In addition, a unique requirement of glycogen as a fuel source for
dendritic cell activation and effector function was recently described (Thwe and
Amiel, 2018; Thwe et al., 2017).
Taken together, these studies indicate that the metabolic state of immune
cells is adapted to promote effector functions, and more detailed analyses of the
metabolic requirements of specific effector functions are currently areas of intense
research. Later in this dissertation, the effects of increased mitochondrial
respiration on the effector functions of CD8+ T cells in the context of viral
immunity will be discussed in detail (CHAPTER 2).
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4. Methylation controlled J protein
4.1. Discovery
Methylation controlled J protein (MCJ) was originally discovered as a gene
expressed in normal ovarian epithelial cells, but little to no expression was
detected in several ovarian cancer cell lines (Shridhar et al., 2001). MCJ is a small
protein of ~150 amino acids in length that is encoded by the DNAJC15 gene
(Kampinga et al., 2009). In humans, the DNAJC15 gene locus spans approximately
86,000 base pairs on chromosome 13 and encodes a 2792 base pair transcript
containing 6 exons and 5 introns (Shridhar et al., 2001). The MCJ protein contains
a short N-terminal sequence (35 amino acids) followed by a single transmembrane
domain (Hatle et al., 2007; Shridhar et al., 2001). The C-terminus contains a
canonical J domain, defining MCJ as a member of the large DNAJ family of protein
co-chaperones (Hatle et al., 2007; Shridhar et al., 2001).
4.2. Classification
DNAJ family members (also called J proteins) are homologous to heat shock
protein 40 (Hsp40) of Escherichia coli. There are currently 49 identified human
DNAJ proteins that all contain a highly conserved J domain, but their specific
function is determined by non-conserved domains (e.g., the N-terminus of MCJ)
(Qiu et al., 2006). The current nomenclature divides DNAJ proteins into three
subfamilies based on the location of the J domain and the presence of other
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conserved protein motifs (Kampinga et al., 2009). Type A members contain a J
domain in the N-terminus, a glycine/phenylalanine rich region, a cysteine rich
region, and a C-terminus that varies in structure. Type B members also contain an
N-terminal J domain and a glycine/phenylalanine rich region, but they lack a
cysteine rich region. Type C members are the most numerous and are defined by
only having a J domain, which can be present in either the N- or C-terminus. MCJ
contains a J domain in the C-terminus but does not have a glycine/phenylalanine
or cysteine rich region, therefore it is a type C DNAJ protein (Hatle et al., 2007;
Shridhar et al., 2001).
4.3. Evolutionary history
MCJ is proposed to have evolved after a gene duplication event involving
the mitochondrial import inner membrane translocase subunit 14 (TIM14) gene of
yeast (Hatle et al., 2007), a vital component of the inner membrane translocase in
mitochondria (Mokranjac et al., 2003). TIM14 is also a DNAJC family member and
is designated as DNAJC19. In humans and other vertebrates, MCJ and DNAJC19
are both paralogs of yeast TIM14 that are found in mitochondria. Both have a
highly conserved J domain in the C-terminus and a predicted transmembrane
domain, however MCJ also contains a unique N-terminal sequence (Hatle et al.,
2007) (Figure 1-19).
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DNAJC15
DNAJC19 iso 1
DNAJC19 iso 2
DNAJC15
DNAJC19 iso 1
DNAJC19 iso 2
DNAJC15
DNAJC19 iso 1
DNAJC19 iso 2

1
MAARGVIAPVGESLRYAEYLQPSAKRPDADVDQQRLVRSLIAVGLGVAALAFAGRYAFR
----------------------------------MASTVV-AVGLTIAAAGFAGRYVLQ
----------------------------------------------------------60
IWKPLE-QVITETAKKISTPSFSSYYKGGFEQKMSRREAGLILGVSPSAGKAKIRTAHR
AMKHMEPQVKQVFQSLPKSAFSGGYYRGGFEPKMTKREAALILGVSPTANKGKIRDAHR
-MKHMEPQVKQVFQSLPKSAFSGGYYRGGFEPKMTKREAALILGVSPTANKGKIRDAHR
120
RVMILNHPDKGGSPYVAAKINEAKDLLETTTKH
RIMLLNHPDKGGSPYIAAKINEAKDLLEGQAKK
RIMLLNHPDKGGSPYIAAKINEAKDLLEGQAKK

Figure 1-19: Comparison of MCJ and DNAJC19

Non-conversed amino acid residues of DNAJC19 isoforms relative to MCJ are
indicated by bold lettering and dashes.

To date, there has only been one phylogenetic analysis of the origin of MCJ
(Hatle et al., 2007). It suggests that MCJ coalesced prior to the divergence of
ecdysozoans and vertebrates, however MCJ homologs are only detectable in
extant vertebrate lineages (Hatle et al., 2007). The absence of homologs in other
animal clades indicates that it was likely lost during the course of their further
divergence from vertebrates over time (Hatle et al., 2007). Interestingly, the amino
acid sequence of MCJ is conserved among a diverse number of vertebrate
populations (Table 1-2), indicating that unknown selective pressure(s) may be
present. Future studies are needed to clarify the origin and evolutionary history of
MCJ.
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Table 1-2. Conservation of MCJ across vertebrate populations
Species
Homo sapiens
Mus musculus
Pan troglodytes
Pongo abelii
Macaca mulatta
Canis lupus
Felis catus
Equus caballus
Ailuropoda melanoleuca
Leptonychotes weddellii
Oryctolagus cuniculus
Orycteropus afer
Loxodonta africana
Myotis lucifugus
Sus scrofa
Camelus dromedarius
Chinchilla lanigera
Heterocephalus glaber
Bos taurus
Capra hircus
Orcinus orca
Tursiops truncatus
Dasypus novemcinctus
Monodelphis domestica
Phascolarctos cinereus
Pogona vitticeps
Python bivittatus
Xenopus tropicalis
Danio rerio
Oryzias latipes
Ictalurus punctatus
Alligator mississippiensis
Chelonia mydas
Haliaeetus leucocephalus
Gallus gallus

Common Name
Human
Mouse
Chimpanzee
Orangutan
Rhesus macaque
Dog
Cat
Horse
Panda
Seal
Rabbit
Aardvark
Elephant
Bat
Pig
Camel
Chinchilla
Naked mole rat
Cow
Goat
Killer whale
Dolphin
Armadillo
Opossum
Koala
Bearded dragon
Burmese python
Western clawed frog
Zebrafish
Medaka
Catfish
American alligator
Green sea turtle
Bald eagle
Chicken

Sequence
MAARG-VIAPVGESLRYAEYL---QPSAKRPDADVDQQMATGGGVTSR--EGLRYAEYL---PPSAQRSDADIDH-T
MAARG-VIAPVGESSRYAEYL---QPSAKRPDADVDQQMAARG-VIAPVGESLRYAEYL---QPSAKRPDADVDQQMAARG-VIAPVGEGLRYAEYL---QPSAKRPDADVDQQMAARGGVAA-AGESLRYAEYS---PPATRRPDADLDK-MAAGGGV-APAGEGLRYAEYS---PPATKRADADIDH-MAARGGV-ASAGEGLRYAEYS---PPSTRRPDADIDQ-MAARGGV-APAGEGLRYAEYS---PPATKRPDADVDQ-MAARGGVAA-AGEGLRYAEYS---PPTTKRPDADVDQ-MAARAGV-APAGEGLRYAEYV---PPSAKRPDAEIDH-MAAGGGVT-PVGEGLRYAEYS---PPSAKRPDADIDQ-MAARGGVL-PAGEGLRYAEYS---PPSARQPDADVDR-MAAFGGV-APAGEDIRHAEYS---PPSTKRPDADIDR-MAGHGGV-LPAGEALRYAEYS---PPQAKRSDTDIDR-MAARGGV-APAGEGLRYAEYS---PPPAKRSDADIDP-MAARGG-AAAAGEGLRYAEYS---PPSARRPDADIDH-MAARSGV-ASASEGLRYAEYS---PPSAKNPDADIDH-MAARVGV-APAGDGLRYSGSL---QPPAQPSDADLDR-MAARVGV-APAGDGLRYAGSS---QPPAQPSDADLDR-MAARGGV-ASAGESLRYAEDS---PPPTKRSDADTDP-MAARGGV-AGAVESLRYAEDS---PPPTKRSDADTDP-MAAGRGV-SATCEGLRHAEFT---PPSATLPEADIDH-MA-GRG-AGPADENLRYAEYM---SHAAKRPESDFDQ-MAAR-G--AGPSESVRYAEYA---PPAAKRAESDFDQ-MTGAHGG---SSEALRYPEYV---AGSG---SPDLNR-MVERAG---SSSESLRYAEYI---ARSGGGQGPDINH-MATSSTGMG-TSEALRYSEYM---PGPNAGSSTDIDR-MASSSGVTL-DGDLMRYAEYT---PKSNMKSETDIDR-MANTAARSNID-DLMRYTEYS---PKTNLRSDAEIDR-MASTGGRIATDSDLLRYAEYT---PRPKQRSETDIDK-MAEAG----ASSEGLRYVEYS----GRGRAGEPDLGR-MEGAG----APWETLRYVEYARVP-GGGRQGEPDTDR-MEGAA----ASSEGLRYAEYARVPTGAGK-GQAELDR-MERAG----ASSEALRYAEYARGPTGAGK-GQTELDR--

Dashes indicate missing amino acid residues relative to other sequences.
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Table 1-2 (continued)
Species
H. sapiens
M. musculus
P. troglodytes
P. abelii
M. mulatta
C. lupus
F. catus
E. caballus
A. melanoleuca
L. weddellii
O. cuniculus
O. afer
L. africana
M. lucifugus
S. scrofa
C. dromedarius
C. lanigera
H. glaber
B. taurus
C. hircus
O. orca
T. truncatus
D. novemcinctus
M. domestica
P. cinereus
P. vitticeps
P. bivittatus
X. tropicalis
D. rerio
O. latipes
I. punctatus
A. mississippiensis
C. mydas
H. leucocephalus
G. gallus

Sequence
RLVRS-LIAVGLGVAALAFAGRYAFRIWKPLEQVITETAKKISTPSFSSYYKGGFEQKMS
AGRRL-L-AVGLGVAAVAFAGRYAFQIWKPLEQVITATARKISSPSFSSYYKGGFEQKMS
GLVRS-LIAVGLGVAALAFAGRYAFRIWKPLEQVITETAKKISTPSFSSYYKGGFEQKMS
GLVRS-LIAVGLGVAAFAFAGRYAFRIWKPLEQVITETAKKISTPSLSSYYKGGFEKKMS
GLVRS-LIAVGLGVAALAFAGRYAFRIWKPLEQVITKTAKKISTPSFSFYYKGGFEQKMS
GLARN-LIAIGLGVAAVAFAGRYAFQFWKPLEQVITETTKKISTPSLSSYYKGGFEQKMS
GLARS-LIAVGLGVATLAFAGRYAFQIWRPLEQVITETAKKISTPSLSSYYKGGFEQKMS
GLARS-LIAVGLGVAALAFAGRYAFQIWKPLEQVITDAAKKISAPSLSSYYKGGFEQKMS
GLARS-LIAVGLGVAALAFAGRYAFQIWKPLEQVITETAKKISTPSLSSYYKGGFEQKMS
GLARS-LIAVGLGVAALAFAGRYAFQIWKPLEQVITETAKKISTPSLSSYYKGGFEQKMS
GLARS-LIAVGLGVAALAFAGRYAFQIWKPLEQVITEATRKISTPSFSSYYKGGFEQKMS
GLARS-LIAVGLGVAAFAFAGRYAFQIWKPLEHVITETAKKISNPGLSSYYKGGFEQKMS
GLARS-LIAVGLGVAAFAFAGRYAFQIWKPLEQVITETAKKISNPSLSSYYKGGFEQKMS
GLARS-FIAVGLGVAAFAFAGRCVFQIWKPLEQVITETAKKISTPSLSSYYKGGFEQKMS
GLARS-LIAVGLGIAALGFAGRYAFQIWKPLGQVITETAKKISAPTFSSYYKGGFEQKMS
GLARS-LITVGLGIAALGFAGRCAFQIWKPLGQVIAETAKKISTPSFSSYYKGGFEQKMS
RLARN-LIAVGLGVAALGFAGRYASQIWKPLQQVITETAKTISSPNLSSYYKGGFEQKMS
RLARN-LIAVGLGVAALGFAGRYAFQIWKPLEQVITQTARNISSPNLSSYYKGGFEQKMS
GLARS-LIAVGLGIAALGFAGRYAFQIWKPLGQVITETAKKISTPSFSSYYKGGFEQKMS
GLARS-LIAVGLGIAALGFAGRYAFQIWKPLGQVITETAKKISTPSFSSYYKGGFEQKMS
RLARS-LIAVGLGIAALGFAGRYTSQIWKPLGQVITETAKKISTPSFSSYYKGGFEQKMS
RLARS-LIAVGLGIAALGFAGRYTSQIWKPLGQVITETAKKISTPSFSSYYKGGFEQKMS
RLARN-LIAVGLGVAAFAFAGRYAYQIWKPLGQVITETAKKISTPSFSYYYKGGFEQKMS
GLART-LIAVGLGVAAFAFAGRYAFQIWKPLEQVITETAKKIQSPSLSSYYKGGFEQKMS
GLART-LIAVGLGVAAFAFAGRCAFQIWKPLEQVITETAKKIQLPSLSSYYKGGFEQKMS
GLARS-MIAVGLGVAAVAFAGRYAFQFWKPLEQVISGTARKISAASLSSYYKGGFEPKMN
GLARS-VIGVGLGIAAIAFGGRYAFQLWKPLEQIITEAARKISTTALPSYYRGGFEPKMN
RLGGT-LIAVGLGVAAAAFAGRFAFQLWKPLGQVIAESAKKIPTPSLSYYYKGGFEQKMN
RLGGALM-AVGLGVAAAGFAGRYAFHLWRPLGQVITETAKKFPSSSFSAYYKGGFEQKMT
KLGGT-LIAVGLCAAAAGFAGRYAFQLWKPLGQVFSETLRKMPSSAFSSYYKGGFEQKMS
RVGST-LIAVGLGVAVAGLAGRYAFHLWKPLGQVITETAKKFPSSAFSTYYKGGFEQKMT
GLAGT-MIAVGLGVAAVAFAGRYAFQLWKPLEQVISETAKKISTSSLSSYYKGGFEQKMS
GLARTMM-AVGLGVAAVAFAGRYAFQVWKPLEQVFTETAKKISASSFSSYYKGGFEQKMS
GLART-MIAVGLGVATVAFAGRYAFHLWKPLEQAMTETAKRILTSSLSSYYKGGFEQKMS
SLARS-MIAVGLSVATVAFAGRYAFHLWKPLGQAITETAKKISTSSLSLYYKGGFEQKMS
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Table 1-2 (continued)
Species
H. sapiens
M. musculus
P. troglodytes
P. abelii
M. mulatta
C. lupus
F. catus
E. caballus
A. melanoleuca
L. weddellii
O. cuniculus
O. afer
L. africana
M. lucifugus
S. scrofa
C. dromedarius
C. lanigera
H. glaber
B. taurus
C. hircus
O. orca
T. truncatus
D. novemcinctus
M. domestica
P. cinereus
P. vitticeps
P. bivittatus
X. tropicalis
D. rerio
O. latipes
I. punctatus
A. mississippiensis
C. mydas
H. leucocephalus
G. gallus

Sequence
RREAGLILGVSPSAGKAKIRTAHRRVMILNHPDKGGSPYVAAKINEAKDLLE-TTTKH
KREASLILGVSPSAGKAKIRTAHKRIMILNHPDKGGSPYLASKINEAKDLLEASSKAN
RREAGLILGVSPSAGKAKIRTAHRRVMILNHPDKGGSPYVAAKINEAKDLLE-TTTKH
RREAGLILGVSPSAGKAKIRTAHRRVMILNHPDKGGSPYVAAKINEAKDLLE-TTTKH
RREAGLILGVSPSAGKARIRTAHKRIMILNHPDKGGSPYVAAKINEAKDLLE-SGTKR
RREASLILGISPSAGKAKIRTAHRRIMILNHPDKGGSPYLATKINEAKDLLE-ATTKH
RREASLILGISPSAGKAKIRTAHRRIMILNHPDKGGSPYLATKINEAKDLLE-ATTKH
RREASLILGVSPSAGKAKIRTAHRRIMILNHPDKGGSPYLATKINEAKDLLE-ATTKH
RREASLILGISPSAGKAKIRTAHRRIMILNHPDKGGSPYLATKINEAKDLLE-ATTKH
RREASLILGISPSAGKAKIRTAHRRIMILNHPDKGGSPYLATKINEAKDLLE-ATTKH
RREASLILGVSPSAGKAKIRTAHRRIMILNHPDKGGSPYLATKINEAKDLLE-ATTKH
RREASLILGVSPSAGKAKIRTAHRRIMILNHPDKGGSPYLATKINEAKDLLE-SSTKH
RREASLILGVSPSADKAKIRTAHRRIMILNHPDKGGSPYLATKINEAKDLLE-SSTKH
RREASLILGVSPSAGKAKIRTAHRRIMILNHPDKGGSPYLATKINEAKDLLE-ETTKH
RREASLILGVSPSAGKAKIRAAHRRIMILNHPDKGGSPYLATKINEAKDLLE-ATTKH
RREASLILGVSPSAGKAKIRAAHRRIMILNHPDKGGSPYLATKINEAKDLLE-ATTKH
RREASLILGISPSAGKAKIRTAHRKIMILNHPDKGGSPYLATKINEAKDLLE-STTKH
RREASLILGISPSANKAKIRTAHRRIMILNHPDKGGSPYLATKINEAKDLLE-STTKN
RREASLILGVSPSASKAKIRAAHRRIMILNHPDKGGSPYLATKINEAKDLLE-ATTKH
RREASLILGISPSASKAKIRAAHRRIMILNHPDKGGSPYLATKINEAKDLLE-AATKH
RQEASLILGVSPSAGKAKIRAAHRRIMILNHPDKGGSPYLATKINEAKDLLE-AATKH
RQEASLILGVSPSAGKAKIRAAHRRIMILNHPDKGGSPYLATKINEAKDLLE-AATKH
RREASLILGISPSADKAKIRTAHRRIMILNHPDKGGSPYLATKINEAKDLLE-SSTKQ
RREASLILGISPSAGKAKIRTAHRRIMILNHPDKGGSPYLATKINEAKDLLE-SSTKQ
RREASLILGISPSAGKAKIRTAHRRIMILNHPDKGGSPYLATKINEAKDLLE-SSTKQ
RREASLILGISPSAGKDKIRTAHRQIMLLNHPDKGGSPYLAAKINEAKDLLE-SSNKH
VREASLILGISPSAGKAKIRNAHRRIMILNHPDKGGSPYLATKINEAKDLLE-SSRKH
RREASLILGVSPSASKSKIRAAHRKIMILNHPDKGGSPYMAMKINEAKDLLE-STTKP
RREASLILGISPTSTKTKVREAHRRIMVLNHPDKGGSPYLAAKINEAKDLLD-SGPRR
RREASLILGISPTSTKNKVREAHRRIMVLNHPDKGGSPYLAAKINEAKDLLD-KETRR
KREASLVLGISPTSTKTKVREAHRRIMVLNHPDKGGSPYLAAKINEAKDLLE-SGHRS
RREASLILGISPSASKAKIRTAHRRIMILNHPDKGGSPYLAAKINEAKDLLE-SSTKN
RREASLILGISPSADKAKIRTAHRRIMILNHPDKGGSPYLATKINEAKDLLE-SSTKN
RQEASLILGVSPSAGKAKIRTAHRRIMILNHPDKGGSPYLATKINEAKDLLE-SSAKN
RREASLILGVSPSADKAKIRAAHRRIMILNHPDKGGSPYLATKINEAKDLLE-SSTKN
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4.4. Regulation of DNAJC15 expression
The expression of MCJ mRNA and protein has been detected in a variety of
cell types. In primary tissues, high expression of MCJ has been shown in several
metabolically active tissues (e.g., heart, liver), while other active tissues (e.g., brain,
skeletal muscle) show substantially less expression (Hatle et al., 2013). MCJ
expression also significantly varies by cell type, including those that are quite
similar. For example, naïve CD8+ T cells highly express MCJ, while CD4+ T cells
do not express MCJ (Hatle et al., 2013). MCJ has also been detected in a number of
cancer cell types as described below. The mechanisms that promote MCJ
expression in most tissues and cells are largely unknown, however DNA
methylation is a known mechanism of silencing expression.
4.4.1. DNA methylation
The first report of MCJ identified it as a gene that is negatively regulated by
DNA methylation (Shridhar et al., 2001). Treatment of ovarian cancer cells with a
methyltransferase inhibitor resulted in the expression of MCJ mRNA in a dose
dependent manner, therefore the gene was named methylation controlled J
protein (Shridhar et al., 2001). The effect of methyltransferase inhibitors resulting
in increased MCJ expression has also been seen in several cancer cell lines
including gastric cancer (Mikata et al., 2006), melanoma (Muthusamy et al., 2006),
and by a different group in ovarian cancer (Menendez et al., 2007), which indicates
that DNA methylation is likely a common regulatory mechanism. Correlations
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between increased methylation of DNAJC15 and low to no MCJ expression have
been reported in brain cancer (Lindsey et al., 2006), breast cancer (Boettcher et al.,
2010), and non-transformed human peripheral blood mononuclear cells (PBMCs)
(Zimmermann et al., 2016).
Interestingly, differences have been found for the specific region of the
DNAJC15 gene that must be methylated in order to silence expression. In ovarian
cancer cells, reduced MCJ expression correlated with increased methylation of a
CpG island in exon 1, however expression was independent of the methylation
status of the promoter (Strathdee et al., 2004). A similar pattern was found in brain
cancer and melanoma, where methylation within the exon 1 CpG island strongly
correlated with lower MCJ expression (Lindsey et al., 2006; Muthusamy et al.,
2006). However, an analysis of transcriptomic data of tumors from a large number
of breast cancer patients showed a strong correlation of increased DNA
methylation at three sites in the proximal promoter region with decreased MCJ
expression (Fernandez-Cabezudo et al., 2016). Additionally, reduced acetylation of
histone markers in both the promoter and exon 1 has been associated with
increased methylation of the exon 1 CpG island in ovarian cancer, indicating that
alterations to overall chromatin structure likely play a role in the regulation of MCJ
expression (Strathdee et al., 2004). Therefore, cell and/or tissue specific differences
in the methylation status of DNAJC15 contribute to the regulation of MCJ
expression, at least in cancer cells.
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It is possible that heterogeneity in DNA methylation within tissues also
leads to differential MCJ expression. Variability in MCJ expression among the
tumor cells of breast cancer patients has been reported, however the mechanism
responsible for this heterogeneity was not addressed (Fernandez-Cabezudo et al.,
2016). Compared to normal kidney tissue, Wilm’s tumors from the same patient
show hypermethylation of DNAJC15 (Ehrlich et al., 2002). Differences in the
degree of DNA methylation between grades of ovarian cancer have been shown
(Houshdaran et al., 2010). Validation of this proposal and whether the regulation
of MCJ expression by DNA methylation can be extended to nontransformed
tissues are topics for future studies.
DNAJC15 methylation has also been shown to vary among individuals and
exhibits a pattern of heritability. An analysis of twins with Dutch ancestry showed
that the DNA methylation pattern of DNAJC15 is significantly heritable (Boks et
al., 2009). This was also seen in a cohort of individuals of Mexican American
descent (Carless et al., 2013). Lower DNAJC15 methylation rates have been
reported in the breast tumors of African American versus non-African American
patients (Conway et al., 2015). In addition, variable expression of MCJ alleles
between European and African populations has been attributed to a single
nucleotide polymorphism in exon 1 (Tian et al., 2018). Therefore, the regulation of
MCJ expression at the gene level can vary by cell and tissue type as well as genetic
background.
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4.4.2. Signaling molecules and transcription factors
Little is known of regulatory factors that control MCJ expression as there
have been only a few studies on the signaling molecules and pathways involved.
The cytokine IL-6 has been shown to downregulate MCJ expression in breast and
liver cancer cell lines, however the mechanistic connection IL-6 signaling and MCJ
expression is currently unknown (Hatle et al., 2007; Navasa, Martin-Ruiz, et al.,
2015). IL-6 has been shown to upregulate DNA methyltransferase 1 (DMNT1)
activity (Li et al., 2012), therefore alterations in DNA methylation may be involved.
In addition, the cytokine IFN-g reduces MCJ expression in macrophages through
a mechanism dependent on the transcription factor Ikaros family zinc finger
protein 1 (Ikaros) (Navasa, Martin-Ruiz, et al., 2015). IFN-g signaling activates
casein kinase 2 (CK2), which regulates Ikaros activity via phosphorylation
(Navasa, Martin-Ruiz, et al., 2015). The activation of this pathway may be specific
to macrophages, however, as no changes in MCJ were detected in a liver cancer
cell line or primary CD8+ T cells after incubation with IFN-g (Navasa, Martin-Ruiz,
et al., 2015).
Ikaros has been shown to regulates the development of several types of
immune cells, including macrophages, T cells, and B cells (Westman et al., 2002).
Two potential binding sites for Ikaros have been identified that are upstream of
the transcriptional start site in the mouse MCJ promoter (Navasa, Martin-Ruiz, et
al., 2015). Binding of Ikaros to the site proximal to the promoter was confirmed in
macrophages (Navasa, Martin-Ruiz, et al., 2015) and as shown later in this thesis,
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in CD8+ T cells (CHAPTER 2). Ikaros directed downregulation of MCJ was also
shown to be independent of DNA methylation (Navasa, Martin-Ruiz, et al., 2015).
4.5. Localization to mitochondria
Initial studies investigating MCJ expression were performed using an
overexpression system, which led to the conclusion that MCJ localized to the Golgi
apparatus and other nonidentifiable vesicles (Hatle et al., 2007). It was later
determined that overexpression of MCJ causes mitochondrial dysfunction and
swelling that substantially alters mitochondrial morphology (Hatle et al., 2013).
Several reports have since established that endogenously derived MCJ localizes to
the mitochondria (Calvo et al., 2016; Hatle et al., 2013; Navasa, Martin, et al., 2015;
Pagliarini et al., 2008; Schusdziarra et al., 2013).
The first indication that MCJ is in a mitochondrial compartment was a
large-scale mitochondrial proteome analysis that detected MCJ in the
mitochondria of several different tissues (MitoCarta) (Pagliarini et al., 2008). A
follow up to this report (MitoCarta2.0) confirmed these results (Calvo et al., 2016).
This finding was also shown in biochemical analyses of murine MCJ in the heart
and CD8+ T cells (Hatle et al., 2013). The localization of MCJ is not affected by
cellular transformation as it has also detected in the mitochondria of several cancer
cell lines (Hatle et al., 2013; Navasa, Martin, et al., 2015; Schusdziarra et al., 2013).
An in silico analysis of the MCJ amino acid sequence indicated that it does
not contain any currently known mitochondrial targeting sequences (Schusdziarra
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et al., 2013). MCJ is, however, predicted to contain a transmembrane domain,
indicating that it is an integral membrane protein (Hatle et al., 2007; Schusdziarra
et al., 2013). Within mitochondria, MCJ localizes to the inner mitochondrial
membrane (Hatle et al., 2013; Schusdziarra et al., 2013; Sinha et al., 2014), which has
been shown in both mouse (heart and CD8+ T cells) and human cells (HeLa and
HEK 293T cells) (Hatle et al., 2013; Schusdziarra et al., 2013; Sinha et al., 2014). MCJ
contains a single putative transmembrane domain (Hatle et al., 2007; Schusdziarra
et al., 2013), indicating that the N- and C-termini face opposite sides of the inner
mitochondrial membrane, however the precise orientation of the termini is
currently unclear as conflicting results have been published in the literature.
Using a Hidden Markov model that predicts protein topology, the
N-terminus of MCJ was predicted to be in an intracellular compartment, while the
C-terminus was predicted to be in an extracellular compartment (Hatle et al., 2007).
Therefore based on the results of this prediction algorithm, MCJ is a single pass
transmembrane protein with its N-terminus in the inner membrane space and Cterminus in the matrix (Hatle et al., 2007).
A biochemical analysis of mitochondria and mitoplasts did not agree with
this prediction (Schusdziarra et al., 2013). Mitoplasts are generated by removing
the outer mitochondrial membrane, while the inner membrane is left intact.
Proteinase treatment induced the loss of the N-terminus of MCJ in mitoplasts,
indicating it resides in the inner membrane space (Schusdziarra et al., 2013). A
major limitation, however, is that untreated mitoplasts were not shown or
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indicated, therefore it cannot be excluded that MCJ loss may have occurred during
mitoplast generation.
In contrast, other studies have reported results that agree with the above
topology prediction. Phage display analysis using the N-terminal sequence of MCJ
as bait indicated that MCJ likely interacts with the Complex I subunit NDUFv1
(Hatle et al., 2013), which is found in the matrix. Additionally, later in this
dissertation (CHAPTER 3) it will be shown that a mimetic of MCJ that is targeted
to the matrix can restore the function of MCJ in deficient cells. Future studies will
clarify these apparent discrepancies in the orientation of MCJ in the inner
mitochondrial membrane.
4.6. Function
As stated above, MCJ is member of the DNAJ family of co-chaperones that
is found in mitochondria. All members of this family contain a canonical DNAJ
domain, however their specific function(s) are mediated by non-conserved
regions. For MCJ, the functional domain is thought to be in the N-terminus as it
has no significant homology to any other known eukaryotic protein.
4.6.1. Negative regulation of mitochondrial metabolism
Biochemical analyses have shown that MCJ is a negative regulator of
Complex I (Hatle et al., 2013). As a consequence of increased Complex I activity in
the absence of MCJ, cells experience significantly higher mitochondrial membrane
potential and ATP production rates (Barbier-Torres et al., 2017; Champagne et al.,
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2016; Hatle et al., 2013). A concomitant increase in mitochondrial oxygen
consumption after MCJ loss has also been shown (Barbier-Torres et al., 2017;
Champagne et al., 2016; Navasa, Martin, et al., 2015). These effects of MCJ
deficiency have been shown in a number of tissues and cell types, including the
heart, liver, macrophages, T cells, and breast cancer cells (Barbier-Torres et al.,
2017; Hatle et al., 2013; Navasa, Martin, et al., 2015). Later in this dissertation, the
negative regulation of mitochondrial metabolism in CD8+ T cells (CHAPTER 2)
and other types of cancer (CHAPTER 3) will be described.
As described previously (§1.2.3), the complexes of the ETC can associated
into supramolecular structures known as respiratory supercomplexes. MCJ
deficiency increases the abundance of supercomplexes in the heart, indicating that
it is refractory to their formation (Hatle et al., 2013). Additionally, biochemical
analyses have revealed that MCJ only associates with Complex I in its monomeric
form and that it does not bind Complex I in supercomplexes (Hatle et al., 2013).
This dissertation will also describe the regulation of supercomplexes by MCJ in
CD8+ T cells (CHAPTER 2).
4.6.2. Regulation of liver metabolism
MCJ is highly expressed in the liver of both mice and humans, however no
obvious differences are observed between the livers of wild-type and MCJ
deficient mice under normal physiological conditions (Hatle et al., 2013). This
indicates that MCJ is not essential for normal liver function. In contrast, substantial
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differences are seen in response to fasting conditions. During a fast, the liver
releases glucose derived from its stores of glycogen for use as an energy source by
other cells of the body. If glycogen becomes limited, adipocytes begin to release
fatty acids. Hepatocytes then import these released fatty acids for repackaging and
release in a form usable by other cells (Berg et al., 2002; Voet and Voet, 2011). In
extreme conditions, such as prolonged fasting, fatty acids build up beyond the
capacity for efficient repackaging producing a condition known as steatosis (fatty
liver).
Using a mouse model of steatosis, it was shown that MCJ deficiency
prevents steatosis as hepatocytes have an increased capacity to metabolize fatty
acids (Hatle et al., 2013). Loss of MCJ also reduced the levels of free fatty acids and
triglycerides in the serum, indicating a systemic overall improvement (Hatle et al.,
2013). In humans, nonalcoholic fatty liver disease (NAFLD) is a spectrum disorder
of the liver (Rinella, 2015). Mild cases present as chronic steatosis, while liver
inflammation and fibrosis are symptoms of progressed disease. While MCJ
significantly affects the development of steatosis in mice, it remains to be
determined whether MCJ plays a role in NAFLD.
A number of therapeutic drugs have off-target effects on mitochondria,
with a notable example being acetaminophen. Overdose is currently the primary
cause of acute liver failure (AFL) and a major cause of drug induced liver injury
(DILI). Furthermore, a significant proportion of liver transplants are secondary to
acetaminophen overdose induced AFL. Hepatotoxicity due to acetaminophen
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overdose is complex and not fully understood (McGill and Jaeschke, 2013; Yoon et
al., 2016), however it is correlated with impaired mitochondrial respiration and
increased oxidative stress due to the production of reactive intermediates (notably
NAPQI) and ROS. N-acetylcysteine (NAC), the only available treatment, mitigates
liver damage by supplementing the cellular antioxidant pool, however treatment
is only effective within the first 8 – 10 hours of the overdose. Thus, there is a
significant need for other therapies for acetaminophen poisoning.
In a mouse model of acetaminophen overdose, MCJ deficiency lead to lower
levels of hepatocyte death, liver damage, serum transaminase levels, and liver
inflammation (Barbier-Torres et al., 2017). This protective effect was correlated to
lower ROS production, reduced oxidative stress, and increased Complex I activity
(Barbier-Torres et al., 2017). Importantly, treatment with an siRNA targeting MCJ
up to 24 hours post drug exposure significantly attenuated liver toxicity and
inflammation (Barbier-Torres et al., 2017), indicating that MCJ is a viable
therapeutic target for drug induced liver toxicity. This was further supported by
the detection of increased levels of MCJ in the liver of patients experiencing DILI
relative to healthy controls (Barbier-Torres et al., 2017). Additionally, MCJ
expression was highest in DILI patients overdosing on drugs known to be
mitotoxic compared to overdoses due to drugs that are not classified as hazardous
to mitochondria (Barbier-Torres et al., 2017).

72

4.6.3. Regulation of immune cell metabolism
CD8+ T cells play a significant role in protection from intracellular
pathogens. Compared to naïve CD4+ T cells, CD8+ T cells abundantly express MCJ
(Hatle et al., 2013). As expected, this leads to lower mitochondrial membrane
potential and Complex I activity in these cells (Hatle et al., 2013). The role of MCJ
in CD8+ T cell immune effector responses is a later focus of this dissertation
(CHAPTER 2).
MCJ is also expressed by macrophages and has a profound effect on their
immune effector functions. Loss of MCJ in macrophages decreases production of
TNF after engagement of multiple TLR ligands, including LPS (Navasa, Martin, et
al., 2015). Interestingly, the decrease in TNF secretion was due to reduced activity
of the metalloprotease tumor necrosis factor α converting enzyme (TACE) rather
than decreased Tnf gene expression or TNF protein production (Navasa, Martin,
et al., 2015). Using a mouse model of fulminant acute liver failure, it was shown
that reduced TNF production in the absence of MCJ is protective (Navasa, Martin,
et al., 2015). MCJ loss in macrophages is therefore beneficial to protection from
inflammatory insults.
4.6.4. Role in chemoresistance
The loss of MCJ expression, however, is not always beneficial. As described
previously, increased methylation of the DNAJC15 gene and/or reduced MCJ
expression has been shown in a number of different cancers (§4.4), however only
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a few studies have shown functional consequences of these differences. The first
report of MCJ showed that restoration of its expression induced sensitivity to
commonly used chemotherapeutic agents in ovarian cancer cell lines, indicating
that loss of MCJ had conferred resistance to these drugs (Shridhar et al., 2001). This
correlation has also been seen in breast cancer as a chemoresistant derivative of
MCF7 cells exhibited increased DNAJC15 methylation and lower MCJ expression
relative to the parental cell line (Boettcher et al., 2010). The ability to prevent
doxorubicin accumulation, thereby mediating chemoresistance, was also
increased in MCJ deficient breast cancer cells (Hatle et al., 2007). These findings
were supported using mouse models as the tumor cells of MCJ deficient mouse
mammary tumor virus (MMTV-PyMT) mice were also highly resistant to
chemotherapy (Fernandez-Cabezudo et al., 2016).
A retrospective study of breast cancer patients indicated that the levels of
MCJ expression in tumors was predictive of relapse free survival after
chemotherapy treatment (Fernandez-Cabezudo et al., 2016). Furthermore, a
prospective analysis of breast cancer patients revealed that MCJ expression
correlated with increased responses to neoadjuvant therapy (FernandezCabezudo et al., 2016). In addition, higher levels of DNAJC15 methylation
correlated with poor responses to chemotherapy and reduced long term survival
in ovarian cancer patients (Strathdee et al., 2005). While the exact mechanism(s) are
unclear, loss of MCJ correlates with increased expression of ATP binding cassette
(ABC) transporters (Hatle et al., 2007). The mechanistic connection between the
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regulation of mitochondrial metabolism by MCJ and ABC transporter mediated
chemoresistance is addressed later in this dissertation (CHAPTER 3).
4.6.5. Other potential functions
MCJ has been reported to affect the import of mitochondrial proteins
(Schusdziarra et al., 2013; Sinha et al., 2014). The import of nuclear encoded
proteins into mitochondria is facilitated by the translocase of the inner membrane
(TIM), formed by the association of the TIM22 complex at the inner membrane and
TIM23 complex in the matrix (Dudek et al., 2013). Protein transport requires the
function of DNAJC19 in yeast (Mokranjac et al., 2003), therefore a potential role for
MCJ was investigated as they share similar evolutionary origins as described
previously (§4.3). MCJ was shown to interact with and stimulate regulators of the
TIM23 complex in cell free assays, however the loss of MCJ was dispensable for
import in whole cells (Schusdziarra et al., 2013; Sinha et al., 2014). MCJ is therefore
nonessential for mitochondrial protein import in intact cells.
MCJ has also been reported to influence the activity of the mitochondrial
permeability transition pore (MPTP) (Sinha and D'Silva, 2014). Mitochondria have
a significant role in the induction of apoptosis via the release of factors through
the MPTP complex, of which expression and increased activity are promoted by
cell death stimuli (Bonora and Pinton, 2014). While the molecular components and
regulators of the MPTP complex are still a matter of debate, peptidylprolyl
isomerase D (also called cyclophilin D or CypD) is a known essential activator
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(Baines and Gutierrez-Aguilar, 2018). MCJ have been shown to directly interact
with CypD and recruits it to the MPTP complex, which thereby enhances MPTP
activity in response to cisplatin treatment (Schusdziarra et al., 2013). However,
these studies were performed using overexpression systems that, as described
previously (§4.5), can dysregulate the localization of MCJ and mitochondrial
morphology. Thus, further studies on the potential role of MCJ in the MPTP
complex are needed.
5. Specific aims of this dissertation
5.1. Aim 1
Determine the role of MCJ in CD8+ T cell immune responses. MCJ is a negative
regulator of Complex I activity that is abundantly expressed by CD8+ T cells
relative to other leukocytes (Hatle et al., 2013; Navasa, Martin, et al., 2015). As such,
loss of MCJ expression in these cells leads to increased mitochondrial respiration,
including higher membrane potential (Hatle et al., 2013). However, the impact of
these changes on the immune function of CD8+ T cells was unknown. The goal of
this aim was to determine how the regulation of mitochondria by MCJ influences
the development, activation, proliferation, and effector functions of CD8+ T cells
in the context of viral immunity.
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5.2. Aim 2
Determine the role of MCJ in maintenance or induction of chemoresistance.
Decreased MCJ expression in cancer cells is correlated with a chemoresistant
phenotype and poor patient responses to chemotherapy (Fernandez-Cabezudo et
al., 2016; Hatle et al., 2007; Strathdee et al., 2005). This has been attributed to
increased ABC transporter expression in the absence of MCJ (Hatle et al., 2007),
however the mechanistic connection to chemoresistance was unclear. The goal of
this aim was to address how increased mitochondrial respiration due to MCJ
deficiency in cancer leads to chemoresistance.
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1. Summary
Mitochondrial respiration is regulated in CD8+ T cells during the transition
from naive to effector and memory cells, but mechanisms controlling this process
have not been defined. Here we show that MCJ (methylation-controlled J protein)
acted as an endogenous break for mitochondrial respiration in CD8+ T cells by
interfering with the formation of electron transport chain respiratory
supercomplexes.

Metabolic

profiling

revealed

enhanced

mitochondrial

metabolism in MCJ-deficient CD8+ T cells. Increased oxidative phosphorylation
and subcellular ATP accumulation caused by MCJ deficiency selectively increased
the secretion, but not expression, of interferon-g. MCJ also adapted effector CD8+
T cell metabolism during the contraction phase. Consequently, memory CD8+
T cells lacking MCJ provided superior protection against influenza virus infection.
Thus, MCJ offers a mechanism for fine-tuning CD8+ T cell mitochondrial
metabolism as an alternative to modulating mitochondrial mass, an energetically
expensive process. MCJ could be a therapeutic target to enhance CD8+ T cell
responses.
2. Introduction
Metabolism is emerging as a major factor that regulates the function and
differentiation of immune cells and influences the course of an immune response
(Pearce et al., 2013; van der Windt and Pearce, 2012; Wang and Green, 2012). Naive,
effector, and memory T cell subsets have distinct metabolic profiles to provide the
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energy and bioenergetic precursors required for cell growth and expansion. Naive
cells use glucose and free fatty acids (FFA) as sources of ATP through
mitochondrial oxidative phosphorylation (OXPHOS) (van der Windt et al., 2012;
Wang et al., 2011). After activation, CD8+ T cells undergo a metabolic
reprograming and switch to glycolysis as a source of ATP. Effector T cells can also
use glutamine to generate ATP through glutaminolysis, which can further fuel
OXPHOS (Carr et al., 2010; Wang et al., 2011). Proliferation of effector CD8+ T cells
appears to be more dependent on glucose than effector CD4+ T cells (Frauwirth et
al., 2002; Macintyre et al., 2011). In contrast, production of some cytokines by
effector CD8+ T cells is not affected by a strong inhibition of glycolysis (Cham et
al., 2008), and cytotoxic activity can occur in the absence of glucose (MacDonald
and Koch, 1977).
Effector CD8+ T cells further reprogram metabolism during memory cell
generation in response to antigen and cytokine withdrawal. Memory CD8+ T cells
primarily use FFA oxidation in mitochondria as the main energy pathway (Araki
et al., 2009; Pearce et al., 2009; van der Windt et al., 2012). Additionally, memory
CD8+ T cells manifest a greater increase in both OXPHOS and aerobic glycolysis
following activation compared with naive cells, and the induction of glycolysis is
dependent on mitochondrial ATP (van der Windt et al., 2013). Importantly,
intervention of metabolism with metformin (AMPK activator) or rapamycin
(mTOR inhibitor) to promote FFA oxidation enhances the generation of memory
CD8+ T cells and protection against viral infection (Araki et al., 2009; Pearce et al.,
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2009). A recent study revealed that memory CD8+ T cells have developed their
own intrinsic pathways to mobilize fatty acids for oxidation (Pearce et al., 2009).
Considering this highly dynamic metabolic reprogramming, CD8+ T cells likely
utilize specific checkpoints to regulate these transitions and their effector
functions. However, while a number of studies have addressed the effect of
different metabolic substrates that fuel the mitochondrial electron transport chain
(ETC), little is known about endogenous mechanisms that control mitochondrial
respiration and, thereby, the immune response.
Methylation controlled J protein (MCJ), a protein encoded by the DNAJC15
gene, is a member of the DnaJ family of chaperones. MCJ is a small protein with
features that distinguish it from other DnaJ family members. While most DnaJ
family members are soluble proteins, MCJ contains a transmembrane domain and
has a unique N-terminal domain that shares no significant sequence similarity
with any other known protein. MCJ was first reported in ovarian cancer cells as a
gene negatively regulated by methylation (Shridhar et al., 2001; Strathdee et al.,
2004). Loss of MCJ is associated with chemoresistance of human breast and
ovarian cancer cell lines (Hatle et al., 2007; Shridhar et al., 2001; Strathdee et al.,
2005). We recently showed that MCJ is abundantly expressed primarily in tissues
with a highly active mitochondrial metabolism, including heart and liver (Hatle et
al., 2013). Within the immune system, MCJ is highly expressed in CD8+ T cells, but
not in CD4+ T and B cells (Hatle et al., 2013), and less in macrophages (Navasa,
Martin, et al., 2015). Importantly, MCJ localizes to the inner membrane of
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mitochondria (Hatle et al., 2013; Schusdziarra et al., 2013) and acts as a negative
regulator of the ETC. MCJ deficiency in vivo results in increased complex I activity
and mitochondrial membrane potential (MMP) without affecting mitochondrial
mass (Hatle et al., 2013). Endogenous MCJ in primary tissues associates with
complex I and acts as a natural inhibitor, making MCJ one of the first described
endogenous negative regulators of complex I. The activity of complex I is
enhanced by assembly in ‘‘respirasomes,’’ which are mitochondrial ETC
supercomplexes containing complexes I, III, and IV (Acin-Perez et al., 2008).
Supercomplexes facilitate efficient transfer of electrons to enhance complex I
activity and minimize electron ‘‘leak’’ that results in ROS production (MorenoLastres et al., 2012). We have shown that MCJ interferes with the formation of these
supercomplexes in heart (Hatle et al., 2013), a mechanism to inhibit complex I
activity and MMP.
Although MCJ is abundantly present in CD8+ T cells, its role in regulating
mitochondrial metabolism and function of these cells is unknown. Here, we show
that MCJ acts a negative regulator of mitochondrial respiration in CD8+ T cells.
MCJ deficiency did not affect proliferation of naive CD8+ T cells upon activation,
nor activation marker or cytokine gene expression. However, increased OXPHOS
in MCJ-deficient CD8+ T cells enhanced the secretion of cytokines and sustained
the metabolic state of effector CD8+ T cells during the contraction phase. MCJdeficient memory CD8+ T cells had greater protective capacity against influenza

101

virus infection. Therefore, MCJ is emerging as an important negative regulator of
mitochondrial activity of CD8+ T cells.
3. Results
3.1. Loss of MCJ Promotes Respiratory Supercomplexes and Mitochondrial
Metabolism in Naive CD8+ T cells
To investigate the role of MCJ in CD8+ T cell development and function, we
used MCJ-deficient mice previously described to have no obvious phenotypic
alterations under physiological conditions (Hatle et al., 2013). Although CD8+ T
cells freshly isolated from MCJ-deficient mice display higher mitochondrial
membrane potential (MMP) (Supplementary Figure 2-1A), there was no difference
in the percentage (Supplementary Figure 2-1B) or number (data not shown) of
CD8+ or CD4+ T cells in the spleen and lymph nodes (LN) of WT and MCJ-deficient
mice. No difference in the expression of activation markers such as CD44 was
observed (Supplementary Figure 2-1C). The percentage (Supplementary Figure
2-1B) and number (data not shown) of single-positive, double-positive (DP), or
double-negative (DN) populations in the thymus were also comparable. Thus,
MCJ deficiency does not affect the development of CD8+ and CD4+ T cells in the
thymus or homeostasis in the periphery.
MMP is the driver for oxidative phosphorylation (OXPHOS), generation of
ATP, and oxygen consumption. To investigate the impact that increased MMP in
MCJ-deficient CD8+ T cells has on mitochondrial respiration, we examined the
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oxygen consumption rate (OCR) in freshly isolated CD8+ T cells using the Seahorse
MitoStress assay. Correlating with the increased MMP, OCR was also elevated in
MCJ-deficient CD8+ T cells compared with WT CD8+ T cells (Figure 2-1A). In
contrast, the extracellular acidification rate (ECAR), a parameter for glycolysis,
was not affected in MCJ-deficient CD8+ T cells (Figure 2-1B). Mitochondrial ATP
production, determined by subtracting the OCR in the presence of oligomycin
(Complex V/ATP Synthase inhibitor) from the OCR at baseline, was also higher
in MCJ-deficient CD8+ T cells (Figure 2-1C). Thus, MCJ is a negative regulator of
mitochondrial respiration in CD8+ T cells.
To identify the impact of MCJ on the overall metabolism of naive CD8+
T cells,

we

performed

nonbiased

high-throughput

metabolic

profiling.

Metabolome analysis of CD8+ T cells freshly isolated from WT and MCJ-deficient
mice showed a large number of metabolic intermediates from different pathways
equally present in both (Supplementary Table 2-1). However, there was a
significant increase in the amounts of several amino acids in MCJ-deficient CD8+
T cells (Figure 2-1D). Most of the amino acids that were significantly elevated
belonged to the essential amino acid group (Figure 2-1D). In contrast, only tyrosine
in the conditionally essential amino acid group and asparagine in the non-essential
group were significantly increased (Figure 2-1D).
The preferential accumulation of amino acids that need to be imported
suggested a greater amino acid transport occurred in the absence of MCJ. Since
amino acid transport is highly dependent on ATP, increased mitochondrial
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OXPHOS due to MCJ deficiency could be responsible for this transport. To
investigate this, we incubated freshly isolated CD8+ T cells in culture medium.
After 16 hours, the metabolic profile of the culture supernatants was analyzed to
determine the amino acid consumption. The amounts of amino acids were
significantly reduced in the culture supernatant of MCJ-deficient CD8+ T cells
(Figure 2-1E). In addition, metabolic flux analyses with 13C- and 15N-labeled amino
acids showed increased uptake of extracellular [13C, 15N]-glutamine (Figure 2-1D).
Thus, the increased mitochondrial respiration resulting from MCJ deficiency in
naive CD8+ T cells in vivo promotes amino acid uptake.
The other metabolite significantly increased in MCJ-deficient CD8+ T cells
was succinate (Figure 2-1F and Supplementary Table 2-1), which is oxidized to
fumarate by succinate dehydrogenase (ETC complex II) in the TCA cycle.
However, the amounts of fumarate and the other components of the TCA cycle
were not different (Figure 2-1F). These results suggested that elevated succinate in
MCJ-deficient CD8+ T cells was the result of impaired complex II activity. Indeed,
reduced complex II activity was found in freshly isolated MCJ-deficient CD8+
T cells as measured by OCR in response to succinate using a Seahorse Extracellular
Flux analyzer (Figure 2-1G). In addition, metabolic flux analyses of freshly isolated
CD8+ T cells incubated with 13C- and 15N-labeled amino acids revealed an increase
in newly synthesized succinate, but not fumarate (the product of complex II), in
MCJ-deficient CD8+ T cells (Figure 2-1H). Thus, complex II appears to be
uncoupled from the rest of the ETC in MCJ-deficient CD8+ T cells.
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We have shown that the absence of MCJ in heart favors the accumulation
of mitochondrial respiratory supercomplexes (Hatle et al., 2013), composed of
complexes I, III, and IV, but not complex II. To investigate whether
supercomplexes were increased in naive MCJ-deficient CD8+ T cells, we generated
mitochondrial extracts with digitonin to preserve supercomplexes and resolved
them by blue native electrophoresis (BNE) as previously described (Yang et al.,
2015). The supercomplex region was excised, resolved by SDS-PAGE, and
analyzed by Western blot for subunits of complexes I (NDUFA9) and IV (CoxIV).
The amount of supercomplexes were higher in MCJ-deficient CD8+ T cells (Figure
2-1I). Monomeric complex IV analyzed as a control and was not different (Figure
2-1I). To further support the accumulation of supercomplexes in MCJ-deficient
CD8+ T cells, we resolved mitochondrial extracts by BNE, followed by immunoblot
analysis for subunits of complexes I (NDUFA9) and III (Core1). Increased
NDUFA9 amounts were present in the supercomplex region in MCJ-deficient
CD8+ T cells, while the amounts of NDUFA9 in the monomeric complex I region
were comparable between MCJ-deficient and WT cells (Figure 2-1J). Similar results
were obtained for Core1 (Figure 2-1J). Thus, loss of MCJ promotes the formation
of respiratory supercomplexes in naive CD8+ T cells. Uncoupling complex III from
complex II could compromise complex II activity and cause the observed
accumulation of succinate. Together, these results indicate that the function of MCJ
in naive CD8+ T cells is to restrict mitochondrial metabolism, and a deficiency in
MCJ alters normal mitochondrial metabolism.
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Figure 2-1. MCJ Restrains Mitochondrial Respiration in Naive
CD8+ T Cells
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(A) Baseline OCR, (B) ECAR, and (C) OCR linked to mitochondrial ATP
production (baseline OCR minus OCR in the presence of oligomycin) of freshly
isolated cells as determined by MitoStress (A and C) or Glycolysis Stress assays
(B). (D and F) Metabolic profiles of cells were determined by UPLC-MS analysis.
Relative amounts of (D) amino acids and (F) TCA cycle metabolites. (E) Equal
numbers of cells were incubated in culture medium for 16 hours, and metabolic
profiles of the culture supernatants were determined. (G) Complex II activity was
determined by examining OCR at baseline and in the response to succinate with
rotenone (Succ + Rote) and malonate. (H) Cells were cultured with 13C- and
15N-labeled amino acids, and metabolic flux was determined by UPLC-MS
analysis. 13C-succinate and 13C-fumarate peak areas shown. (I and J) Mitochondrial
extracts were resolved by BNE. (I) Bands corresponding to supercomplexes (SC)
or monomeric complex IV were excised, resolved by SDS-PAGE, and examined by
Western blot analysis for NDUFA9 (complex I) and CoxIV (complex IV). (J)
Proteins separated by BNE were examined by Western blot analysis for NDUFA9
and Core1 (complex III). Bands corresponding to supercomplexes (SC) and
monomeric complexes I (CI) and III (CIII) regions of the Western blot shown.
*p < 0.05 by unpaired t test. Avg ± SD (n ³ 3) shown. Results are representative of
2 - 3 experiments. See also Supplementary Figure 2-1 and Supplementary Table
2-1.

3.2. MCJ Deficiency Does Not Affect Proliferation, but Enhances the Secretion
of Cytokines in Activated CD8+ T cells
We investigated whether the enhanced mitochondrial metabolism found in
MCJ-deficient CD8+ T cells could alter proliferation. Freshly isolated CD8+ T cells
were stained with CFSE and activated with anti-CD3 and anti-CD28 antibodies,
and proliferation was analyzed by flow cytometry. No differences were observed
in the frequency of proliferating cells or number of cell divisions (Figure 2-2A), the
survival of cells after 2 days of activation (Figure 2-2B), or expression of the cell
surface activation markers CD69 and CD25 (Figure 2-2C). In contrast, greater
IFN-g (Figure 2-2D) and IL-2 (Figure 2-2E) production was detected in activated
MCJ-deficient CD8+ T cells as determined by ELISA. Thus, loss of MCJ does not
interfere with activation or expansion of CD8+ T cells, but results in a greater
production of cytokines.
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Production of cytokines by CD8+ T cells upon activation is primarily
regulated at the level of gene expression either by transcription or mRNA stability.
However, analysis of cytokine mRNA by quantitative RT-PCR showed no
difference in the amounts of IFN-g and IL-2 mRNA between activated MCJdeficient and WT CD8+ T cells (Figure 2-2F). Thus, MCJ had no effect on cytokine
gene expression in CD8+ T cells. A recent study reported that aerobic glycolysis
promotes IFN-g production at the translational level in effector CD4+ T cells
(Chang et al., 2013). However, intracellular staining analysis for IFN-g showed no
difference between WT and MCJ-deficient CD8+ T cells (Figure 2-2G). Similarly,
there was no difference in IL-2 intracellular staining (Figure 2-2G). Thus, the
increased amounts of cytokines in MCJ-deficient CD8+ T cell supernatants were
not due to increased gene or protein expression.
Secretion of cytokines is another mechanism that regulates the overall
amount of cytokines being produced, although little is known about the pathways
involved. To investigate whether the increased IFN-g in the supernatants of MCJdeficient CD8+ T cells was caused by enhanced secretion, we activated CD8+ T cells
with anti-CD3 and anti-CD28 antibodies for 2 days, washed, and then incubated
equal numbers of cells in medium alone without any additional stimuli for
different periods of time. IFN-g in the supernatants from MCJ-deficient CD8+
T cells after 2 hours was higher than WT CD8+ T cells (Figure 2-2H). IFN-g in MCJdeficient CD8+ T cell supernatants continued increasing for at least 4 hours and
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then remained constant, while the amount secreted by WT CD8+ T cells did not
increase (Figure 2-2H). Treatment with cycloheximide (CHX), an inhibitor of
protein synthesis, did not affect the IFN-g produced during this period
(Supplementary Figure 2-2A), although CHX prevented new protein synthesis
triggered by the activation of naive CD8+ T cells (Supplementary Figure 2-2B).
These results further support the conclusion that increased protein translation was
most likely not the primary cause of enhanced IFN-g production by MCJ-deficient
CD8+ T cells. IL-2 and GM-CSF were also elevated in the supernatant of MCJdeficient CD8+ T cells after 4 hours (Supplementary Figure 2-2C), indicating that
the effect of MCJ on secretion is not restricted to IFN-g. To further confirm the
enhanced capacity of secretion by MCJ-deficient CD8+ T cells, we performed
ELISpot assays for IFN-g. The number of spots with a larger area (high IFN-g
producers) was increased in MCJ-deficient CD8+ T cells (Figure 2-2I). Enhanced
secretion should result in lower accumulation of intracellular IFN-g if no
additional synthesis takes place. Intracellular staining for IFN-g after activated
cells were washed and incubated in medium alone showed lower IFN-g in MCJdeficient CD8+ T cells after 1 hour (Supplementary Figure 2-2D). Together these
results indicate that MCJ deficiency augments cytokine production primarily by
promoting the cytokine secretion capacity of effector CD8+ T cells.
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Figure 2-2. MCJ Deficiency Does Not Affect Effector CD8+ T Cell
Proliferation but Increases the Secretion of Cytokines
WT (blue) and MCJ-deficient CD8+ T cells (MCJ def, red) were activated for 2 days
with anti-CD3 and anti-CD28 antibodies. (A) Proliferation determined by CFSE
staining. Grey histograms show unstimulated cells. (B) Cell survival determined
by Live Dead staining. (C) Cell surface expression of CD69 and CD25. Grey
histograms show unstained cells. (D and E) Culture supernatants of activated cells
were examined for (D) IFN-g and (E) IL-2 by ELISA. (F) IL-2 and IFN-g mRNA
expression determined by qRT-PCR. (G) Intracellular staining for IFN-g and IL-2.
Champagne
et al. Figure
2
Grey histograms show unstained cells. (H) Activated cells
were washed
and
replated at equal numbers in medium alone. IFN-g in the culture supernatants over
time was determined by ELISA. (I) Number of IFN-g producing cells determined
by ELISpot assay. *p < 0.05 by unpaired t test. Avg ± SD (n ³ 3) shown. Results are
representative of 2 – 3 experiments. See also Supplementary Figure 2-2.
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3.3. Localized Mitochondrial Production of ATP in the Absence of MCJ
Promotes Cytokine Secretion
We used an unbiased metabolomics approach to investigate which
metabolic pathways were regulated by MCJ in effector CD8+ T cells. Metabolic
profiling was obtained from equal numbers of WT and MCJ-deficient CD8+ T cells
after 2 days of activation and 4 hours of resting. Although no obvious phenotypic
differences in terms of size or activation markers could be detected between the
cell types, MCJ deficiency caused well-defined metabolic changes (Supplementary
Table 2-2). Similar to naive CD8+ T cells, the absence of MCJ in activated CD8+
T cells resulted in increased amounts of amino acids, but this increase was not
restricted to essential amino acids (Figure 2-3A). In addition, a number of
intermediate metabolites of the TCA and urea cycle pathways, two of the main
mitochondrial pathways, were among the most elevated components in activated
MCJ-deficient CD8+ T cells relative to WT CD8+ T cells (Supplementary Table 2-2).
Similar to naive CD8+ T cells, succinate was also drastically increased in activated
MCJ-deficient CD8+ T cells, but fumarate, malate, and 2-hydroxyglutarate were
also higher (Figure 2-3B). Citrulline and arginosuccinate, components of the urea
cycle, were also increased (Figure 2-3C). Although there was no difference in
proliferation, nucleotide pathways were also upregulated in the absence of MCJ
(Figure 2-3D). Nucleotide synthesis is primarily cytosolic, however mitochondrial
metabolic pathways feed into these pathways, as purine salvage reactions
consume aspartate to produce fumarate and recover AMP upon deamination to
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IMP. Thus, an unbiased metabolic screening revealed increased mitochondrial
activity in MCJ-deficient effector CD8+ T cells.
Effector CD8+ T cells are primarily glycolytic and use ATP from glycolysis
instead of mitochondrial OXPHOS as the major source of energy. Because the
absence of MCJ enhances overall mitochondrial activity, we examined
intracellular ATP. Higher amounts of total ATP were present in MCJ-deficient
CD8+ T cells that were activated for 2 days and rested for 4 hours (Figure 2-4A).
To determine whether this increased production of ATP resulted from increased
mitochondrial respiration, we performed Seahorse MitoStress analysis. OCR was
higher in activated MCJ-deficient CD8+ T cells, as shown by the effect of
oligomycin on baseline OCR (Figure 2-4B). These data indicate that the rate of ATP
synthesis by mitochondria was increased in the absence of MCJ. In contrast,
analysis of ECAR in response to glucose showed no difference between the two
cell types (Figure 2-4C). Thus, loss of MCJ promotes mitochondrial respiration
without altering the glycolytic rate of effector CD8+ T cells.
The normal rate of glycolysis as determined by ECAR analysis correlated
with the normal rate of proliferation and gene expression observed in MCJdeficient CD8+ T cells. While glycolysis-derived ATP represents the predominant
source of energy and is sufficient for these processes in activated cells,
mitochondrial derived ATP could be essential for other CD8+ T cell functions such
as cytokine secretion. Due to the dynamic characteristics of mitochondria, this
organelle could provide a subcellular microenvironment rich in ATP without the
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need to raise total cytosolic ATP. We investigated the presence of ATP-rich
microdomains within activated CD8+ T cells using a fluorescent probe used to
identify ATP and ADP intracellular accumulation. Confocal microscopy of live
cells showed only a few punctate ATP probe accumulations in activated WT CD8+
T cells, while ATP puncta were abundant and prominent in MCJ-deficient CD8+
T cells (Figure 2-4D). The subcellular ATP accumulation in MCJ-deficient CD8+
T cells represented the mitochondrial derived ATP pool since treatment with
oligomycin prevented their formation (Supplementary Figure 2-3A). Moreover,
costaining with the ATP probe and Mitotracker, a mitochondrial marker, revealed
colocalization of the ATP puncta with mitochondria in activated MCJ-deficient
CD8+ T cells (Figure 2-4E). Thus, MCJ deficiency facilitates the formation of ATPrich microdomains within activated CD8+ T cells.
To address whether the increased secretion of IFN-g found in MCJ-deficient
CD8+ T cells was mediated by increased mitochondrial ATP production, we
activated CD8+ T cells for 2 days and treated them with oligomycin during the last
4 hours of activation. Cells were then washed and incubated at equal numbers in
medium alone for 4 hours. IFN-g in the supernatants was determined by ELISA.
Inhibition of mitochondrial ATP synthesis by oligomycin suppressed the
enhanced secretion of IFN-g by MCJ-deficient CD8+ T cells (Figure 2-4F). In
contrast, oligomycin did not reduce intracellular IFN-g (Supplementary Figure
2-3B). Thus, MCJ acts as an endogenous negative regulator of mitochondrial
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respiration, restricting the production of mitochondrial ATP and secretion of
cytokines such as IFN-g.
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Figure 2-3. MCJ Deficiency Enhances Mitochondrial Metabolism in
Effector CD8+ T Cells
(A – D) WT (blue) and MCJ-deficient (MCJ def, red) CD8+ T cells were activated
for 2 days with anti-CD3 and anti-CD28 antibodies, and metabolic profiles were
determined by UPLC-MS. Relative peak areas of (A) amino acids and metabolites
of the (B) TCA cycle, (C) urea cycle, and (D) nucleotide pathways shown. *p < 0.05
by unpaired t test. Avg ± SD shown (n = 3 mice). See also Supplementary Table
2-2.
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Figure 2-4 Increased Oxidative Phosphorylation in MCJ-Deficient
Effector CD8+ T Cells Facilitates IFN-g Secretion
WT (blue) and MCJ-deficient CD8+ T cells (MCJ def, red) were activated with antiCD3 and anti-CD28 antibodies for 2 days. (A) ATP concentration in cells rested in
medium without stimuli for 4 hours. (B) OCR of cells rested for 12 hours at baseline
and in response to oligomycin (O), FCCP (F), and rotenone with antimycin (R+A)
by Seahorse MitoStress assay. (C) ECAR in cells after addition of glucose by
Seahorse Glycolysis Stress assay. (D) Live cells stained with ATP probe (green)
were visualized by confocal microscopy. Right panels show a magnification of the
cells indicated by the white arrows. (E) Live cells costained with ATP probe (green)
and Mitotracker (red) were visualized by confocal microscopy. (F) Cells were
incubated with oligomycin during the last 4 hour of activation and then rested for
4 hours. IFN-g in the supernatants was determined by ELISA. *p < 0.05 by
unpaired t test. Avg ± SD (n ³ 3) shown. Scale bar represents 10 nm. Results are
representative of 2–3 experiments. See also Supplementary Figure 2-3.
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4
3.4. MCJ Attenuates Mitochondrial Metabolism duringChampagne
the Contraction
of Effector CD8+ T cells In Vivo

CD8+ T cells reprogram their mitochondrial metabolism during the
differentiation from naive to effector and from effector to memory stages. Memory
CD8+ T cells also have greater mitochondrial mass and maximum respiratory
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capacity (van der Windt et al., 2012). Because MCJ acts as an internal break for
mitochondrial function in tissues with a high content of active mitochondria, we
investigated MCJ expression during the contraction phase of effector CD8+ T cells.
To examine MCJ expression in individual cells, we used MCJ-deficient mice
because they contain a b-galactosidase reporter gene inserted in the MCJ locus,
while WT CD8+ T cells served as negative controls (Supplementary Figure 2-3C).
We performed b-galactosidase activity assays by flow cytometry analysis in CD8+
T cells that were freshly isolated, activated (effector), and rested in medium alone
after activation (rested effector) to mimic the contraction phase of effector cells and
development of memory cells. The frequency of MCJ expressing cells was
dramatically decreased in effector cells relative to naive cells (Figure 2-5A). We
recently showed that Ikaros, a transcriptional repressor known to attenuate gene
expression (John and Ward, 2011), binds the DNAJC15 gene (encodes MCJ)
promoter in macrophages to silence MCJ expression (Navasa, Martin-Ruiz, et al.,
2015). Because Ikaros has been previously reported in CD8+ T cells (O'Brien et al.,
2014), we performed chromatin immunoprecipitation analysis (ChIP) to determine
whether Ikaros also binds the DNAJC15 promoter in CD8+ T cells. Relative to
naive CD8+ T cells, greater Ikaros binding to the DNAJC15 promoter was found in
activated CD8+ T cells (Figure 2-5B). Thus, MCJ is present in naive CD8+ T cells as
an additional checkpoint to restrict potential effector function.
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The frequency of CD8+ T cells expressing MCJ increased again when
effector cells were rested in the presence of medium without additional stimuli
(Figure 2-5A). During the contraction phase, effector CD8+ T cells modulate their
metabolism, become smaller and less active, and most die except for a few that
survive to become memory cells (D'Cruz et al., 2009). We examined whether the
observed reacquisition of MCJ in resting effector CD8+ T cells contributed to the
attenuation of metabolism or cell survival in vitro during the contraction phase.
CD8+ T cells were activated for 2 days, washed, and then incubated in medium
alone (without addition of cytokines). After 24 hours of resting, most WT and MCJdeficient CD8+ T cells remained alive (Figure 2-5C). However, after 48 hours only
a few WT CD8+ T cells remained alive, whereas many MCJ-deficient CD8+ T cells
were still viable even at 72 hours (Figure 2-5C). In addition, the surviving MCJdeficient CD8+ T cells maintain the ‘‘blastic cell stage’’ (large) reminiscent of
effector cells (data not shown). Analysis of MMP in live cells after 48 hours of
resting showed that a high proportion of WT CD8+ T cells had low MMP (Figure
2-5D), similar to naive CD8+ T cells (Supplementary Figure 2-1A). In contrast, a
large fraction of rested effector MCJ-deficient CD8+ T cells displayed high MMP
(Figure 2-5D). To determine whether the increased survival in rested MCJdeficient CD8+ T cells in vitro was due to their intrinsic metabolic state (high MMP)
or due to increased IL-2 production that can promote cell expansion, a blocking
anti-IL-2 antibody was added during the resting period. No differences were
detected in the survival of MCJ-deficient CD8+ T cells after blocking IL-2
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(Supplementary Figure 2-3D). Furthermore, the addition of small amounts of
recombinant IL-2 during the resting period resulted in increased expansion of both
WT and MCJ-deficient CD8+ T cells (Supplementary Figure 2-3E). Thus,
reacquisition of MCJ in rested effector CD8+ T cells contributes to the reduction of
mitochondrial activity, restoration of a quiescent metabolic state and fitness
impairment of effector CD8+ T cells during the contraction phase in vitro.
To address the role of MCJ in the contraction phase of antigen specific
effector CD8+ T cells in vivo, we crossed MCJ-deficient mice with OT-I TCR
transgenic mice, which express a TCR that recognizes ovalbumin. MCJ deficiency
did not affect the development of OT-I CD8+ T cells (Supplementary Figure 2-4A).
Similar to polyclonal CD8+ T cells, naive MCJ-deficient OT-I CD8+ T cells also
displayed high MMP relative to WT CD8+ T cells (Figure 2-5E). CD8+ T cells were
purified from OT-I and MCJ-deficient OT-I mice, activated for 2 days in vitro, and
then further expanded for 3 days. An equal number of cells from each genotype
were combined and cotransferred into the same WT recipient mice (Figure 2-5F).
After 2 weeks, donor cells present in LN and spleen of host mice were examined
by flow cytometry using CD90.1 and CD90.2 markers (Supplementary Figure 2-4B
and C). Phenotypic characterization of the cells based on CD44 and CD62L
(memory and homing markers) as well as KLRG1 and CD127 (markers that define
subsets of long lived effector and memory T cells (Jameson and Masopust, 2009;
Kaech and Wherry, 2007; Sarkar et al., 2008)) did not show differences between WT
and MCJ-deficient CD8+ OT-I T cells (Supplementary Figure 2-4B and C). The
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overall percentage of cell recovery in both donors was comparable (data not
shown). However, as determined by forward scatter (Figure 2-5G), only a few WT
OT-I CD8+ T cells showed a large blastic phenotype (Figure 2-5H). In contrast, a
greater fraction of MCJ-deficient OT-I CD8+ T cells displayed the large blastic
phenotype (Figure 2-5H). Thus, in vivo MCJ does not seem to contribute to cell
survival but does participate in the attenuation of metabolism during the
transition from effector to rested effector cells.
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Figure 2-5. MCJ Deficiency Sustains the Metabolic Activity of
Effector CD8+ T Cells during the Contraction Phase
WT (blue) and MCJ-deficient CD8+ T cells (MCJ def, red). (A) Frequency of
b-galactosidase+ MCJ-deficient CD8+ T cells that were naive, activated for 2 days
with anti-CD3 and anti-CD28 antibodies, or activated for 2 days and then rested
in medium without stimuli for 48 hours (2 d + 48 h) or 72 hours (2 d + 72 h) as
Champagne et al. Figure 5
determined by flow cytometry analysis. (B) Ikaros binding to the DNAJC15 gene
(encodes MCJ) promoter in naive and activated (2 days) cells by ChIP assay. Fold
increase over rabbit IgG immunoprecipitates relative to input shown. (C) Cells
were activated for 2 days, washed, and rested in medium. The number of live cells
recovered relative to the initial number is shown. (D) MMP was examined by
TMRE staining in cells activated for 2 days and rested for 48 hours. (E) MMP in
freshly isolated OT-I and MCJ-deficient OT-I CD8+ T cells. (F – H) OT-I (CD90.1+)
and MCJ-deficient OT-I (CD90.1+ CD90.2+) CD8+ T cells were activated for 2 days
and then expanded with IL-2 for 3 days. Equal numbers of each cell type were then
adoptively transferred into WT (CD90.2+) recipient mice. LN and spleen of
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recipients were harvested after 2 weeks and analyzed for donor cells. (G and H)
Forward scatter of CD8+ OT-I T cells as determined by flow cytometry analysis.
*p < 0.05 by unpaired t test. Avg ± SD (n ³ 3) shown. Results are representative of
2 – 3 experiments. See also Supplementary Figure 2-3 and Supplementary Figure
2-4.

3.5. MCJ Deficiency Enhances the Antiviral Protective Activity of Memory CD8+
T cells
Memory CD8+ T cells are believed to play an important role in protection
against influenza viral infection (La Gruta and Turner, 2014). Recent studies
indicate that increased mitochondrial respiration in CD8+ T cells results in
increased memory activity (van der Windt et al., 2013). We investigated the role of
MCJ in protective memory CD8+ T cell responses using an influenza virus
infection model. WT and MCJ-deficient mice were intranasally infected with a
sublethal dose of influenza A/Puerto Rico/8/34 (PR8) H1N1 virus. As expected,
based on the predominant role of innate immunity in primary infection with
influenza virus, no significant differences were observed in weight loss and
recovery or survival between infected WT and MCJ-deficient mice during primary
infection (Figure 2-6A). Analysis of influenza NP-tetramer+ CD8+ T cells 2 weeks
post-infection also showed a similar frequency between infected WT and MCJdeficient mice (Figure 2-6B), indicating that the loss of MCJ did not affect the
expansion of effector CD8+ T cells in vivo, consistent with the in vitro studies.
However, ex vivo analysis of IFN-g production by CD8+ T cells showed higher
IFN-g in the supernatants of MCJ-deficient CD8+ T cells (Figure 2-6C). Thus, MCJ
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deficiency results in increased IFN-g production by effector CD8+ T cells in vivo
during virus infection.
We then addressed whether the lack of MCJ could affect memory CD8+
T cell development. Analysis of influenza NP-tetramer+ CD8+ T cells 3 and 5 weeks
post-infection showed a lower percentage relative to 2 weeks post-infection as
expected, but there was no difference in the frequency between WT and MCJdeficient mice (Figure 2-6B and Supplementary Figure 2-5A). This further
supported the finding that lack of MCJ does not affect cell survival during the
generation of memory CD8+ T cells from effector cells in vivo. Phenotypic analysis
of NP-tetramer+ CD8+ T cells for CD44, CD62L, KLRG1, and CD127 showed no
substantial

difference

between

WT

and

MCJ-deficient

CD8+

T

cells

(Supplementary Figure 2-5B and data not shown). Lower CD27 expression was
found in the MCJ-deficient CD8+ T cell memory population (Supplementary
Figure 2-5B). CD27low memory cells mediate rapid protective immunity against
acute infection and manifest high cytolytic activity (Olson et al., 2013).
To investigate the protective capacity of memory MCJ-deficient CD8+
T cells, we performed adoptive transfer of equal numbers WT and MCJ-deficient
CD8+ T cells obtained 5 weeks post-infection separately into WT recipient mice.
Recipient mice were then infected with a lethal dose of PR8 virus. As expected,
recipient mice that received cells from infected WT mice were not protected, did
not recover their weight, and died between 8 and 9 days post lethal infection
(Figure 2-6E and F). In contrast, most recipient mice that received cells from
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infected MCJ-deficient mice were protected and survived (Figure 2-6E). Mice
receiving MCJ-deficient CD8+ T cells lost weight initially, indicating that they had
been infected, but they recovered to a healthy state (Figure 2-6F). Thus, the absence
of MCJ in memory CD8+ T cells confers greater protective capacity against
influenza virus infection.
Death caused by some of the highly pathogenic influenza viruses (such as
H5N1 influenza) is often associated with a strong systemic immune response and
cytokine storm. To rule out that the death of the recipients of WT CD8+ T cells was
caused by an exuberant immune response, we examined cytokine production 6
days post-infection with the lethal dose. The concentration of inflammatory
cytokines (IL-6, KC) and chemokines (CXCL10) in brochoalveolar lavage fluid
(Figure 2-6G) and serum (Supplementary Figure 2-6A) were comparable. These
results indicate that the protection found in mice that received MCJ-deficient CD8+
T cells was not due to an attenuated immune response relative to mice that
received WT CD8+ T cells.
To investigate whether the protective capacity of memory MCJ-deficient
CD8+ T cells was due to an improved effector function to clear virus, we examined
PR8 virus titers in the lung of recipient mice 6 days post-infection with the lethal
dose. Higher virus titers were present in host mice that received WT CD8+ T cells
(Figure 2-6H), indicating that memory MCJ-deficient CD8+ T cells were more
efficient in clearing influenza virus. To examine the effector function of memory
MCJ-deficient CD8+ T cells, we isolated CD8+ T cells from the mediastinal LN
123

(MLN) 6 days after the lethal infection and determined ex vivo IFN-g production
by culturing cells in medium without stimuli. IFN-g was higher in MCJ-deficient
CD8+ T cells (Figure 2-6I); however, the NP-tetramer+ cell frequency was not
different (Supplementary Figure 2-6B). Ex vivo IFN-g production by MCJ-deficient
CD8+ T cells isolated from the lung was also increased (Supplementary Figure
2-6C), as was the number of IFN-g secreting cells as determined by ELISpot assay
(Figure 2-6J). However, the frequency of NP-tetramer+ CD8+ T cells in the lung
was comparable (Supplementary Figure 2-6D), showing a great secretory capacity
of memory MCJ-deficient CD8+ T cells.
Secretion of granules by exocytosis is dependent on both Ca2+ and ATP. We
investigated whether increased mitochondrial ATP production in MCJ-deficient
CD8+ T cells could also facilitate an increase in exocytosis of cytotoxic granules
present in effector cells by CD107a mobilization assay. CD8+ T cells were isolated
from the MLN 6 days after lethal infection and incubated in medium containing
monensin with or without ionomycin to provide the Ca2+ signal. The frequency of
CD107a+ MCJ-deficient CD8+ T cells treated with ionomycin was significantly
higher than WT CD8+ T cells (Figure 2-6K), indicating that MCJ-deficient CD8+
T cells have a greater capacity to function as cytotoxic cells. Thus, increased
mitochondrial respiration caused by the loss of MCJ in CD8+ T cells results in
increased antiviral protective activity during memory responses by enhancing the
secretion both of effector cytokines as well as cytotoxic granules.
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Figure 2-6. Loss of MCJ Confers Viral Protective Activity to
Memory CD8+ T Cells
WT (blue) and MCJ-deficient CD8+ T cells (MCJ def, red). (A – D) Mice were
infected with a sublethal dose of PR8 virus (primary infection). (A) Percent weight
loss over time. (B) Percentage of NP-tetramer+ cells in the spleen 2 weeks post
infection. (C) Ex vivo IFN-g production of cells isolated from the spleen and MLN
+ cells from the
2 weeks post infection by ELISA. (D) Percentage of NP-tetramer
Champagne et al. Figure 6
spleen and MLN of mice 5 weeks post infection. (E – K) Mice were infected with a
sublethal dose of PR8 virus (primary infections). CD8+ T cells were isolated 5
weeks post infection and adoptively transferred into naive WT recipients, which
were then infected with a lethal dose of PR8 virus. (E) Survival and (F) percent
weight loss over time. (G–K) Recipients were sacrificed 6 days post lethal infection.
(G) BALF cytokines and chemokines. (H) Lung PR8 virus titer by quantitative RTPCR. (I) Ex vivo production of IFN-g by MLN CD8+ T cells by ELISA. (J) IFN-g
secretion by lung CD8+ T cells by ELISpot assay. (K) CD107a mobilization assay of
MLN CD8+ T cells cultured with (Iono) or without (Med) ionomycin. *p < 0.05 by
log-rank test for Kaplan-Meier survival curve and by unpaired t test for all others.
Avg ± SD (n ³ 3) shown. Results are representative of 2 – 3 experiments. See also
Supplementary Figure 2-5 and Supplementary Figure 2-6.
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4. Discussion
Mitochondria play a key role in balancing cellular metabolism primarily as
the site for OXPHOS through the ETC and as a source of ATP. Recently, it has
become clear that tight regulation of mitochondrial metabolism occurs during the
reprograming of CD8+ T cells. A number of molecules have been shown to be
required for maximum efficiency of the ETC and OXPHOS. However, very little is
known about negative regulatory mechanisms that restrict mitochondrial
respiration. We have recently identified MCJ as one of the first known negative
regulators of complex I activity through its effect on the formation of respiratory
supercomplexes (Hatle et al., 2013). Our earlier studies demonstrated that the
absence of MCJ prevents the development of steatosis by accelerating fatty acid
metabolism within the liver (Hatle et al., 2013). Here we have shown that MCJ
restrains mitochondrial respiration in CD8+ T cells. In the absence of this natural
break, CD8+ T cells have enhanced OXPHOS leading to increased secretion of
cytokines by effector CD8+ T cells. In addition, MCJ deficiency interferes with the
metabolic adaptation during the contraction phase of effector CD8+ T cells and
results in greater antiviral protective activity of memory CD8+ T cells.
Effector and memory CD8+ T cells need ATP for effector functions in
addition to cell growth and expansion. While CD8+ T cells primarily use glycolysis
instead of OXPHOS for proliferation (Frauwirth et al., 2002; Macintyre et al., 2011)
other sources might provide the ATP required for processes with high ATP
consumption. Production of some cytokines by effector CD8+ T cells is not affected
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by strong inhibition of glycolysis (Cham et al., 2008), and cytotoxic activity can take
place in the absence of glucose (MacDonald and Koch, 1977). Considering the
dynamic aspect of mitochondria as organelles that can rapidly relocate in the
cytosol, it is quite possible that mitochondria can create a microenvironment that
is highly rich in ATP in specific locations without elevating overall cytosolic ATP.
Mitochondria have been shown to relocate to the edge of lamellipodia and are
critical for providing the energy for migration of cells (Morlino et al., 2014). Our
studies revealed the presence of microenvironments where ATP and ADP
accumulate in CD8+ T cells located in the proximity of mitochondria. Here we have
shown that increased mitochondrial respiration in CD8+ T cells lacking MCJ had
no effect on CD8+ T cell proliferation or cytokine gene expression, but it enhanced
the secretion of cytokines such as IFN-g. Little is known about the mechanisms of
cytokine secretion in T cells; however, secretion of intracellular components often
is dependent on ATP (Jena, 2013; Monteleone et al., 2015) and the source of this
ATP, whether mitochondrial or cytosolic, has yet to be determined. Secretion of
IFN-g by CD8+ T cells in the absence of MCJ is dependent on ATP derived from
mitochondria. Thus, through OXPHOS mitochondria can regulate effector
function of CD8+ T cells independently of cell expansion.
The presence of respiratory supercomplexes in mammalian cells has been
demonstrated in tissues such as heart. Respirasomes bring the individual
complexes together to facilitate the efficient transfer of electrons between
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complexes while preventing electron leak and, thereby, production of ROS. Here
we revealed the presence of supercomplexes in naive CD8+ T cells and increased
supercomplex formation in the absence of MCJ. Naive CD8+ T cells primarily use
mitochondria and OXPHOS relative to activated CD8+ T cells; however,
mitochondrial ROS are almost undetectable (Hatle et al., 2013). It is possible that
the presence of supercomplexes prevents the formation of ROS and enhances
survival of naive cells. Although increased MMP is normally associated with
increased ROS, in MCJ-deficient CD8+ T cells MMP is higher but ROS is not (Hatle
et al., 2013). This is most likely due to abundance of supercomplexes in these cells.
To date, there is no clear evidence that complex II (succinate dehydrogenase) is
also recruited to supercomplexes. Because complex III receives electrons from both
complex I and complex II, the recruitment of complex III to supercomplexes might
cause an uncoupling of complex III from complex II. Therefore, the attenuation of
complex II activity in the absence of MCJ could be a mechanism to prevent electron
leakage since its corresponding acceptor, complex III, is sequestered, explaining
the accumulation of succinate in MCJ-deficient CD8+ T cells.
Memory CD8+ T cells utilize mitochondrial respiration for both their
generation and effector function. However, instead of using glucose to feed
mitochondrial respiration through pyruvate, memory CD8+ T cells perform
b-oxidation of fatty acids. Recently, it has been shown that these cells utilize
lipolysis to generate their own fuel (O'Sullivan et al., 2014). Pathways leading to
increased mitochondrial respiration are associated with a superior memory CD8+
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T cell response. In our study, we have identified MCJ as an endogenous negative
regulator of OXPHOS in CD8+ T cells. Lack of MCJ sustained the active
metabolism of effector CD8+ T cells during the contraction phase and resulted in
greater effector memory CD8+ T cell responses to influenza virus. Although MCJ
deficiency had an impact in the metabolic adaptation during the contraction phase
of effector CD8+ T cells, it did not seem to have a substantial effect on overall
survival of those effector cells in vivo. MCJ deficiency appeared to provide a
survival advantage to effector cells when these cells were rested in medium alone
without additional cytokines in vitro. This is most likely due to the fact that during
in vitro resting effector WT CD8+ T cells undergo cytokine withdrawal. We also
show here that WT memory CD8+ T cells alone failed to provide protection against
a lethal dose of influenza virus. Strikingly, MCJ-deficient memory CD8+ T cells
were highly protective against lethal infection with influenza. Using the LCMV
infection model, it has been shown that CD4+ T cells can rescue exhausted CD8+ T
cells during chronic viral infection (Aubert et al., 2011). We also observed that a
small frequency of CD4+ T cells was sufficient for WT memory CD8+ T cells to
provide protection against influenza virus infection (data not shown). Because
MCJ deficiency results in enhanced CD8+ T cell responses, it is not evolutionarily
clear why MCJ is expressed in CD8+ T cells. While CD8+ T cells are key for
protection, an exaggerated cytotoxic CD8+ T cell response could cause non-specific
tissue damage. We propose that MCJ was acquired in CD8+ T cells as a strategy to
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restrain their metabolism and prevent a prolonged effector function that could be
harmful.
5. Experimental Procedures
5.1. Mice
Mouse strains used were C57BL/6J (WT), MCJ-deficient C57BL/6 (Hatle et
al., 2013), OT-I TCR transgenic, and MCJ-deficient OT-I. All mice were maintained
at the University of Vermont animal care facility and used under procedures
approved by the University of Vermont Institutional Animal Care and Use
Committee (IACUC).
5.2. Cell Preparation and Culture
Cells were purified by negative selection or positive selection using the
MACS Cell Separation System (Miltenyi). Cytokine production was determined
by ELISA. Detailed protocols are described in Supplemental Experimental
Procedures.
5.3. Extracellular Flux Analysis
Oxygen consumption (OCR) and extracellular acidification rates (ECAR)
were analyzed using a XF24 Extracellular Flux analyzer (Seahorse Bioscience).
Detailed protocols are described in Supplemental Experimental Procedures.
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5.4. Intracellular ATP Concentration
ATP concentration was determined using the ATPlite Luminescence Assay
System and a TD-20/20 Luminometer. Detailed protocols are described in
Supplemental Experimental Procedures.
5.5. Flow Cytometry Analyses
Flow cytometry analyses were performed using an LSRII Flow Cytometer
(BD Biosciences). Cell proliferation, survival, and MMP were determined using
CFSE, Live Dead Cell Viability Assay, and TMRE (Molecular Probes).
b-galactosidase activity was determined using the FACS Fluorescent Blue lacZ
b-Galactosidase Detection Kit (Marker Gene Technologies). Intracellular cytokine
staining was performed without brefeldin A or monensin. CD107a mobilization
assay was performed using monensin and an anti-CD107a PE antibody
(Biolegend) with or without ionomycin. Detailed protocols are described in
Supplemental Experimental Procedures.
5.6. Chromatin Immunoprecipitation
ChIP assays were performed using the SimpleChip Enzymatic Chromatin
IP Kit (Cell Signaling) with anti-Ikaros or rabbit IgG. Detailed protocols are
described in Supplemental Experimental Procedures.
5.7. Influenza Infection and Analyses
Mice were infected intranasally with a sublethal dose of PR8 virus. CD8+
T cells were isolated after 5 weeks, equal numbers of NP-tetramer+ cells were
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transferred to naive WT mice. Recipients were infected with a lethal dose and
sacrificed 6 days later. CD8+ T cells from the MLN and lung were examined for
ex vivo IFN-g production by ELISA and/or ELISpot assay and for effector and
memory cell surface markers, NP-tetramer+ cell frequency, and/or CD107a
mobilization by flow cytometry. BALF and serum were analyzed by Luminex
assay (Millipore). Lung was examined for PR8 virus titer by quantitative RT-PCR
for acid polymerase. Detailed protocols are described in Supplemental
Experimental Procedures.
5.8. Confocal Microscopy
Cells were examined by confocal microscopy using ATP probe and/or
Mitotracker and a Zeiss LSM 510 Meta Confocal Laser Scanning microscope (Carl
Zeiss

Microscopy).

Detailed

protocols

are

described

in

Supplemental

Experimental Procedures.
5.9. Statistical Analyses
Statistical significance was determined by t test or long-rank test as
indicated. Bars represent average ± SD or SEM as indicated. p < 0.05 was
considered statistically significant.
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7. Supplementary Information
7.1. Supplementary Figures
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and incubated without stimuli for 4 hours. IL-2 and GM-CSF in the culture
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CD8+ T cells were analyzed for β-galactosidase activity by flow cytometry. The
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percentage of β-galactosidase+ MCJ-deficient cells is indicated. WT cells are shown
as a negative control. (D and E) WT (blue) and MCJ-deficient (MCJ def, red) CD8+
T cells were activated for 2 days, washed, and replated at equal numbers in
medium without stimulation. After 24 hours, culture supernatants were
supplemented with (D) anti-IL-2 antibody or (E) recombinant IL-2. The number of
live cells was determined 24 hours later (48 hours after replating) by Trypan blue
exclusion. Bars indicate cell survival relative to the initial number of cells. *p < 0.05
by unpaired t test. Avg ± SD (n ≥ 3) shown. See also Figure 2-4 and Figure 2-5.
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OT-I, blue; OT-I MCJ-deficient (MCJ def), red. (A) CD4 and CD8 expression by
splenocytes and lymph node (LN) cells was examined by flow cytometry analyses.
Numbers indicate the percentage of cells in each gate. (B and C) OT-I and OT-I
MCJ-deficient CD8+ T cells were activated with anti-CD3 and anti-CD28
antibodies for 2 days and then expanded with recombinant IL-2 for an additional
3 days. Equal numbers of OT-I (CD90.1+) and OT-I MCJ-deficient (CD90.1+
CD90.2+) CD8+ T cells were combined and adoptively transferred to C57BL/6
(CD90.2+) recipient mice (n = 4). LN and spleen were harvested after 2 weeks and
analyzed by flow cytometry. (B) Dot plots showing FSC and SSC of total spleen
and LN cells from recipients (upper panel) and CD90.1 and CD90.2 expression
used to discriminate donor and recipient cells (lower panel). (C) OT-I and OT-I
MCJ-deficient CD8+ Vα2+ (OT-I TCR) T cells gated as shown in (B) were examined
for FSC and surface expression of CD44, CD62L, KLRG1, and CD127. Numbers
indicate the percentage of cells in each gate. Note the increased fraction of OT-I
MCJ-deficient CD8+ T cells that have a large, blastic size (higher FSC). See also
Figure 2-5.
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infection. (A) The number of NP-tetramer+ CD8+ cells in the spleen was
determined 3 weeks postinfection by flow cytometry analysis. (B) Five weeks post
primary infection, CD8+ T cells were isolated from the spleen and draining MLN
and pooled for adoptive transfer into naïve WT (C57BL/6) recipient mice. Shown
is the phenotype of the donor CD8+ T cells analyzed for CD8, NP-tetramer,
KLRG1, CD127, CD62L, CD27, and CD44 surface expression by flow cytometry
analysis. *p < 0.05 by unpaired t test. Avg ± SD (n ≥ 3) shown. See also Figure 2-6.
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Supplementary Figure S6. Effector function of influenza-specific memory CD8+ T cells. WT recipient
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(B) Influenza specific CD8 T cells in the spleen were determined by staining with
NP-tetramer and flow cytometry analysis. (C) CD8+ T cells from the lung were
incubated in medium without stimulation for 11 hours, and IFN-g in the culture
supernatant was determined by ELISA. (D) Influenza specific CD8+ T cells in the
lung were determined as in (B). *p < 0.05 by unpaired t test. Avg ± SD (n ≥ 3)
shown. See also Figure 2-6.
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7.2. Supplementary Tables
Supplementary Table 2-1. Metabolome Analysis of Naive CD8+ T Cells
Pathway

Amino Acids

Nucleotides

*Peak

Compound

WT
5.11E+05
5.06E+05
3.93E+05
4.70E+05
1.04E+06
2.35E+05
4.69E+06
1.05E+06
6.82E+05
6.31E+06
1.72E+05
8.59E+05
1.12E+06
1.36E+06
8.64E+06
4.55E+06
1.42E+07
7.14E+06
3.74E+03
8.41E+06
7.37E+03
1.42E+04
2.32E+05
1.14E+04
1.12E+05
3.79E+04
6.37E+04
2.86E+06
6.79E+06
6.15E+05
1.12E+07
1.11E+06
3.98E+05
9.11E+04
3.63E+05

lysine
methionine
histidine
asparagine
tyrosine
tryptophan
leucine
arginine
serine
valine
cysteine
threonine
phenylalanine
glutamine
alanine
proline
glutamate
glycine
cystine
aspartate
inosine
guanosine
adenosine
5-hydroxyisourate
UMP
cytidine
guanine
AMP
nicotinamide
uracil
4-pyridoxate
5-6-dihydrothymine
hypoxanthine
NAD+
adenine

*Median

†Fold
Area
Increase
KO
9.69E+05
1.90
8.87E+05
1.75
6.66E+05
1.70
7.51E+05
1.60
1.53E+06
1.47
3.41E+05
1.45
6.75E+06
1.44
1.51E+06
1.44
9.54E+05
1.40
8.69E+06
1.38
2.35E+05
1.37
1.17E+06
1.36
1.45E+06
1.30
1.76E+06
1.29
1.05E+07
1.22
5.45E+06
1.20
1.58E+07
1.11
7.83E+06
1.10
3.73E+03
1.00
7.65E+06
0.91
7.20E+04
9.78
3.42E+04
2.40
4.83E+05
2.08
1.69E+04
1.49
1.50E+05
1.34
5.07E+04
1.34
7.72E+04
1.21
3.42E+06
1.19
7.97E+06
1.17
7.19E+05
1.17
1.15E+07
1.03
1.12E+06
1.01
3.72E+05
0.93
6.93E+04
0.76
1.83E+05
0.50

‡p-value

0.036
0.006
0.030
0.004
0.012
0.047
0.018
0.127
0.079
0.002
0.058
0.051
0.032
0.115
0.086
0.165
0.302
0.086
0.524
0.621
0.399
0.400
0.129
0.459
0.143
0.634
0.675
0.416
0.631
0.155
0.991
0.427
0.370
0.291
0.329

value of 3 independent biological replicates. †Fold increase of median peak area calculated
as KO/WT. ‡Determined by unpaired t test (n = 3).
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Supplementary Table 2-1 (continued)
Pathway

Glycolysis & Sugars

TCA Cycle

Pentose Phos. Pathway
Glutathione
Homeostasis
Gamma-glutamyls
Serine Biosynthesis
& 1C Metabolism
Urea cycle
Aminosugars
Arginine &
Proline Metabolism

Sulfur metabolism

*Peak

Compound

WT
D-glucose
6.22E+04
pyruvate
3.75E+06
mannitol
5.30E+05
lactate
1.24E+07
succinate
3.39E+04
2-hydroxyglutarate
4.00E+04
oxaloacetate
9.54E+04
citrate
1.82E+05
malate
1.53E+05
2-oxoglutaramate
5.05E+05
cis-aconitate
4.03E+05
fumarate
1.24E+05
α-D-ribose 1-phosphate 9.01E+03
glutathione
1.61E+07
5-oxoproline
4.74E+06
dehydroascorbate
4.03E+05
ascorbate
1.10E+06
γ-L-glutamyl-[acp]
8.73E+04
γ-L-glutamyl-L-cysteine 4.86E+03
D-O-phosphoserine
2.45E+04
N-N-dimethylglycine
2.57E+06
L-citrulline
6.67E+04
ornithine
9.93E+05
N-(L-rginino)succinate
9.52E+03
N-acetylneuraminate
3.09E+04
N-glycoloyl-neuraminate 2.64E+04
creatinine
5.46E+05
creatine
2.97E+06
L-selenomethionine
1.40E+04
L-cysteate
3.93E+04
hypotaurine
4.00E+04
taurine
3.05E+07
Cys-Gly
1.89E+05
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†Fold
Area
Increase
KO
8.48E+04
1.36
3.89E+06
1.04
5.46E+05
1.03
1.27E+07
1.02
2.00E+05
5.89
6.50E+04
1.63
1.26E+05
1.32
2.23E+05
1.23
1.62E+05
1.06
4.91E+05
0.97
3.45E+05
0.86
1.03E+05
0.83
1.04E+04
1.15
2.00E+07
1.24
5.06E+06
1.07
3.45E+05
0.86
8.20E+05
0.75
1.46E+05
1.68
4.70E+03
0.97
3.13E+04
1.28
2.72E+06
1.06
9.90E+04
1.48
9.24E+05
0.93
5.14E+03
0.54
4.18E+04
1.35
3.29E+04
1.25
5.71E+05
1.05
3.01E+06
1.02
2.10E+05
15.00
4.71E+04
1.20
4.20E+04
1.05
3.13E+07
1.02
1.93E+05
1.02

‡p-value

0.508
0.222
0.402
0.508
0.014
0.023
0.166
0.128
0.482
0.318
0.269
0.106
0.550
0.319
0.386
0.269
0.223
0.119
0.727
0.456
0.360
0.015
0.464
0.975
0.015
0.116
0.806
0.680
0.004
0.194
0.463
0.604
0.881

Supplementary Table 2-2. Metabolome Analysis of Activated CD8+ T Cells
Pathway

Amino Acids

Nucleotides

*Peak

Compound

WT
2.00E+07
9.84E+07
1.06E+07
4.56E+06
8.51E+05
7.11E+07
1.94E+07
8.41E+06
2.97E+06
1.68E+07
2.91E+06
2.34E+07
1.19E+08
2.69E+07
1.41E+07
7.92E+06
6.28E+07
1.95E+06
1.18E+07
4.07E+05
4.07E+05
1.91E+06
3.99E+05
2.80E+06
6.21E+05
2.05E+06
9.04E+05
1.38E+07
3.42E+05
3.44E+07
1.02E+06
6.58E+05
8.31E+05
1.68E+06
2.10E+05

alanine
proline
glycine
serine
cysteine
glutamate
glutamine
asparagine
histidine
threonine
tryptophan
phenylalanine
leucine
tyrosine
methionine
arginine
valine
lysine
aspartate
cystine
cytidine
guanine
adenosine
AMP
hypoxanthine
5-hydroxyisourate
UMP
nicotinamide
inosine
4-pyridoxate
5-6-dihydrothymine
uracil
guanosine
NAD+
adenine

*Median

†Fold
Area
Increase
KO
3.73E+07
1.86
1.63E+08
1.66
1.75E+07
1.66
7.24E+06
1.59
1.34E+06
1.57
1.11E+08
1.56
2.95E+07
1.52
1.25E+07
1.49
4.31E+06
1.45
2.44E+07
1.45
4.11E+06
1.41
3.22E+07
1.38
1.60E+08
1.35
3.57E+07
1.33
1.85E+07
1.31
9.99E+06
1.26
7.83E+07
1.25
2.19E+06
1.13
1.24E+07
1.05
3.61E+05
0.89
1.29E+06
3.17
4.11E+06
2.15
7.46E+05
1.87
4.75E+06
1.70
1.02E+06
1.64
3.24E+06
1.58
1.24E+06
1.37
1.86E+07
1.35
4.55E+05
1.33
4.34E+07
1.26
1.23E+06
1.20
7.88E+05
1.20
9.64E+05
1.16
1.80E+06
1.07
1.62E+05
0.77

‡p-value

0.211
0.418
0.007
0.032
0.001
0.005
0.008
0.011
0.000
0.006
0.000
0.001
0.001
0.228
0.000
0.004
0.000
0.022
0.005
0.223
0.271
0.508
0.065
0.010
0.022
0.307
0.003
0.516
0.217
0.262
0.295
0.004
0.010
0.784
0.153

value of 3 independent biological replicates. †Fold increase of median peak area calculated
as KO/WT. ‡Determined by unpaired t test (n = 3).
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Supplementary Table 2-2 (continued)
Pathway

Glycolysis & Sugars

TCA Cycle

Pentose Phos. Pathway
Glutathione
Homeostasis
Gamma-glutamyls
Serine Biosynthesis
& 1C Metabolism
Urea cycle
Aminosugars
Arginine &
Proline Metabolism

Sulfur metabolism

*Peak

Compound

WT
lactate
1.77E+07
pyruvate
3.43E+06
D-glucose
6.10E+05
mannitol
1.08E+06
succinate
5.14E+05
2-hydroxyglutarate
1.70E+05
malate
1.98E+06
fumarate
2.35E+05
citrate
7.12E+05
2-oxoglutaramate
5.09E+05
cis-aconitate
1.80E+04
oxaloacetate
2.49E+05
α-D-ribose 1-phosphate 7.26E+04
dehydroascorbate
4.63E+03
5-oxoproline
4.18E+07
glutathione
7.21E+07
ascorbate
1.75E+04
γ-L-Glutamyl-L-cysteine 1.60E+05
γ-L-Glutamyl-[acp]
2.03E+05
D-O-phosphoserine
3.34E+05
N-N-dimethylglycine
2.40E+06
L-citrulline
1.77E+05
N-(L-arginino)succinate 2.33E+05
ornithine
9.32E+05
N-glycoloyl-neuraminate 5.43E+04
N-acetylneuraminate
7.21E+04
creatine
4.83E+06
creatinine
6.31E+05
L-selenomethionine
9.25E+03
L-cysteate
1.98E+05
taurine
2.56E+07
hypotaurine
1.10E+05
Cys-Gly
9.83E+05
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†Fold
Area
Increase
KO
2.42E+07
1.37
3.89E+06
1.13
4.59E+05
0.75
7.74E+05
0.72
1.39E+06
2.70
3.50E+05
2.06
3.64E+06
1.84
4.26E+05
1.81
8.68E+05
1.22
5.11E+05
1.00
1.53E+04
0.85
2.01E+05
0.81
6.92E+04
0.95
ND
--5.45E+07
1.30
9.00E+07
1.25
2.02E+04
1.16
2.25E+05
1.40
2.38E+05
1.17
5.95E+05
1.78
2.49E+06
1.04
3.97E+05
2.24
4.62E+05
1.98
9.98E+05
1.07
6.20E+04
1.14
7.78E+04
1.08
7.71E+06
1.60
5.60E+05
0.89
2.00E+05
21.62
2.89E+05
1.46
2.97E+07
1.16
1.20E+05
1.09
9.92E+05
1.01

‡p-value

0.397
0.008
0.075
0.063
0.058
0.314
0.711
0.306
0.011
0.038
0.033
0.373
0.951
0.340
0.009
--0.088
0.018
0.906
0.326
0.071
0.051
0.134
0.000
0.564
0.082
0.039
0.134
0.154
0.001
0.030
0.685
0.014

7.3. Supplemental Experimental Procedures
7.3.1. Mice
All mice were bred and maintained under sterile conditions at the
University of Vermont animal care facility and used under procedures approved
by the University of Vermont Institutional Animal Care and Use Committee
(IACUC). Mouse strains used were WT C57BL/6J (Jackson Laboratories), MCJdeficient C57BL/6 (Hatle et al., 2013), OT-I TCR transgenic (Hogquist et al., 1994),
and MCJ-deficient OT-I.
7.3.2. Cell preparation and culture
CD8+ T cells were purified from spleen and lymph nodes (LN) by negative
selection as previously described (Farley et al., 2006) and by positive selection
using the MACS Cell Separation System (Miltenyi) as recommended by the
manufacturer. The purity of isolated cells was confirmed by flow cytometry. Cells
were activated in vitro using plate bound anti–CD3 (5 µg/mL) and soluble anti–
CD28 (1 µg/mL) antibodies (BioXcell). For analysis of cytokine secretion during
resting, cells were activated for 2 days, washed, and incubated at equal numbers
in medium alone without additional stimuli for 4 – 12 hours. Culture supernatants
of activated and rested cells were analyzed for IFN-g, IL-2, and/or GM-CSF by
ELISA. Cells were also incubated with or without oligomycin (20 µM, Sigma) or
cycloheximide (5 µg/ml, Sigma). For cell survival analysis, activated cells were
washed and incubated at equal numbers in medium without further stimulation
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or the presence of exogenous cytokines. In some cases, the culture medium was
supplemented with a blocking anti-IL-2 antibody or recombinant IL-2 after 24
hours. Live cells were determined by Trypan blue exclusion at 24, 48, and 72 hours
after replating.
7.3.3. Mitochondrial respiration and extracellular acidification
Oxygen consumption rates (OCR) of CD8+ T cells were analyzed under
basal conditions and in response to sequential injections of oligomycin, FCCP, and
rotenone with antimycin A (1 µM each) using the Seahorse MitoStress Test Kit.
Extracellular acidification rates (ECAR) were analyzed under basal conditions and
in response to glucose (10 mM) using the Seahorse Glycolysis Stress Test Kit. OCR
linked to mitochondrial ATP production (ATP linked OCR) was determined by
subtracting OCR of CD8+ cells reached after treatment with oligomycin from OCR
obtained at baseline. Complex II linked respiration was determined using a
modified version of a previously described method (Salabei et al., 2014). Briefly,
XF24 cell culture microplates were coated with Cell-Tak (50 uL at 22.4 µg/mL,
Corning) and freshly isolated CD8+ T cells were plated in MAS-BSA assay solution
(220 mM mannitol, 70 mM sucrose, 10 mM KH2PO4, 5 mM MgCl2, 2 mM HEPES,
1 mM EGTA, 0.2% fatty acid free BSA) containing XF Plasma Membrane
Permeabilizer (PMP, 1 nM, Seahorse Bioscience) and ADP (4 mM, Sigma). Oxygen
consumption rates were measured at baseline and in response to sequential
injections of succinate (10 mM, Sigma) with rotenone (2 µM, Seahorse Bioscience)
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and malonate (500 µM, Sigma). All extracellular flux analyses were performed
using an XF24 Extracellular Flux Analyzer (Seahorse Bioscience) as recommended
by the manufacturer.
7.3.4. Mass spectrometry based metabolomics
For metabolomics analyses, CD8+ T cells from WT and MCJ KO mice were
purified and either left unstimulated or activated for 2 days prior to mass
spectrometry analysis. For culture supernatants, unstimulated CD8+ T cells were
incubated in medium without stimulation for 16 hours. For heavy isotope and flux
analyses, unstimulated cells were incubated in medium supplemented with Cell
Free Amino Acid Mixture -

13C, 15N

(2 mM, Sigma) for 5 minutes or 5 hours.

Metabolomics and flux analyses were performed as previously reported
(D'Alessandro et al., 2015). Briefly, 2 x 106 cells and 20 µl of cell media were
extracted in 1 ml and 980 µl of cold lysis and extraction buffer (methanol :
acetonitrile : water at 5 : 3 : 2), respectively. After discarding protein pellets, 10 µl
of water and methanol soluble fractions were run through a Kinetex C18 1.7 µm,
100 x 2.1 mm reversed phase column (phase A: water, 0.1 % formic acid; phase B:
acetonitrile, 0.1 % formic acid; Phenomenex) via an ultra high performance
chromatographic system (UHPLC, Ultimate 3000, ThermoFisher). UHPLC was
coupled in line with a high resolution quadrupole Orbitrap instrument run in both
polarity modes (QExactive, ThermoFisher) at 140,000 resolution (at 200 m/z).
Metabolite assignment, heavy isotopologue distributions and peak integration for
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relative quantitation were performed using Maven software (Princeton) against
the KEGG pathway database and an in house validated standard library (>650
compounds, Sigma, IROATech). Integrated peak areas were exported to Excel
(Microsoft) and elaborated for statistical analysis (t test, ANOVA) and hierarchical
clustering analysis (HCA) through Prism (GraphPad Software) and GENE-E
(Broad Institute), respectively.
7.3.5. Mitochondrial respiratory supercomplexes
Mitochondrial fractions were obtained by differential centrifugation,
solubilized with 2 % digitonin (Sigma), and resolved by electrophoresis using
NativePAGE Novex 4 – 16 % Bis-Tris protein gels (Invitrogen) as previously
described (Hatle et al., 2013; Yang et al., 2015). Bands corresponding to respiratory
supercomplexes and monomeric Complex IV were excised from the Blue Native
gel, eluted, resolved by SDS-PAGE, and analyzed by Western blot for NDUFA9
and CoxIV (MitoScience). Proteins were also transferred directly from the Blue
Native gel to PVDF membrane for Western blot analysis for NDUFA9 and Core1
(MitoScience).
7.3.6. Intracellular ATP Concentration
Intracellular ATP concentration in 104 CD8+ T cells was determined using
the ATPlite Luminescence Assay System (PerkinElmer) and a TD-20/20
Luminometer (Turner BioSystems) as recommended by the manufacturers.
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7.3.7. Flow cytometry analyses
For cell proliferation analysis, cells were stained with CFSE (5 µM,
Molecular Probes), activated for 24 or 48 hours, and examined by flow cytometry
analysis to determine proliferation. Control (unstimulated) cells were stained and
incubated in medium alone for 16 hours before analysis. For cell survival analysis,
cells were stained using the Live Dead Cell Viability Assay (Molecular Probes) as
recommended by the manufacturer and examined by flow cytometry analysis. For
expression of cell surface markers, cells were stained with antibodies for CD4,
CD8, CD25, and CD69, and then analyzed by flow cytometry. For mitochondrial
membrane potential analysis, cells were staining with TMRE (Molecular Probes)
as previously described (Hatle et al., 2013) and examined by flow cytometry
analysis. For β-galactosidase activity analysis, cells were incubated in
β-galactosidase substrate (FACS Fluorescent Blue lacZ β-Galactosidase Detection
Kit, Marker Gene Technologies) as recommended by the manufacturer and
analyzed by flow cytometry. WT cells were used as negative controls. For
intracellular cytokine staining analysis, cells were fixed after activation in
paraformaldehyde,

permeabilized

with

saponin

and

stained

with

the

corresponding antibodies for IFN-g or IL-2 (BD Bioscience) as previously described
(Yang et al., 1998). No preincubation with brefeldin A or monensin was used prior
to intracellular staining. For CD107a mobilization assay, cells were cultured in the
presence of monensin (1 µM, Sigma) and anti-CD107a (4 µL/ml, Biolegend) for 4
hours using a modified version of a previously described method (McElroy et al.,
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2007). Additionally, cells were cultured with or without ionomycin (250 ng/ml).
Cells cultured without anti-CD107a were used as negative controls. All flow
cytometry analyses were performed using an LSRII Flow Cytometer (BD
Biosciences) and FlowJo software.
7.3.8. Cytokine Analyses
For cytokine gene expression analysis, total RNA was isolated from
activated cells using an RNeasy Mini Kit (Qiagen) as recommended by the
manufacturer, cDNA was synthesized as previously described (Yang et al., 2015),
and IL-2 and IFN-g mRNA were determined by qRT-PCR using Assays–on–
Demand TaqMan Gene Expression Assays (Applied Biosystems). Values were
normalized to β2-microglobulin and analyzed by the comparative delta CT
method. For cytokine production analysis, IFN-g and IL-2 in culture supernatants
were determined by ELISA as previously described (Yang et al., 1998). For IFN-g
ELISpot assays, cells were washed and plated in an ELISpot assay plate using
capture and biotinylated anti-IFN-g antibodies (MabTech) as previously described
(Dienz et al., 2009). Total and larger spots (high IFN-g producing cells) were
quantified using an Axio Imager and software system (Zeiss).
7.3.9. Chromatin immunoprecipitation.
Ten to fifteen million purified CD8+ T cells were activated for 2 days or left
unstimulated. ChIP assays were performed as previously described (Navasa,
Martin-Ruiz, et al., 2015) using the SimpleChip Enzymatic Chromatin IP kit152

Magnetic beads (Cell Signaling) following the manufacturer’s instructions using
anti-Ikaros

antibody

or

normal

rabbit

IgG

as

a

negative

control.

Immunoprecipitated DNA was subjected to qPCR using primers encompassing
the Ikaros binding site (5’ - TCA TTT GCT GTG AGC GCA AG - 3’ and 5’ - GCC
TCC TTA GGT CTA CCT TGA - 3'). Results are presented as fold induction over
rabbit IgG immunoprecipitates relative to input (percent input method).
7.3.10. Influenza infection and analyses
WT and MCJ-deficient mice were infected intranasally with a sublethal
dose (3×103 EIU) of Puerto Rico A/PR/8/34 H1N1 influenza A (PR8) virus as
previously described (Dienz et al., 2012). Mice were monitored for weight loss
every other day. CD8+ T cells were isolated by positive selection from the draining
mediastinal lymph node (MLN) and spleen 5 weeks later. Equal numbers of NPtetramer+ CD8+ T cells (2 - 2.5 x 106) were then transferred to WT mice, and a day
later recipient mice were infected with a lethal dose of PR8 virus (104 EIU). Mice
were monitored for weight loss every other day. Animals that lost >30% of their
body weight at the day of infection or became grossly moribund were euthanized.
BALF and serum were collected 6 days after the lethal dose. Cytokines and
chemokines in BALF and serum were examined using Luminex Mouse Cytokine
and Chemokine Panel I (Millipore) according to the manufacturer's protocol. Ex
vivo production of IFN-g by CD8+ T cells from the MLN and lung were determined
by ELISA and/or ELISpot assay as described above. CD8+ T cells were also stained
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with NP366-374/Db tetramer containing peptide from the PR8 influenza virus
(Powell et al., 2007) and antibodies for CD44, CD62L, KLRG1, CD127, and CD27
(Biolegend) and analyzed by flow cytometry. For virus copy determination, total
RNA extracted from whole lung tissue by RNeasy Kit (Qiagen) was used for
cDNA synthesis (2 µg RNA) as previously described (Dienz et al., 2012). Viral titers
were determined by quantitative RT-PCR for PR8 virus acid polymerase (PA)
gene, a method validated as equivalent to PFU (Jelley-Gibbs et al., 2007).
7.3.11. Confocal microscopy
Cells were activated for 2 days, transferred to glass bottom plates (MatTek),
and incubated at 37°C for 1 hour to sediment. Live cells were examined by confocal
microscopy prior to staining (background). ATP probe (Rao et al., 2012) was then
added (100 µM), cells were incubated for 5 minutes, washed, and visualized using
a 405 nm laser. For costaining with Mitotracker, prior to incubation with the ATP
probe cells were incubated with Mitotracker (Thermo Fisher) for 30 minutes.
Confocal microscopy was performed using a Zeiss LSM 510 Meta Confocal Laser
Scanning microscope (Carl Zeiss Microscopy).
7.3.12. Statistical analyses
Statistical significance was determined by t test or long-rank test as
indicated. Bars represent the mean with the standard deviation (SD) or standard
error of the mean (SEM). p < 0.05 was considered statistically significant.
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CHAPTER 3. ABC Transporter Mediated Cancer Chemoresistance is Overcome
by Targeted Disruption of Mitochondrial ATP
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1. Summary
Chemotherapy remains the standard of care for most cancers worldwide,
however development of chemoresistance due to the presence of the drugeffluxing ABC transporters remains a significant problem. The development of
safe and effective means to overcome chemoresistance is critical for achieving
durable remissions in many cancer patients. We have investigated the energetic
demands of ABC transporters in the context of the metabolic adaptations of
chemoresistant cancer cells. Here we show that mitochondrial-derived ATP, but
not glycolysis-derived ATP, provides the energy needed for ABC transporters to
efflux drugs out of cancer cells. We further demonstrate that the loss of MCJ
(DNAJC15), an endogenous negative regulator of mitochondrial respiration, in
chemoresistant cancer cells enhances their ability to produce ATP from
mitochondria and fuel ABC transporters. We have developed novel MCJ mimetics
that can attenuate mitochondrial respiration and safely overcome chemoresistance
in vitro and in vivo. Administration of MCJ mimetics in combination with standard
chemotherapeutic drugs could therefore become an affordable new strategy for
treatment of multiple cancers.
2. Introduction
Despite the development of novel therapies, including immunotherapies,
chemotherapy prior to or following surgery remains the most commonly used
systemic treatment for most cancers. However, it is also evident that
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chemotherapy treatment still faces major challenges as chemoresistance usually
develops in cancer patients. In some cases, patients fail the initial chemotherapy
course due to intrinsic properties of tumor cells. Frequently, following a successful
response to the first-round chemotherapy, the cancer recurs following acquisition
of adaptive mechanisms of chemoresistance, which can extend to families of drugs
distinct from the chemotherapy used (i.e., multidrug resistance). Once
chemoresistance is established, one of the approaches used to attempt to overcome
this problem is increased drug dosing, but this approach is limited by increased
toxicity, including off-target effects (e.g., cardio- or neurotoxicity) (Lyman, 2009;
Pai and Nahata, 2000). The alternative use of different chemotherapeutic drugs is
often hampered by multidrug resistance. Until now, the lack of a mechanistic
understanding of the energetics of chemoresistance has hampered the
development of effective strategies to overcome this major hurdle in cancer
therapy. While there is growing interest in cancer cell metabolism as a novel
approach to interfere with cancer growth, little is known about how metabolic
changes contribute to the development of chemoresistance.
Different mechanisms of chemoresistance have been identified (Fodale et
al., 2011), but the most common mechanism is the upregulation of ATP binding
cassette (ABC) transporters that mediate drug efflux and decrease intracellular
accumulation of anti-cancer drugs (Kathawala et al., 2015). ABC transporters are a
large family of proteins classified in seven subclasses (ABCA, B, C, D, E, F, and G)
that use the energy of ATP hydrolysis to mediate the transport of substrates
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(Ambudkar et al., 2003; Dean et al., 2001; Szakacs et al., 2006). In cancer cells, ABC
transporters remove chemotherapeutic agents from cells, thereby reducing
intracellular concentrations and thus drug efficacy. Several ABC transporters have
been associated with the development of multidrug resistance in cancer (Dlugosz
and Janecka, 2016). The most characterized ABC transporters associated with
chemoresistance in cancer are ABCB1 (also known as P-gp or MDR1), ABCG2
(BCRP), and ABCC1 (MRP1) (Allikmets et al., 1998; Cole et al., 1992; Doyle et al.,
1998; Miyake et al., 1999; Roninson et al., 1986; Ueda et al., 1987). A correlation
between the expression of ABCB1 and ABCG2 and multidrug resistance in cancer
cell lines in vitro is well established (Bugde et al., 2017; Doyle et al., 1998; Ozvegy et
al., 2001; Riordan et al., 1985; Roninson et al., 1984), but the correlation between the
expression of these transporters and chemoresistance in cancer patients is less
clear, and therefore neither can be used as predictive markers for chemoresistance.
The presence of ABC transporters therefore may not be sufficient to cause
chemoresistance in cancer cells and other factors could be required for these efflux
pumps to be active.
ABC transporters are energy consuming pumps that require significant
amounts of ATP as biochemical studies have indicated that up to two ATP
molecules are required to efflux one molecule of substrate (Patzlaff et al., 2003;
Poolman et al., 2005). Despite this energy demand and the distinct metabolism of
cancer cells, little is known about the mechanisms that regulate their activity in the
chemoresistant cancer cells other than substrate availability as well as how the
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activity of these transporters is regulated by the metabolic state of the cell (Robey
et al., 2018). Therefore, determining how the metabolic state of the cell affects ABC
transporter activity could provide alternative pathways for the generation of novel
inhibitors for these transporters to overcome chemoresistance.
The two main pathways for ATP synthesis are glycolysis in the cytosol and
oxidative phosphorylation in mitochondria. Cancer cells predominantly utilize
aerobic glycolysis to generate ATP for proliferation and biosynthesis (Liberti and
Locasale, 2016; Vander Heiden et al., 2009) (Koppenol et al., 2011; Warburg, 1956).
While historically switching to a glycolytic metabolism at the expense of
mitochondrial respiration was viewed as an approach to promote cancer
progression, it is now clear that mitochondria contribute to a number of functions
in cancer cells (DeBerardinis and Chandel, 2016; Wallace, 2012; Zong et al., 2016).
Several studies have shown an upregulation of the mitochondrial respiratory
machinery in slow-cycling, chemoresistant melanoma cells with a quiescent
phenotype generated upon drug treatment (Cierlitza et al., 2015; Roesch et al.,
2013). This has also been reported in cancer stem cells, which are also more
quiescent and resistant to therapy (Abdullah and Chow, 2013). Inhibition of the
electron transport chain (ETC) with different pharmacological inhibitors in these
slow-cycling resistant cells has been shown to restore drug sensitivity (Roesch et
al., 2013). Interestingly, the increased response to drug treatment is not thought to
be mediated by the reduction of mitochondrial metabolism but by increasing the
production of reactive oxygen species that together with the drug effect promote
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death of these quiescent cancer cells (Cierlitza et al., 2015). The regulation of
mitochondrial respiration in normal-cycling chemoresistant cancer cells and the
contribution of mitochondrial versus glycolytic ATP to ABC transporter mediated
chemoresistance remain unclear.
Here we show that mitochondrial ATP is essential for drug efflux mediated
by ABC transporters in chemoresistant cancer cells. In contrast, ATP from
glycolysis is dispensable, therefore upregulation of mitochondrial metabolism
contributes to this mechanism of chemoresistance. Methylation controlled J
protein (MCJ, encoded by DnaJC15) is an endogenous brake on mitochondrial
respiration that negatively regulates Complex I activity (Barbier-Torres et al., 2017;
Champagne et al., 2016; Hatle et al., 2013; Navasa, Martin, et al., 2015).
Retrospective and prospective studies have shown that loss of MCJ expression in
tumors correlates with chemotherapy resistance and poor prognosis in breast and
ovarian cancer patients (Fernandez-Cabezudo et al., 2016; Strathdee et al., 2005).
Here we show increased mitochondrial respiration due to the loss of MCJ in
normal-cycling chemoresistant cancer cells. Importantly, we have developed
therapeutic MCJ mimetics that attenuate mitochondrial respiration and ABC
transporter activity in chemoresistant cancer cells both in vitro and in vivo.
Restoring MCJ function is therefore a viable therapeutic strategy to inhibit ABC
transporter function and overcome chemoresistance in cancer.
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3. Results
3.1. Cancer cells reprogram mitochondrial metabolism when acquiring
multidrug resistance
Increased mitochondrial respiration due to upregulation of the ETC
machinery has been found in slow-cycling drug resistant cancer cells (e.g., stem
cells, quiescent cells). However, it remains unclear whether mitochondrial
respiration is also enhanced in normal-cycling cancer cells that are multidrug
resistant due to mechanisms other than a slow-cycling rate. To examine differences
in mitochondrial respiration between chemosensitive and chemoresistant normalcycling cancer cells, we used the well-known multidrug resistant NCI/ADR-RES
ovarian cancer cell line and its chemosensitive parental OVCAR-8 cell line. The
difference in drug response between the two cell lines was verified using
doxorubicin, a standard clinical chemotherapeutic agent and the selective agent
used to obtain NCI/ADR-RES cells. (Supplementary Figure 3-1A).
Mitochondrial respiration was examined using the Seahorse Mito Stress test
for mitochondrial oxygen consumption rates (OCR). NCI/ADR-RES cells had
higher basal OCR than OVCAR-8 cells (Figure 3-1A and B), indicating that overall
mitochondrial respiration is increased in NCI/ADR-RES cells. In contrast, baseline
extracellular acidification (ECAR), a parameter for the rate of glycolysis, was
comparable between NCI/ADR-RES cells and OVCAR-8 cells (Supplementary
Figure 3-1B). The maximal respiratory capacity, determined by subtracting the
OCR obtained after rotenone plus antimycin from OCR after the un-coupler FCCP,
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was also higher in NCI/ADR-RES cells relative to OVCAR-8 cells (Figure 3-1B),
indicating that the overall ability to employ mitochondrial respiration was higher
in chemoresistant cells. We also determined the OCR linked to mitochondrial ATP
production by subtracting OCR after oligomycin from baseline OCR. The levels of
ATP-linked OCR were significantly higher in NCI/ADR-RES cells than OVCAR-8
cells (Figure 3-1B), suggesting that production of mitochondrial ATP was
increased in NCI/ADR-RES cells. To further investigate the fraction of total ATP
production that was derived from mitochondrial respiration we used the Seahorse
XF Real Time ATP Rate assay. The fraction of ATP production derived from
mitochondria within the total ATP production was increased in NCI/ADR-RES
cells compared with OVCAR-8 cells (Figure 3-1C). Thus, chemoresistant
NCI/ADR-RES have an increased ability to undergo mitochondrial respiration
and to produce ATP via OXPHOS.
To show that increased mitochondrial respiration is also characteristic of
other chemoresistant cells, we used the chemoresistant MES/Dox uterine cancer
cell line and its chemosensitive parental MES-SA (MES) cell line. The difference in
chemotherapy responses between the two cell lines was verified using
doxorubicin (Supplementary Figure 3-1C). Using the Seahorse Mito Stress assay,
MES/Dox cells were found to have higher basal OCR compared with MES cells
(Figure 3-1D), while no differences were found in baseline ECAR (Supplementary
Figure 3-1D). In addition, ATP-linked OCR and maximal respiratory capacity were
also elevated in MES/Dox cells (Figure 3-1E). Furthermore, like NCI/ADR-RES
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cells, the relative contribution of mitochondrial ATP production to the total ATP
production was also higher in MES/Dox cells than in their chemosensitive
parental cell line (Figure 3-1F). Therefore, enhanced mitochondrial respiration is a
common phenotype in independently generated chemoresistant cancer cell lines
from distinct origins (ovarian and uterine cancer).
Since both chemoresistant NCI/ADR-RES and MES/Dox cancer cells were
derived from their parental cell lines using doxorubicin as a selective agent, we
examined MCF7/Tx400 breast cancer cells that were derived from the
chemosensitive MCF7 cell line using paclitaxel as a selective agent. Increased
resistance to doxorubicin in MCF7/Tx400 cells was validated (Supplementary
Figure 3-1E). Relative to MCF7 cells, MCF7/Tx400 cells exhibited increased basal
OCR (Figure 3-1G), but comparable baseline ECAR (Supplementary Figure 3-1F).
ATP-linked OCR and maximal respiratory capacity were also higher in
MCF7/Tx400 cells (Figure 3-1H). The relative contribution of mitochondrial ATP
production to the total ATP production was more prominent in MCF7/Tx400 cells
as well (Figure 3-1I). Thus, chemoresistant breast cancer cells also have greater
capacity to produce mitochondrial ATP.
To further demonstrate a prominent selective mitochondria component in
the overall cell metabolism of chemoresistant cancer cells, we performed mass
spectrometry-based, high-throughput metabolic profiling using chemoresistant
NCI/ADR-RES cancer cells and their chemosensitive parental OVCAR-8 cells. The
nonbiased metabolome analysis revealed distinct metabolic profiles for the two
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cancer cell lines (Figure 3-1J and Supplementary Table 3-1). While the levels of
some metabolites were decreased, the levels of other metabolites were increased
in NCI/ADR-RES cells compared to OVCAR-8 cells (Figure 3-1J). Consistent with
the increased mitochondrial respiration of NCI/ADR-RES described above, these
cells exhibited (i) an enrichment for the products of substrates of mitochondrial
metabolism (including several amino acids), (ii) decreases in glycolytic metabolites
and byproducts (pyruvate, lactate) accompanied by increases in carboxylic acids
from the TCA cycle (citrate, succinate), (iii) increases in products of amino acid
catabolism (urea cycle intermediates and creatine/creatinine), (iv) increases in
NADPH and pentose phosphate pathway intermediates (glucose 6-phosphate and
sedoheptulose phosphate) as well as glutathione precursors (g-glutamyl cysteine)
and metabolites (glutathione disulfide, ascorbate), (v) increases in high energy
phosphate compounds (e.g. ATP) and nucleotide metabolism, and (vi) increased
NAD+, the product of Complex I of the ETC (Supplementary Figure 3-2). Taken
together, these results show an enhanced mitochondrial metabolism and a
predominant contribution of mitochondria to overall ATP synthesis in normalcycling chemoresistant cancer cells.
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Figure 1 – Champagne et al.
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Figure 3-1. Chemoresistant cancer cells exhibit increased
mitochondrial respiration and ATP production
(A and B) OVCAR-8 and NCI/ADR-RES cells were analyzed by Seahorse
MitoStress Assay for (A) oxygen consumption rates (OCR) at baseline and in
response to sequential injections of oligomycin (O), FCCP (F), and rotenone with
antimycin (RA) and for (B) basal, ATP linked (ATP), and maximal respiration rates
(Max) relative to OVCAR-8 cells (n ≥ 5). (C) Rates of mitochondrial production of
ATP relative to the total ATP production rate in OVCAR-8 and NCI/ADR-RES
cells as determined by Seahorse ATP Production Rate Assay (n ≥ 7). (D and E) OCR
of MES and MES/Dox cells were determined as in (A and B) (n ≥ 7). (F)
Mitochondrial ATP production rates of MES and MES/Dox cells were determined
as in (C) (n = 11). (G and H) OCR of MCF7 and MCF7/Tx400 cells were determined
as in (A and B) (n ≥ 6). (I) Mitochondrial ATP production rates of MCF7 and
MCF7/Tx400 cells were determined as in (C) (n = 9). (J) Relative abundances of
metabolic intermediates in OVCAR-8 and NCI/ADR-RES cells as determined by
mass spectrometry based metabolomics (n = 4). Mean ± SD provided. *denotes
p < 0.05 by unpaired t test. Results are representative of 2 - 3 experiments.
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3.2. Mitochondrial respiration prevents drug accumulation in chemoresistant
cancer cells
NCI/ADR-RES

cells

are

resistant

to

doxorubicin

and

other

chemotherapeutic drugs because drugs fail to accumulate in the cells, and higher
doses are needed to cause cell death. To investigate whether increased
mitochondrial respiration could contribute to preventing drug accumulation in
NCI/ADR-RES cells, we took advantage of the intrinsic fluorescence of
doxorubicin. NCI/ADR-RES cells were incubated in the presence or absence of the
mitochondrial respiration inhibitors oligomycin, which blocks mitochondrial ATP
synthase (Complex V), or rotenone, which blocks Complex I. After 2 h doxorubicin
was added to the cells, and they were incubated for an additional 3 h. Doxorubicin
cellular accumulation was then examined by confocal microscopy. Neither
oligomycin nor rotenone had an effect on cell survival for this short period of time
(data not shown). As expected, in the absence of oligomycin or rotenone,
NCI/ADR-RES cells treated with doxorubicin contained little to no intracellular
doxorubicin. Strikingly, the addition of either rotenone or oligomycin resulted in
a pronounced accumulation of doxorubicin in the cells (Figure 3-2A and B). We
also examined the effect of inhibiting mitochondrial respiration on doxorubicin
accumulation by flow cytometric analysis. NCI/ADR-RES cells were treated with
increasing doses of oligomycin or rotenone for 2 h followed by incubation with
doxorubicin for an additional 3 h. Cells were then fixed and analyzed by flow
cytometry for doxorubicin fluorescence. Similar to the analysis by microscopy,
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both oligomycin (Figure 3-2C) and rotenone (Figure 3-2D) robustly increased
doxorubicin accumulation in the cells in a dose-dependent manner. Thus,
mitochondrial-derived ATP is necessary to prevent doxorubicin accumulation in
NCI/ADR-RES cells.
Cancer cells are typically highly dependent on glycolytic pathways for ATP
generation and for cell proliferation. We therefore examined whether glycolysis as
source of ATP was also necessary to prevent drug accumulation in chemoresistant
cells. NCI/ADR-RES cells were treated with 2-deoxyglucose (2-DG), an inhibitor
of glycolysis, for 2 h. As a control, we also treated cells with oligomycin as
described above. Doxorubicin was added and 3 h later cells were fixed and
analyzed by confocal microscopy. In contrast to oligomycin, treatment with 2-DG
did not increase doxorubicin accumulation (Figure 3-2E and F). As another
approach to inhibit glycolysis, we incubated NCI/ADR-RES cells in medium
lacking glucose for 24 h prior to addition of doxorubicin, however a lack of glucose
also did not restore doxorubicin accumulation (Figure 3-2E and F). We performed
similar experiments examining doxorubicin fluorescence by flow cytometry in
NCI/ADR-RES cells treated with increasing doses of 2-DG. The results further
showed that inhibition of glycolysis with a high dose of 2-DG does not restore
drug accumulation in NCI/ADR-RES cells cancer cells (Figure 3-2G). To verify the
activity of the 2-DG used for these studies we measured total ATP levels in the
cells. NCI/ADR-RES cells were treated with the highest concentration of
oligomycin or 2-DG used in the above assays for 5 h (same period of time used in
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the efflux experiments) and then total ATP levels were determined. Relative to
untreated cells, ATP levels were strongly reduced in NCI/ADR-RES cells treated
with either oligomycin or 2-DG (Figure 3-2H), indicating that 2-DG was active.
Thus, inhibition of mitochondrial respiration, but not glycolysis, promotes
doxorubicin accumulation. Neither oligomycin, rotenone, nor 2-DG had an effect
in the accumulation of doxorubicin in the parental chemosensitive OVCAR-8 cells
(Supplementary Figure 3-3A), further demonstrating that regulation of drug
accumulation is restricted to chemoresistant cancer cells.
To investigate whether the differential contribution of mitochondrial
respiration versus glycolysis to the failure of drug accumulation occurs in other
chemoresistant cells, MES/Dox cells were treated with oligomycin, rotenone, and
2-DG, followed by incubation with doxorubicin for an additional 3 h and flow
cytometry analysis. Similar to NCI/ADR/RES cells, treatment of MES/Dox cells
with either oligomycin or rotenone caused a marked doxorubicin accumulation
(Figure 3-2I). In contrast, treatment with 2-DG did not restore doxorubicin
accumulation (Figure 3-2I). No effect of oligomycin, rotenone, or 2-DG was
detected on doxorubicin accumulation in the parental MES cells (Supplementary
Figure 3-3B). Together, these results demonstrate the selective contribution of
mitochondrial respiration, but not glycolysis, in preventing chemotherapeutic
agent accumulation in chemoresistant cancer cells.
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Figure 2 – Champagne et al.
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Figure 3-2. Mitochondrial respiration, but not glycolysis, is
responsible for reduced drug accumulation in chemoresistant cells
(A and B) NCI/ADR-RES cells were incubated with or without (Veh) oligomycin
(Oligo, 5 µM) or rotenone (Rote, 50 µM) for 2 h followed by incubation with
doxorubicin (Dox, 3 µM) for 3 h. Cells were then fixed, stained with DAPI (nuclear
dye, blue), and analyzed by confocal microscopy for doxorubicin fluorescence
(red). (A) Representative images. Scale bars represent 20 µm. (B) Quantification of
doxorubicin intensity relative to nuclear area (n ≥ 12 cells). (C and D)
NCI/ADR-RES cells were incubated with increasing concentrations of (C)
oligomycin or (D) rotenone as indicated for 2 h followed by incubation with
doxorubicin as in (A). Cells were then fixed and analyzed for doxorubicin
fluorescence by flow cytometry. Median fluorescence intensity (MFI) is shown
(n = 3). (E and F) NCI/ADR-RES cells were incubated with oligomycin (5 µM) or
2-deoxyglucose (2-DG, 50 mM) for 2 h or without glucose (No Gluc) for 24 h
followed by incubation with doxorubicin as in (A). Cells were then fixed, stained,
and analyzed as in (A and B). (E) Representative images. Scale bars represent
20 µm. (F) Quantification of doxorubicin intensity relative to nuclear area (n ≥ 46
cells). (G) NCI/ADR-RES cells were incubated with increasing concentrations of
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2-deoxyglucose as indicated for 2 h followed by incubation with doxorubicin as in
(A). Cells were then fixed and analyzed as in (C and D) (n = 3). (H) NCI/ADR-RES
cells were incubated with oligomycin (5 µM) or 2-deoxyglucose (50 mM) for 5 h
and then total ATP levels were determined by Luciferase assay (n = 4). (I)
MES/Dox cells were incubated with oligomycin (5 µM), rotenone (50 µM), or 2-DG
(50 mM) for 2 h followed by incubation with doxorubicin as in (A). Cells were then
fixed and analyzed as in (C and D) (n = 3). Mean ± SD provided. *denotes p < 0.05
by one-way ANOVA and Tukey’s multiple comparisons test. Results are
representative of 2 - 3 experiments.

3.3. ABC transporter activity in chemoresistant cancer cells is selectively
dependent on mitochondrial ATP
A major mechanism that chemoresistant cancer cells use to avoid
accumulation of chemotherapeutic drugs is the acquisition of ABC transporters
that actively promote drug efflux. ABC transporters utilize the energy of ATP
hydrolysis to actively transport substrates against concentration gradients. While
the expression of specific ABC transporters has been largely studied in
chemoresistant cancer cells, including NCI/ADR-RES cells (Fairchild et al., 1987;
Robey et al., 2018), little is known about the regulation of their activity and capacity
to promote drug efflux. Since the results above show that drug accumulation in
chemoresistant cancer cells is highly dependent on mitochondrial-derived ATP
but not glycolytic ATP, we examined the contribution of these two pathways of
generating energy on the activity of ABC transporters.
ABCB1 is overexpressed in NCI/ADR-RES cells (Fairchild et al., 1987). We
therefore

measured

ABCB1

activity

using

a

calcein

retention

assay.

NCI/ADR-RES cells were treated with oligomycin or 2-DG for 2 h followed by
incubation with calcein for 15 min. Cells were then dissolved in DMSO, and calcein
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fluorescence was determined. Inhibition of mitochondrial respiration by
oligomycin caused a marked reduction of ABCB1 activity as indicated by
increased retention of calcein (Figure 3-3A). In contrast, 2-DG treatment had no
effect on ABCB1 activity (Figure 3-3A). To further demonstrate the contribution of
mitochondrial respiration to ABCB1 activity, we used HEK 293T cells which do
not express ABCB1 (HEK 293T), and HEK 293T-ABCB1 cells generated by stable
transfection of ABCB1. As expected, relative to control HEK 293T cells, HEK 293TABCB1 cells failed to accumulate calcein due to the presence of ABCB1 (Figure
3-3B). However, treatment of HEK 293T-ABCB1 cells with oligomycin markedly
increased calcein levels (Figure 3-3B), while 2-DG treatment had no effect (Figure
3-3B). Since doxorubicin is also a substrate of ABCB1, we examined doxorubicin
accumulation by flow cytometry in HEK 293T-ABCB1 cells in the presence or
absence of different metabolic inhibitors. As expected, almost no doxorubicin
could be detected in HEK 293T-ABCB1 cells relative to control HEK 293T cells
(Figure 3-3C). However, treatment with oligomycin or rotenone prevented
doxorubicin efflux by ABCB1 transporter, while 2-DG had no effect (Figure 3-3C).
Thus, ABCB1 activity requires mitochondrial-derived ATP.
To investigate the need of mitochondrial respiration for the activity of other
ABC transporters, we examined the accumulation of Hoechst 33258, a known dye
substrate for ABCG2, which is also abundantly expressed by NCI/ADR-RES cells.
Hoechst accumulation was examined in NCI/ADR-RES cells after pre-treatment
oligomycin, rotenone, or 2-DG. As expected, no Hoechst could be detected in
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NCI/ADR-RES cells, but treatment with either oligomycin or rotenone blocked
ABCG2-mediated efflux and restored Hoechst accumulation (Figure 3-3D). In
contrast, treatment with 2-DG had no effect (Figure 3-3D). To further verify the
effect of mitochondrial respiration on ABCG2 activity, we analyzed HEK 293T
cells that stably overexpress ABCG2 (HEK 293T-ABCG2). Relative to control HEK293T cells that do not express ABCG2, the presence of ABCG2 in HEK 293TABCG2 cells prevented these cells from accumulating Hoechst (Figure 3-3E).
However, treatment with either oligomycin or rotenone restored the ability of
HEK 293T-ABCG2 cells to accumulate Hoechst, while 2-DG had no effect (Figure
3-3E), further demonstrating that, as for ABCB1, efflux activity of ABCG2 is also
dependent on mitochondrial respiration. Thus, while ABC transporters can
mediate drug efflux and confer resistance to chemotherapy, their activity requires
ATP specifically generated by mitochondrial respiration.
To determine the actual ATP cost of ABC transporters relative to the total
cellular ATP pool, we examined the impact of the high use of ABC transporters on
total ATP levels. NCI/ADR-RES cells were incubated for 5 h with increasing
amounts of rhodamine B, a non-chemotherapeutic substrate of ABCB1, with the
goal of inducing excess ABCB1 activity mediating rhodamine efflux. Total ATP
levels were then determined by Luciferase assay. Interestingly, relative to cells
without substrate, rhodamine caused a substantial reduction of total ATP levels in
a dose-dependent manner (Figure 3-3F). Although rhodamine does not seem to
have harmful effects, to rule out potential toxic effects of high concentrations of
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rhodamine that may cause a reduction in the total ATP levels, we performed
similar experiments using HEK 293T-ABCB1 cells and control HEK 293T cells.
HEK 293T-ABCB1 cells treated with a high concentration of rhodamine also
experienced a significant reduction in total ATP levels (Figure 3-3G). In contrast,
ATP levels in the control HEK 293T cells were not affected by the high
concentration of rhodamine (Figure 3-3G). Taken together, these results indicate
that a high concentration of ATP is needed to sustain ABC transporter activity.
Similar to high Ca2+ microdomains in the cytoplasm, intracellular ATP-rich
microdomains have been identified using an intracellular probe for ATP
(Champagne et al., 2016). We have previously shown that these ATP-rich
microdomains are dependent on high mitochondrial respiration in CD8+ T cells
triggered by the lack of the negative regulator of mitochondrial respiration MCJ.
Since it is thought that ABC transporters have a low affinity for ATP in the absence
of substrate (Linton and Higgins, 2007) and that their activity is highly dependent
on mitochondrial ATP based on results presented above, we examined the
presence ATP-rich microdomains in NCI/ADR-RES cells using a fluorescent
probe for ATP and live cell confocal microscopy analysis. The presence of ATPrich microdomains was clear in NCI/ADR-RES cells as determined by distinct
puncta throughout the cytosol (Figure 3-3H). These areas of high ATP
concentration were the result of mitochondrial ATP production as they were
significantly reduced by pre-treatment of NCI/ADR-RES cells with oligomycin or
rotenone for 2 h prior to analysis (Figure 3-3H). However, treatment with 2-DG
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had no effect on the presence of these ATP-rich microdomains (Figure 3-3H). Thus,
increased mitochondrial respiration in chemoresistant cells results in the presence
of ATP-rich microdomains that serve to increase local ATP levels and can fuel
energy-demanding ABC transporters.
Figure 3 – Champagne et al.
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Figure 3-3. Mitochondrial respiration provides the energy required
for ABC transporter activity.
(A) NCI/ADR-RES cells were treated with or without (Veh) oligomycin (Oligo,
5 µM) or 2-deoxyglucose (2-DG, 50 mM) for 2 h followed by incubation with
calcein (0.25 µM) for 15 min. Cells were then washed, dissolved in DMSO, and
calcein fluorescence relative to untreated cells was determined (n = 3). (B) Calcein
fluorescence in HEK 293T cells (293T) and ABCB1-expressing HEK 293T cells
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(293T-ABCB1) was determined as in (A) (n ≥ 3). (C) 293T and 293T-ABCB1 cells
were treated with oligomycin (5 µM), rotenone (50 µM), or 2-DG (50mM) for 2 h
followed by incubation with doxorubicin (Dox, 3 µM) for 3 h. Cells were then fixed
and analyzed for doxorubicin fluorescence by flow cytometry. Median
fluorescence intensity (MFI) is shown (n = 3). (D) NCI/ADR-RES cells were treated
with oligomycin (5 µM), rotenone (50 µM), or 2-DG (50 mM) for 2 h followed by
incubation with Hoechst (100 ng/mL) for 3 h. Cells were then fixed and analyzed
for Hoechst fluorescence by flow cytometry. Median fluorescence intensity (MFI)
is shown (n = 3). (E) 293T and 293T-ABCB1 cells were treated and analyzed as in
(D) (n = 3). (F) NCI/ADR-RES cells were incubated with increasing concentrations
of rhodamine (Rho) B as indicated for 5 h and then total ATP levels were
determined by Luciferase assay. The percent reduction in ATP relative to
untreated cells is shown (n = 3). (G) 293T and 293T-ABCB1 cells were incubated
with or without rhodamine B (100 µM) for 5 h and then analyzed as in (F) (n ≥ 3).
(H) NCI/ADR-RES cells were incubated with oligomycin (5 µM), rotenone (50
µM), or 2-DG (50 µM) for 2 h, stained with a fluorescent ATP probe (100 µM) for 5
min, and then analyzed by live cell confocal microscopy. ATP probe fluorescence
(green) and bright light differential interference contrast (DIC) are shown. Scale
bars represent 10 µm. Mean ± SD provided. *denotes p < 0.05 by one-way ANOVA
and Tukey’s multiple comparisons test. Results are representative of 2 - 3
experiments.

3.4. Increased mitochondrial respiration due to the loss of MCJ fuels drug efflux
The above results indicate that increased mitochondrial respiration
contributes to chemoresistance in cancer cells by promoting drug efflux,
suggesting that drug-mediated selection for genetic or epigenetic changes within
cancer cells that affect mitochondrial respiration could lead to chemoresistance.
The mitochondrial protein MCJ (encoded by the DNAJC15 gene) is an endogenous
negative regulator of Complex I that restricts the activity of the ETC (Hatle et al.,
2013). In CD8+ T cells and hepatocytes, MCJ deficiency results in increased
Complex I activity, increased mitochondrial respiration, and the presence of ATPrich microdomains (Barbier-Torres et al., 2017; Champagne et al., 2016; Hatle et al.,
2013). Interestingly, we and others have shown that MCJ deficiency in cancer cells
is linked to increased chemoresistance in breast and ovarian cancer patients and
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in mouse models of breast cancer (Fernandez-Cabezudo et al., 2016; Strathdee et
al., 2005). However, previous studies have not addressed the effect of MCJ on
mitochondrial respiration in cancer cells nor its association with ABC transporter
activity.
We first examined whether MCJ acts as a negative regulator of
mitochondrial respiration in drug sensitive cancer cells. MCF7 cells express high
levels of MCJ (Hatle et al., 2007). We transfected MCF7 cells with an siRNA specific
for MCJ (siMCJ) or a control siRNA (C-siRNA). After 2 d, decreased levels of MCJ
were verified by Western blot analysis (Figure 3-4A). We then examined
mitochondrial respiration by measuring OCR using the Seahorse MitoStress assay.
MCF7 cells transfected with siMCJ had higher basal OCR than those transfected
with control siRNA (Figure 3-4B and C). ATP-linked OCR and maximal
respiratory capacity were also higher in siMCJ transfected cells (Figure 3-4C).
Furthermore, the relative production of mitochondrial ATP within the total ATP
pool was also elevated after MCJ knock down (Figure 3-4D). To determine
whether increased mitochondrial respiration caused by the loss of MCJ could also
lead to the presence of ATP-rich microdomains identified in chemoresistant cells,
siMCJ-transfected MCF7 cells were stained with the ATP probe and analyzed by
live cell confocal microscopy. Almost no ATP puncta could be found in C-siRNA
transfected cells (Figure 3-4E). In contrast, MCF7 cells transfected with siMCJ had
a large number of well-defined ATP-rich domains (Figure 3-4E). Pre-treatment of
siMCJ transfected MCF7 cells with either oligomycin or rotenone for 2 h prior to
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analysis reduced the presence of ATP-rich domains, while treatment with 2-DG
did not (Figure 3-4E). Thus, increased mitochondrial respiration due to the loss of
MCJ in human drug-sensitive breast cancer cells promotes the formation of
mitochondrial-derived ATP-rich domains.
To demonstrate the effect of MCJ on the mitochondrial respiration of
primary cancers in addition to cancer cell lines, we used mammary tumor cells
from MMTV-PyMT mice (WT MMTV) and MMTV-PyMT mice crossed with MCJdeficient mice (MCJ KO MMTV) previously generated (Fernandez-Cabezudo et al.,
2016). We previously showed that mammary tumor development and tumor
growth in MCJ KO MMTV mice was comparable to their development in MMTV
mice, although tumors from MCJ KO MMTV mice are more resistant to
doxorubicin treatment (Fernandez-Cabezudo et al., 2016). We first examined OCR
in cells isolated from MMTV and MCJ KO MMTV tumors. MCJ KO tumor cells
had higher basal OCR compared with wildtype MMTV tumor cells (Figure 3-4F
and G). Moreover, ATP-linked OCR and maximal respiratory capacities were also
higher in MCJ KO cancer cells compare to wildtype cancer cells (Figure 3-4G).
Thus, loss of MCJ in primary cancer cells results in increased mitochondrial
respiration.
Since MCJ deficiency leads to resistance to doxorubicin and other
chemotherapeutic drugs, we investigated whether the lack of MCJ in MCJ KO
MMTV tumor cells prevented accumulation of doxorubicin due to increased
mitochondrial-derived ATP. Primary tumor cells isolated from WT MMTV and
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MCJ KO MMTV mice were expanded in vitro and then pretreated with oligomycin
for 2 h followed by the addition of doxorubicin for 3 h. Intracellular doxorubicin
accumulation was then examined by confocal microscopy. While doxorubicin was
clearly present in WT MMTV tumor cells, it was almost undetectable in MCJ KO
MMTV cells (Figure 3-4H). However, inhibiting mitochondrial ATP production
with oligomycin restored doxorubicin accumulation in MCJ KO MMTV cells
(Figure 3-4H). Oligomycin had little to no effect on doxorubicin accumulation in
WT MMTV cells (Figure 3-4H). Together these results reveal the mechanism
whereby loss of MCJ as a mitochondrial regulator can cause chemoresistance in
cancer cells. Loss of MCJ results in enhanced mitochondrial respiration that is
necessary to fuel ABC transporter-mediated drug efflux.
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Figure 4 – Champagne et al.

E
Oligo

Rote

H

WT MMTV

WT MMTV
MCJ KO MMTV

2.5
2.0
1.5
1.0
0.5
0.0

*

*

500
250
0

0 25 50 75 100
Time (min)

MCJ KO MMTV
Veh
Oligo

M
ax

AT
P

Ba
s

al

Dox

*

Oligo

750

WT MMTV
MCJ KO MMTV
O F RA

DAPI

Veh

OCR
(Relative)

iR
N
si A
M
C
J

OCR (pmol/min)

DIC

G

*

2-DG

ATP Probe

Veh

50
40
30
20
10
0

-s

F

siMCJ
C-siRNA

*

C

0 20 40 60 80
Time (min)

sa
l

0

*

Mitochondrial ATP
Production Rate
(% of Total)

2

*

D

C-siRNA
siMCJ

M
ax

4

2.5
2.0
1.5
1.0
0.5
0.0

Ba

GAPDH

C

C-siRNA
siMCJ
F RA

OCR
(Relative)

MCJ

6

O

AT
P

B
OCR
(pmol/min/103 cells)

A

Figure 3-4. Loss of MCJ in cancer cells enhances mitochondrial
respiration
(A) MCJ expression in MCF7 cells transfected with a control siRNA (C-siRNA) or
an siRNA specific for MCJ (siMCJ) as determined by Western blot analysis.
GAPDH is shown as a loading control. (B and C) MCF7 cells transfected with
C-siRNA or siMCJ were analyzed by Seahorse MitoStress Assay for (B) oxygen
consumption rates (OCR) at baseline and in response to sequential injections of
oligomycin (O), FCCP (F), and rotenone with antimycin (RA) and for (C) basal,
ATP linked (ATP), and maximal respiration rates (Max) relative to C-siRNA
transfected cells (n ≥ 5). (D) Rates of mitochondrial production of ATP relative to
the total ATP production rate in MCF7 cells transfected with a c-siRNA or siMCJ
as determined by Seahorse ATP Production Rate Assay (n = 10). (E) MCF7 cells
transfected with C-siRNA or siMCJ were incubated with or without (Veh)
oligomycin (Oligo, 5 µM), rotenone (Rote, 50 µM), or 2-deoxyglucose (2-DG, 50µM)
for 2 h, stained with a fluorescent ATP probe (100 µM) for 5 min, and then analyzed
by live cell confocal microscopy. ATP probe fluorescence (green) and bright light
differential interference contrast (DIC) are shown. Scale bars represent 10 µm. (F
and G) Cancer cells were isolated from mammary tumors of WT MMTV-PyMT
mice (WT MMTV) and MCJ deficient MMTV-PyMT mice (MCJ KO MMTV),
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expanded in vitro, and then analyzed for OCR as in (B and C). (B, n = 3; C, n ≥ 8).
(H) WT MMTV and MCJ KO MMTV cells were incubated with oligomycin (5 µM)
for 2 h followed by incubation with doxorubicin (Dox, 3 µM) for 3 h. Cells were
then fixed, stained with DAPI (nuclear dye, blue), and analyzed by confocal
microscopy for doxorubicin fluorescence (red). Scale bars represent 20 µm. Mean
± SD provided. *denotes p < 0.05 by unpaired t test. Results are representative of
2 - 3 experiments.

3.5. MCJ mimetics attenuate mitochondrial respiration in chemoresistant cells
The results above indicate that inhibiting mitochondrial respiration could
be a novel approach to overcome cancer chemoresistance. However, rotenone and
other inhibitors of the ETC are highly toxic as they potently and indiscriminately
block mitochondrial respiration. Ideally, an approach that safely attenuates ETC
without a full blockage could be more appropriate as a potential therapeutic. MCJ
is the first identified endogenous negative regulator of Complex I and
mitochondrial respiration, and it is abundantly expressed in some of the highly
metabolically active tissues (e.g., liver, heart) (Hatle et al., 2013). Since the absence
of MCJ causes chemoresistance, we investigated whether MCJ mimetics could
restore MCJ function as a brake on the ETC in chemoresistant cancer cells. The Nterminal region (35 aa) of MCJ has no significant homology to any other currently
known eukaryotic protein, and it has been predicated to interact with the NDUFv1
subunit of Complex I (Hatle et al., 2013). We therefore designed peptide mimetics
of MCJ containing the first 20 aa of the N-terminus of human MCJ (N-MCJ). Two
different MCJ mimetics were designed with different sequences added to mediate
delivery into mitochondria (Supplementary Figure 3-4). The MITOx20 mimetic
contains the N-MCJ sequence in addition to the HIV TAT tag that is routinely used
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to confer cell permeability to peptides (Nagahara et al., 1998; Schwarze et al., 1999)
and a mitochondrial targeting sequence (mts) (Addya et al., 1997) (Supplementary
Figure 3-4). For the MITOx30 mimetic, the same N-MCJ sequence was added to a
previously described mitochondria-penetrating peptide (MPP) (Horton et al.,
2008). The MPP contains hydrophobic, noncanonical amino acids and provides for
efficient delivery both into cells and into mitochondria (Supplementary Figure
3-4).
We tested whether these N-MCJ mimetics could restore MCJ function in
inhibiting mitochondrial respiration in cancer cells lacking MCJ using the Seahorse
Cell MitoStress assay. NCI/ADR-RES cells were incubated with MITOx20 for 12 h
prior to analysis. As a control we used a peptide similar to MITOx20 that contains
the HIV TAT tag but lacks the mitochondrial targeting sequence (Control-20).
Therefore, it can penetrate the cell membrane, but cannot accumulate in
mitochondria (Supplementary Figure 3-4). MITOx20-treated cells exhibited lower
basal OCR relative to Control-20-treated cells (Figure 3-5A and B). MITOx20
treatment also reduced ATP-linked OCR and the maximal respiratory capacity of
NCI/ADR-RES cells (Figure 3-5B). To confirm that the effects of MITOx20 were
due to the MCJ N-terminal component, similar experiments were performed using
MITOx30. As control for MITOx30, we used a peptide comparable to MITOx30
except that the MCJ sequence was reversed (Control-30). NCI/ADR-RES cells
treated with MITOx30 showed lower basal OCR relative to cells treated with
Control-30 (Figure 3-5C and D). In addition, ATP-linked OCR and the maximal
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respiratory capacity of NCI/ADR-RES cells treated with MITOx30 were also lower
compared with cells treated with Control-30 (Figure 3-5D). We also examined
whether the treatment with N-MCJ mimetics had an impact on the overall ATP
levels in NCI/ADR-RES cells. Both treatment with MITOx20 and MITOx30
significantly lowered total ATP levels after 12 h of treatment compared to
untreated cells (Figure 3-5E). In addition, to show that the effect of the N-MCJ
mimetics was directly on ETC activity, similar to oligomycin or rotenone, we used
a modified Seahorse MitoStress assay where MITOx30 was injected instead of
oligomycin (Figure 3-5F). While slower and less pronounced than the effect
induced by oligomycin, MITOx30 injection caused a major and prolonged
reduction in baseline OCR as well as in the maximal respiratory capacity of
NCI/ADR-RES cells (Figure 3-5F). Thus, together these results show that these NMCJ mimetics can restore MCJ function by attenuating (but not abrogating)
mitochondrial respiration in chemoresistant cells.
Our results above (Figure 3-1) show an enhanced mitochondrial
metabolism in NCI/ADR-RES cells. To determine whether the treatment with NMCJ mimetics could also affect overall mitochondrial metabolism, NCI/ADR-RES
cells were treated with MITOx30 for 12 h and then analyzed by mass spectrometrybased metabolomics. Results showed that this short period of treatment with
MITOx30 was sufficient to alter cell metabolism, primarily by decreasing
mitochondrial metabolism, as demonstrated by (i) decreases in TCA cycle
intermediates (citrate, fumarate, malate), (ii) decreases in NAD+, the product of
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Complex I, and (iii) increases in the levels of low energy phosphate compounds
(nucleoside di- and monophosphates) and decreases in nucleoside triphosphates
(ATP), creatine, and phosphocreatine – markers of energy reservoirs in
mitochondria (Figure 3-5G, Supplementary Figure 3-5, and Supplementary Table
3-2). Overall these results indicate that N-MCJ mimetics are sufficient to attenuate
mitochondrial function in MCJ-deficient cells.
Figure 5 – Champagne et al.

1.0

M
ax

AT
P

al
OCR
(Relative)

* *

200
Ve
M hic
IT le
M Ox2
IT 0
O
x3
0

0

500
400
300
200
100
0

*

Vehicle
MITOx30

0

50

ax
M

AT
P

l

F
800

*

0.0

25 50 75
Time (min)

sa

0

*

0.5

Ba

OCR (pmol/min)

25

E
ATP (nM)

Control-30
MITOx30
1.0

50

400

*

0.5

D

75

600

*

0.0

25 50 75
Time (min)

Control-30
MITOx30
O F RA

100

*

Ba
s

0

C

0

G
Control-20
MITOx20

OCR
(Relative)

125
100
75
50
25
0

B

Control-20
MITOx20
O F RA

OCR (pmol/min)

OCR (pmol/min)

A

F RA

100 150 200 250
Time (min)

Vehicle

MITOx30

UMP
γ-Glutamylcysteine
Octanoic acid
ADP
CMP
N-Acetylneuraminate
Adenylosuccinic acid
AMP
Guanine
GMP
Nonanoic acid
Diphosphate
Phosphate
Cytidine
Cysteine
Glutamine
Succinate
IMP
Shikimate-3-phosphate
Allantoate
Lysine
Glycine
Leucine
Arginine
Citrulline
Threonine
Nicotinamide
Sedoheptulose-1-phosphate
Phenylalanine
4-Aminobenzoate
Methionine-S-oxide
3-Methyleneoxindole
Valine
Cys-Gly
Alanine
Creatine
NAD+
Glutathione disulfide
Methylenediurea
Triacanthine
Fumarate
Glucose
Malate
Acetylcholine
Dimethylglycine
5,6-Dihydrothymine
Citrate
Hypoxanthine
2/3-Phosphoglycerate
Hypotaurine
Inosine
Phosphoenolpyruvate
Catechin
Guanosine
Taurine
Thioredoxin disulfide
Spermine
Phosphocreatine

Figure 3-5. MCJ mimetics attenuate mitochondrial respiration in
chemoresistant cancer cells
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(A and B) NCI/ADR-RES cells were treated with MITOx20 (25 µM) or Control-20
(25 µM) for 12 h and the analyzed by Seahorse MitoStress Assay for (A) oxygen
consumption rates (OCR) at baseline and in response to sequential injections of
oligomycin (O), FCCP (F), and rotenone with antimycin (RA) and for (B) basal,
ATP linked (ATP), and maximal respiration rates (Max) relative to Control-20
treated cells (n ³ 4). (C and D) NCI/ADR-RES cells were treated with MITOx30
(25 µM) or Control-30 (25 µM) for 12 h and then analyzed as in (A and B) (n = 4).
(E) NCI/ADR-RES cells were incubated with or without (Vehicle) MITOx20
(25 µM) or MITOx30 (25 µM) for 5 h and then total ATP levels were determined
by Luciferase assay (n = 4). (F) NCI/ADR-RES cells were analyzed for OCR at
baseline and in response to sequential injections of MITOx30 (25 µM), FCCP, and
rotenone with antimycin (n ³ 4). (G) NCI/ADR-RES cells were treated with
MITOx30 (25 µM) for 12 h and then the relative abundances of metabolic
intermediates compared to vehicle treated cells were determined by mass
spectrometry based metabolomics (n = 4). Mean ± SD shown. *denotes p < 0.05 by
unpaired t test or one-way ANOVA and Tukey’s multiple comparisons test.
Results are representative of 2 - 3 experiments.

3.6. MCJ mimetics decrease
mitochondrial respiration

chemoresistance

in

vitro

by

attenuating

Since ABC transporter-mediated chemoresistance is dependent upon
mitochondrial respiration, and N-MCJ mimetics can attenuate mitochondrial
respiration and ATP production in chemoresistant cells, we investigated whether
N-MCJ mimetics could restore doxorubicin accumulation in NCI/ADR-RES cells.
We choose a low concentration of MITOx20 that had no effect on the viability of
NCI/ADR-RES cells by itself even after 2 d of treatment (Figure 3-6A). To examine
the effect of MITOx20 on drug efflux, NCI/ADR-RES cells were treated with
MITOx20 for 2 h followed by incubation with doxorubicin for 3 h. Doxorubicin
fluorescence was then examined by confocal microscopy. MITOx20-treated cells
accumulated higher levels of doxorubicin compared with cells treated with vehicle
(Figure 3-6B). We also tested the effect of MITOx30. Similar to MITOx20, treatment
with MITOx30 also restored doxorubicin accumulation in NCI/ADR-RES cells
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(Figure 3-6C). To confirm that N-MCJ mimetics could reduce ABC transporter
activity, we examined doxorubicin accumulation by confocal microscopy in HEK
293T-ABCB1 cells. Cells were treated with MITOx30 for 2 h followed by incubation
with doxorubicin for 3 h and confocal microscopy analysis. MITOx30 treatment
enhanced doxorubicin retention in HEK 293T-ABCB1 cells (Figure 3-6D). Thus, by
attenuating mitochondrial respiration, N-MCJ mimetics lower ABC transporter
activity and drug efflux in chemoresistant cancer cells.
To determine whether the treatment with N-MCJ mimetics could overcome
the resistance to doxorubicin in multidrug resistant cancer cells, NCI/ADR-RES
cells were incubated with doxorubicin alone or in combination with MITOx30 or
Control-30 for 3 d and then the number of viable cells was determined by Trypan
blue exclusion. Neither doxorubicin, MITOx30 or Control-30 alone affected cell
survival relative to untreated cells (Figure 3-6E). Similarly, the combination of
doxorubicin and Control-30 had no effect on cell survival (Figure 3-6E). In contrast,
the combination of doxorubicin with MITOx30 markedly reduced NCI/ADR-RES
cell viability (Figure 3-6E). Treatment with MITOx20 also enhanced the response
of NCI/ADR-RES cells to doxorubicin after 2 d (Figure 3-6F). We also examined
the effect of N-MCJ mimetics on doxorubicin responses in the chemoresistant
MES/Dox cancer cells. Consistent with results for NCI/ADR-RES cells, while
doxorubicin alone had no effect, the combination of doxorubicin and MITOx30
decreased cell survival after 3 d (Figure 3-6G).
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To further demonstrate the effect of N-MCJ mimetics in overcoming
chemoresistance in cancer cells in vitro, we performed clonogenic assays.
NCI/ADR-RES cells were treated with doxorubicin alone or in combination with
MITOx20 or MITOx30 for 2 d. Cells were then replated at a low density and grown
in normal culture medium. After 1 wk, cell colonies were counted. Both MITOx20
and MITOx30 in combination with doxorubicin reduced the number of colonies
relative to doxorubicin alone (Figure 3-6H). No effect was observed with either
MITOx20 or MITOx30 alone in the absence of doxorubicin (Figure 3-6I). We also
examined the effect of MITOx30 in combination with doxorubicin on the
clonogenicity of MES/Dox cells. Similar to NCI/ADR-RES cells, MITOx30
together with doxorubicin reduced the number of MES/Dox cell colonies relative
to doxorubicin alone (Figure 3-6J). Thus, together these results show the efficacy
of combination therapies of N-MCJ mimetics and chemotherapy in overcoming
chemoresistance of cancer cells in vitro.
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Figure 6 – Champagne et al.
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Figure 3-6. MCJ mimetics sensitize chemoresistant cells to
chemotherapy treatment
(A) NCI/ADR-RES cells were treated with or without (Vehicle) MITOx20 (5 µM)
for 3 d and then surviving cell counts were determined by Trypan blue exclusion.
Viability relative to untreated cells is shown (n ³ 4). (B) NCI/ADR-RES cells were
incubated with MITOx20 (5 µM) for 2 h followed by incubation with doxorubicin
(Dox, 3 µM) for 3 h. Cells were then fixed, stained with DAPI (nuclear dye, blue),
and analyzed by confocal microscopy for doxorubicin fluorescence (red).
Representative images and quantification of doxorubicin intensity relative to
nuclear area (n ≥ 32 cells) are shown. Scale bars represent 20 µm. (C)
NCI/ADR-RES and (D) ABCB1-expressing HEK 293T cells were incubated with
MITOx30 (5 µM) for 2 h followed by incubation with doxorubicin and analysis as
in (B). Representative images and quantification of doxorubicin intensity relative
to nuclear area (C, n ≥ 74 cells; D, n ≥ 106 cells) are shown. Scale bars represent
20 µm. (E) NCI/ADR-RES cells were treated with doxorubicin (3 µM), Control-30
(5 µM), and/or MITOx30 (5 µM) for 3 d and then cell viability was determined as
in (A) (n = 4). (F) NCI/ADR-RES cells were treated with doxorubicin (3 µM)
and/or MITOx20 (5 µM) for 2 d and then cell viability was determined as in (A)
(n = 3). (G) MES/Dox cells were treated with doxorubicin (3 µM) alone or in
combination with MITOx30 (5 µM) for 3 d and then cell viability was determined
as in (A) (n = 3). (H) NCI/ADR-RES cells were treated with doxorubicin (3 µM) in
combination with MITOx20 (5 µM) or MITOx30 (5 µM) for 2 d, replated at a low
density (500 cells), grown in normal culture medium for 1 wk, and then the
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number of colonies formed was determined (n = 4). (I) NCI/ADR-RES cells were
treated with MITOx20 (5 µM) or MITOx30 (5 µM) for 2 d and then analyzed for
clonogenicity as in (H) (n = 3). (J) MES/Dox cells were treated with doxorubicin (3
µM) alone or in combination with MITOx30 (5 µM) for 2 d, replated at a low
density (400 cells), and then analyzed for clonogenicity as in (H) (n = 4). Mean ±
SD provided. *denotes p < 0.05 by unpaired t test or one-way ANOVA and Tukey’s
multiple comparisons test. Results are representative of 2 - 3 experiments.

3.7. MCJ mimetics reverse cancer chemoresistance in vivo
To determine whether MCJ mimetics show efficacy in reversing cancer
chemoresistance in vivo, we used MCJ KO MMTV mice since the mammary tumors
are resistant to doxorubicin and continue to grow with the treatment (FernandezCabezudo et al., 2016). Once tumors reached a measurable size, mice were treated
with doxorubicin alone or in combination with MITOx20, MITOx30 or Control-30.
We first tested the stability of MITOx20 and MITOx30 to serum proteases by
incubating them in the presence of serum in vitro for 3 and 6 h. Spot blot analysis
using a specific anti-MCJ antibody that recognizes the N-terminus showed
minimal reduction even after 6 h of incubation (Figure 3-7A), indicating that these
peptides are relatively stable. Following the doxorubicin treatment schedule used
in our previous studies (Fernandez-Cabezudo et al., 2016), treatments with
doxorubicin (i.p.) and/or N-MCJ or control mimetics (s.c.) were given every other
day for a total of 12 d after which mice treated with doxorubicin alone had to be
euthanized as tumors reached the maximum approved size. As determined by the
increase in tumor volume at 12 d relative to the initial size, the tumors of mice
treated with doxorubicin alone or doxorubicin with Control-20 were markedly
increased (Figure 3-7B). In contrast, tumors of mice treated with doxorubicin in
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combination with either MITOx20 or MITOx30 showed a prominent reduction in
size (Figure 3-7B). We found no obvious harmful effects of MITOx20 or MITOx30
in combination with doxorubicin in these mice even after the 12 d of treatment,
and mice remained highly active with no signs of stress. Following H&E staining,
histological analysis of the liver and heart showed no evidence of toxicity
(Supplementary Figure 3-6). In addition to the final tumor size, we also followed
tumor volume over time. Tumors of mice that received either doxorubicin alone
or in combination with Control-30 did not respond to treatment and continued
growing (Figure 3-7C). In contrast, there was a rapid delay (evident after 4 d) in
the growth of tumors followed by a progressive reduction in tumor size in mice
treated with doxorubicin in combination with either MITOx20 or MITOx30 (Figure
3-7C). Thus, N-MCJ mimetics show efficacy in vivo in overcoming chemoresistance
of mouse tumors that lack MCJ.
To further demonstrate the potential of N-MCJ mimetics to overcome
chemoresistance in human cancer, we used a xenograft model with the
chemoresistant NCI/ADR-RES cells grafted into immunocompromised NSG mice
commonly used for human tumor studies. Once tumors reach sufficient size, mice
were treated with doxorubicin alone or in combination with MITOx20 or
MITOx30. As determined by the change in tumor volume relative to the initial size,
the combination of doxorubicin with either MITOx20 or MITOx30 successfully
reduced the final tumor volume (Figure 3-7D). Similar to the mouse tumor model,
the response to doxorubicin in combination with N-MCJ mimetics was evident
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shortly after initiation of therapy (Figure 3-7E). Thus, restoring MCJ function with
N-MCJ mimetics increased responses to standard chemotherapy even in highly

Figure 7 – Champagne et al.

resistant human cancer cells that lack MCJ.
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Figure 3-7. Reversal of chemotherapy resistance in mouse models
of chemoresistant cancer
(A) Spot blot analysis of MITOx20, MITOx30, and Control-30 prior to (0 h) or after
incubation with serum (3 or 6 h) using an antibody specific for the N-terminus of
MCJ. (B and C) MCJ deficient MMTV-PyMT mice were treated with doxorubicin
alone (Dox, n = 5) or in combination with Control-30 (n = 4), MITOx20 (n = 6), or
MITOx30 (n = 5) every other day for 12 d. (B) Tumor volumes at the end of
treatment relative to the initial size. (C) Change in tumor volume over time during
treatment relative to the initial tumor size. (D and E) NSG mice with
NCI/ADR-RES cell xenografts were treated with doxorubicin alone or in
combination with MITOx20 or MITOx30 every other day for 8 d (n = 6). (D) Tumor
volumes at the end of treatment relative to the initial size. (E) Change in tumor
volumes over time during treatment relative to the initial tumor size. Dotted lines
represent initial tumor volumes prior to treatment (100 %). Mean ± SD provided.
* denotes p < 0.05 by one-way ANOVA and Tukey’s multiple comparisons test.
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4. Discussion
Chemotherapy (e.g., anthracyclines, taxanes, cyclophosphamides) remains
part of the standard of care for most types of cancers worldwide. In addition to
being used as frontline therapy, chemotherapy is also used as neoadjuvant therapy
to reduce tumor size prior to surgery or in combination with several of the newer
biological therapies (e.g., antibodies against CTLA4, PD1, Her2) (Apetoh et al.,
2015; Wargo et al., 2015). Thus, while the development of new immunotherapy
strategies (e.g., immune checkpoints and adoptive T cell therapies) is currently the
main focus in cancer treatment, chemotherapy remains the frontline therapy for
many cancers and also represents an affordable option worldwide. However, the
development of chemoresistance and the resulting need for high doses of
chemotherapeutic drugs with associated toxicity still represent the major
limitation of this cancer treatment (Lyman, 2009; Pai and Nahata, 2000).
Unraveling the mechanisms of chemoresistance and developing novel strategies
to overcome them while minimizing drug toxicity is therefore still a priority
(Gottesman et al., 2002; Robey et al., 2018). In this study, we uncover a novel
approach to overcome chemoresistance informed by a new understanding of a
common mechanism that protects cancer from chemotherapy. We show that
mitochondrial metabolism and mitochondrial-derived ATP are essential for the
activity of the ABC transporters to promote drug efflux and chemoresistance in
cancer cells. In addition, we demonstrate a novel target that acts as negative
regulator of mitochondrial metabolism and new compounds that restore activity
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of that target and can be further developed as therapeutic agents for combination
with standard chemotherapy.
ABC transporters have the ability to transport multiple substrates across
the cytoplasmic membrane against the gradient by using ATP as the source of
energy (Pan et al., 2016; Ween et al., 2015). Some of these transporters can mediate
the efflux of a number of chemotherapeutic drugs. While the correlation between
the presence of these transporters and chemoresistance in cancer cell lines is clear,
the correlation between the presence of specific drug efflux transporters and poor
chemotherapy response in primary tumors in cancer patients is not well
established despite a number of clinical studies (Chen et al., 2016; Robey et al., 2018;
Ween et al., 2015). As a result, the presence of ABC transporters has not yet been
used as biomarker for poor response to chemotherapy, and interest in these
transporters in cancer has waned. Other than gene expression, little is known
about the regulation of ABC transporter activity. ABC transporters are thought to
have a low affinity for ATP in the absence of substrate, and up to two ATP
molecules are needed for the transport of one molecule of substrate (Linton and
Higgins, 2007; Patzlaff et al., 2003; Poolman et al., 2005). Here we reveal for the first
time the unique need of ATP derived from mitochondria for the activity of ABC
transporters. Interestingly, we also show that ATP derived from glycolysis is
unnecessary for the activity of ABC transporters in cancer cells. Our findings could
explain the paradox of why the sole presence of the ABC transporters in tumors
may not correlate with poor response to chemotherapy. In line with the Warburg
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effect, it is well known that cancer cell metabolism is biased towards glycolysis
instead of mitochondria respiration (Koppenol et al., 2011; Warburg, 1956). Thus,
expression of ABC transporters in highly glycolytic cancer cells with minimal
mitochondrial respiration would not be sufficient to confer chemoresistance. Here
we also show that, relative to parental drug-sensitive cancer cells, derived
chemoresistant cancer cells have elevated mitochondrial respiratory capacity.
Thus, acquisition of ABC transporters as well as highly effective mitochondrial
respiration are needed to establish chemoresistance in cancer cells.
In this regard, it is well known that stem cancer cells respond poorly to
chemotherapy and are most likely the cause of acquired chemoresistance after the
initial successful response of the primary tumor (Abdullah and Chow, 2013). In
contrast to glycolytic cancer cells, stem cancer cells display elevated mitochondrial
respiration (Peiris-Pages et al., 2016; Viale and Draetta, 2015). Interestingly, ABCB1
and ABCG2 have been used as markers for identification of stem cancer cells (Ding
et al., 2010; Haraguchi et al., 2006; Moitra, 2015), although their potential roles in
mediating chemoresistance in these cells has not been established. Thus, this is
another case where chemoresistance is associated with increased levels of
mitochondrial-derived ATP in addition to the overexpression of ABC transporters.
An association between mitochondrial respiration and chemoresistance has also
been reported in slow-cycling melanoma cancer cell lines, but the potential
involvement of ABC transporters was not investigated (Cierlitza et al., 2015;
Roesch et al., 2013).
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A question that remains following our findings: why is only mitochondrial
ATP but not glycolytic ATP required for ABC transporter activity? Because of the
potential low affinity of ABC transporters for ATP (Linton and Higgins, 2007), a
high concentration of ATP would be needed for their activity. This requirement
could be difficult to achieve only with cytoplasmic levels of ATP generated by
glycolysis. However, since mitochondria are dynamic organelles that can move
throughout the cytosol, they can traffic to the cytoplasmic membrane where most
ABC transporters localize and contribute to the generation of ATP-rich
microdomains. We have previously shown the presence

of ATP-rich

microdomains that are dependent on mitochondrial ATP synthesis in CD8+ T cells
with high mitochondrial activity (Champagne et al., 2016). Here we also show the
presence of these ATP-rich domains in chemoresistant cancer cell lines with high
mitochondrial activity. These microdomains with high concentrations of ATP
could be required to sustain the activity of ABC transporters.
MCJ has been shown to be an endogenous negative regulator of
mitochondrial respiration in a number of primary tissues including the heart, liver,
CD8+ T cells, and macrophages (Barbier-Torres et al., 2017; Champagne et al., 2016;
Hatle et al., 2013; Navasa, Martin, et al., 2015). MCJ restricts OXPHOS and
mitochondrial ATP production by limiting Complex I activity (Barbier-Torres et
al., 2017; Hatle et al., 2013). Here we show that MCJ also acts as a negative regulator
of mitochondrial respiration in cancer cells and that loss of MCJ leads to increased
mitochondrial ATP production. Importantly, we show for the first time that high
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levels of mitochondrial derived ATP achieved in the absence of MCJ are sufficient
to fuel the activity of ABC transporters and promote drug efflux. Loss of MCJ
expression correlates with poor responses to chemotherapy and poor prognoses
in ovarian cancer patients (Shridhar et al., 2001; Strathdee et al., 2005). We have
shown that loss of MCJ expression causes chemoresistance in vitro in cancer cell
lines and in vivo in mouse models of mammary cancer (Fernandez-Cabezudo et al.,
2016; Hatle et al., 2007). In addition, retrospective and prospective studies in breast
cancer patients revealed that loss of MCJ in primary tumors correlates with poor
responses to chemotherapy, but not with responses to hormone therapy (which is
not affected by ABC transporters) (Fernandez-Cabezudo et al., 2016). Thus, it is
possible that a combination of the expression of MCJ together with ABCB1 or other
ABC transporters will serve as a biomarker that effectively predicts
chemoresistance with high confidence. Thus, cancer cells that express drug-efflux
ABC transporters, but have lost MCJ expression, will have the highest probability
of chemoresistance.
A number of ABC inhibitors have been developed and clinically tested,
most of which interfere with substrate binding to the transporter (Kathawala et al.,
2015; Li et al., 2016; Saraswathy and Gong, 2013). Despite promising preclinical
studies, these inhibitors failed to show efficacy in clinical trials. Toxicity due to off
target effects was the main problem for first generation inhibitors of ABCB1. A
lack of sufficient efficacy in combination with chemotherapy relative to
chemotherapy alone was the challenge for second generation inhibitors despite
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significant inhibition of the three most commonly expressed ABC transporters
(ABCB1, ABCG2, ABCC1) (Coley, 2010; Kohler and Stein, 2003). The third
generation of ABCB1 inhibitors showed some efficacy in clinical trials, but their
high toxicity has compromised their use for cancer treatment. Thus, no ABC
transporters inhibitors have been highly successful (Robey et al., 2018; Ween et al.,
2015). Here we show the efficacy of deliverable N-MCJ mimetics in attenuating
mitochondrial respiration, reducing ABC transporter drug efflux, and increasing
responses to standard chemotherapy in cancer cells in vitro. Moreover, N-MCJ
mimetics showed efficacy in reducing tumor size in vivo when administered in
combination with doxorubicin without increasing drug toxicity. Together, these
results suggest that attenuating mitochondrial respiration by restoring MCJ
expression in combination with standard chemotherapy can be a novel therapeutic
approach in cancer patients by increasing sensitivity to lower chemotherapy doses
in those cancer cells that have lost MCJ. We therefore propose that N-MCJ
mimetics could be developed as a novel “adjuvant” chemotherapy to be
administered with lower doses of standard chemotherapy.
5. Experimental Procedures
5.1. Cell lines and culture conditions
NCI/ADR-RES (formerly MCF7/Adr), MES, MES/Dox, and MCF7/Tx400
cells were previously described (Batist et al., 1986; Harker et al., 1983; Hatle et al.,
2007; Huff et al., 2006; Robey et al., 2003; Robey et al., 2008). MCF7 cells were
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purchased from American Type Culture Collection (ATCC). OVCAR-8 cells were
kindly provided by Dr. Ernst Lengyel at the University of Chicago. All cancer cell
lines were maintained in RPMI 1640 supplemented with 10 % FBS, 2 mM
glutamine, 100 units/mL penicillin, and 100 µg/mL streptomycin. HEK 293T cell
lines were previously described (Robey et al., 2003; Robey et al., 2008) and
maintained in RPMI as above additionally supplemented with 2 mg/mL
Geneticin.

Chemotherapeutic

agents

added

to

maintain

chemoresistant

phenotypes were removed at least 1 wk prior to experiments. MCF7 cell
transfections were performed using siPORT NeoFX Transfection Agent
(ThermoFisher

Scientific) following

the

recommended

protocol

for

an

oligonucleotide siRNA based on the previously described MCJ targeting sequence
(Hatle et al., 2007). FBS was obtained from Serum Source International, while all
other cell culture reagents were from ThermoFisher Scientific. Doxorubicin was
obtained from the University of Vermont Medical Center Pharmacy. Oligomycin,
rotenone, 2-deoxyglucose, paclitaxel, and Hoechst 33258 were purchased from
Sigma Aldrich.
5.2. Mouse models
All mice were maintained in the animal facility at the University of Vermont
under Institutional Animal Care and Use Committee (IACUC) approved
conditions. WT and MCJ deficient MMTV-PyMT were previously described
(Fernandez-Cabezudo et al., 2016). NSG mice (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ,
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Jackson Laboratories) were injected with 5 – 7 x 106 NCI/ADR-RES cells (i.p.) in
150 µL PBS. For both models, mice were treated with vehicle, doxorubicin (i.p., 2
mg/kg for MMTV mice, 1 mg/kg for NSG mice), and/or and MCJ mimetics (s.c.,
10 mg/kg) every other day after tumors reached 0.15 - 0.25 cm3. Tumor
measurements were performed using a caliper to determine the tumor volumes
using the formula Vol = length x width x height (above skin level). Animal studies
were performed under the oversight of the University of Vermont IACUC.
5.3. Extracellular flux analysis
Oxygen consumption rates (OCR) and extracellular acidification rates
(ECAR) were analyzed under basal conditions and in response to sequential
injections of oligomycin (2 µM), FCCP (2 µM), and rotenone with antimycin A (1
µM each) using the Seahorse MitoStress Test Kit. OCR analysis was also performed
after incubation with N-MCJ mimetics for 12 h. ATP production rates were
determined using the XF Real-Time ATP Rate Assay Kit following the
recommended protocol. All extracellular flux analyses were performed using an
XF24 or XF96 Extracellular Flux Analyzer as recommended by the manufacturer
(all Agilent Technologies).
5.4. Mass spectrometry based metabolomics
Metabolic profile comparisons of OVCAR-8 and NCI/ADR-RES cells were
performed on equal numbers of cells. Cells were cultured under normal
conditions, detached using trypsin-EDTA (0.05 %), counted, normalized to 0.5 x
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106 in each sample, and then cell pellets were snap frozen in liquid nitrogen prior
to analysis. To determine the effect of N-MCJ mimetic treatment, equal numbers
of NCI/ADR-RES cells were plated and allowed to adhere for 2 d followed by the
addition of vehicle or MITOx30 (25 µM) for 12 h. Cells were then collected and
processed as above. Metabolomics and flux analyses were performed as
previously reported (D'Alessandro et al., 2015). Briefly, 2 x 106 cells and 20 µl of
cell media were extracted in 1 mL and 980 µL of cold lysis and extraction buffer
(methanol : acetonitrile : water, 5:3:2), respectively. After discarding protein
pellets, 10 µL of water and methanol soluble fractions were run through a Kinetex
C18 1.7 µm, 100 x 2.1 mm (Phenomenex) reversed phase column (Positive ion
mode - phase A: water, 0.1 % formic acid; B: acetonitrile, 0.1 % formic acid;
Negative ion mode - phase A: 1 mM NH4Ac 95:5 water : acetonitrile; phase B: 1
mM NH4Ac 95:5 acetonitrile : water) via an ultra-high performance
chromatographic system (UHPLC - Vanquish, Thermo Fisher). UHPLC was
coupled in line with a high-resolution quadrupole Orbitrap instrument run in both
polarity modes (QExactive, Thermo Fisher) at 70,000 resolution (at 200 m/z).
Gradients and other technical parameters and the variants employed herein have
been extensively described (D'Alessandro et al., 2017; Nemkov et al., 2017).
Metabolite assignment and peak integration for relative quantitation were
performed through the software Maven (Princeton), against the KEGG pathway
database and an in-house validated standard library (> 1,000 compounds, Sigma
Aldrich, IROATech). Integrated peak areas were exported to Excel (Microsoft) and
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elaborated for statistical analysis (unpaired t test) and hierarchical clustering
analysis (HCA) through Prism (GraphPad Software) and GENE-E (Broad
Institute), respectively.
5.5. Flow cytometry analysis
For detection of ABC transporter substrate accumulation, cells were
pretreated with metabolic inhibitors as indicated for 2 h followed by the addition
of doxorubicin (3 µM) or Hoechst 33258 (100 ng/mL) for 3 h. Cells were then
washed, fixed in PBS supplemented with 1 % paraformaldehyde, and then
immediately analyzed using a BD Biosciences LSRII Flow Cytometer at the
University of Vermont Flow Cytometry and Cell Sorting Facility. Median
fluorescence intensities relative to intreated cells were determined using FlowJo
Software.
5.6. Confocal microscopy analysis
All confocal microscopy analyses were performed using a Zeiss LSM 510
Meta Confocal Laser Scanning microscope (Carl Zeiss Microscopy) at the
University of Vermont Microscopy Imaging Center as previously described
(Champagne et al., 2016). Analysis of doxorubicin pixel fluorescence intensity per
nuclear area was performed using ImageJ software (version 1.51h, NIH). For
analysis of subcellular ATP distribution, cells were plated in glass bottom plates
(MatTek) and allowed to adhere for 3 d. Cells were then pretreated with metabolic
inhibitors as indicated for 2 h followed by the addition of a fluorescent ATP/ADP
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probe (Rao et al., 2012) (100 µM) for 5 min. Cells were then washed with and
immediately imaged in PBS. For analysis of doxorubicin accumulation, cells were
plated on glass coverslips and allowed to adhere for 3 d. Cells were then pretreated
with metabolic inhibitors as indicated for 2 h followed by the addition of
doxorubicin (3 µM) for 3 h. Cells were then washed, fixed in PBS supplemented
with 1 % paraformaldehyde, and stained with DAPI. Coverslips were mounted to
glass microscope slides using Vectashield Antifade Mounting Medium (Vector
Laboratories) and sealed with nail polish prior to imaging.
5.7. Calcein retention
Effects of metabolic inhibitors on calcein retention were determined using
the Vybrant Multidrug Resistance Assay Kit (ThermoFisher Scientific). Cells were
pretreated with metabolic inhibitors as indicated for 2 h followed by the addition
of calcein (0.25 µM) for 15 min. Cells were then washed, dissolved in DMSO, and
then calcein absorbance was determined using an ELx800 Absorbance Microplate
Reader (BioTek).
5.8. Intracellular ATP concentration
Intracellular ATP concentration in cells (104) was determined using the
ATPlite Luminescence Assay System (PerkinElmer) and a TD-20/20 Luminometer
(Turner BioSystems) as recommended by the manufacturers.
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5.9. MCJ expression
Western blot analyses were performed on whole cell lysates derived using
RIPA buffer supplemented with 1 mM PMSF, 1 mM Na3VO4, and 0.5 % Protease
Inhibitor Cocktail (Sigma Aldrich). Lysates were separated by electrophoresis,
transferred to PVDF membranes, and then analyzed using anti-MCJ and antiGAPDH antibodies as previously described (Fernandez-Cabezudo et al., 2016;
Hatle et al., 2013).
5.10. Cell viability in response to drug treatments
For analysis of cell survival, cells were plated in normal culture medium
and allowed to adhere for 2 d. Culture medium was then replaced with medium
containing doxorubicin and/or N-MCJ mimetics, and cells were incubated for an
additional 2 - 3 d as indicated. Cells were then washed with PBS, detached with
0.05 % trypsin-EDTA, and live cell counts were determined by Trypan blue
exclusion. Viability was then calculated relative to untreated cells. For
clonogenicity assays, cells were plated and allowed to adhere for 2 d followed by
the addition of doxorubicin (1 µM for MES/Dox cells, 3 µM for NCI/ADR-RES
cells) and/or N-MCJ mimetics (5 µM) in fresh culture medium for 2 d. Cells were
then replated in normal culture medium, incubated for 1 wk, washed with PBS,
fixed with PBS supplemented with 1 % paraformaldehyde, stained with crystal
violet (0.01 % in water), and then colony counts were determined. MTT cell
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viability assays were performed as previously described (Hatle et al., 2007). MTT
(thiazolyl blue tetrazolium bromide) was purchased from Acros Organics.
5.11. Peptide stability
N-MCJ mimetic stability was determined by diluting stocks (1 mM in
water) 1:1 in human serum and incubating at ambient temperature for the
indicated times. For detection, 1 µL of diluent was spotted onto nitrocellulose and
allowed to air dry. Blots were then subjected to UV crosslinking for 30 s (UVP
Ultraviolent Crosslinker CL-1000) and analyzed by Western blot as described
above.
5.12. Statistical analyses
Statistical significance was determined by unpaired t test for two groups or
by one-way ANOVA with Tukey’s multiple comparisons test for three or more
groups using Graphpad Prism software. P < 0.05 was considered statistically
significant. Figures depict mean ± standard deviation (SD) in all cases.

206

6. Supplementary Information
6.1. Supplementary Figures

B
2

50

1

25

100
75
50
25

0

MCF7
MCF7/Tx400

2.0
1.5
1.0
0.5

75
50
25
0
10-7 10-6 10-5 10-4
Dox (M)

F
4
3
2
1
0

M

C

M ME
ES S
/D
ox

0.0

100

10-6
10-5
Dox (M)

M
F7 C
/T F7
x4
00

E

0
10-7

ECAR
(mpH/min/103 cells)

10-7 10-6 10-5
Dox (M)

Viability (%)

Viability (%)

75

D
ECAR
(mpH/min/103 cells)

MES
MES/Dox

3

100

0

C

ECAR
3
N OV
(mpH/min/10
cells)
C C
I/A A
D RR 8
-R
ES

OVCAR-8
NCI/ADR-RES

Viability (%)

A

Supplementary Figure 3-1. Derived chemoresistant cancer cells do
Supplementary Figure 1. Derived chemoresistant cancer cells do not have increased rates
notof glycolysis
have increased
rates
of glycolysis
compared
to oftheir
compared to their
chemosensitive
parental cell
lines. (A) Viability
OVCAR-8
and
NCI/ADR-RES
cells
in
the
presence
of
increasing
concentrations
of
doxorubicin
(Dox) as
chemosensitive parental cell lines

determined by MTT assay. (B) Baseline extracellular acidification rates (ECAR) of OVCAR-8 and
NCI/ADR-RES cells as determined by extracellular flux analysis. (C) Viability of MES and
(A)MES/Dox
Viability
of in
OVCAR-8
andof NCI/ADR-RES
cells inofthe
presence
increasing
cells
the presence
increasing concentrations
doxorubicin
asof
determined
by MTT
concentrations
of
doxorubicin
(Dox)
as
determined
by
MTT
assay.
(B)
Baseline flux
assay. (D) Baseline ECAR of MES and MES/Dox cells as determined by extracellular
analysis. (E)
Viability of rates
MCF7(ECAR)
and MCF7/Tx400
cells
the presence of
increasing
extracellular
acidification
of OVCAR-8
andinNCI/ADR-RES
cells
as
concentrations
of doxorubicinflux
as determined
by MTT
assay.
Baseline
ECAR of MCF7
determined
by extracellular
analysis. (C)
Viability
of(F)
MES
and MES/Dox
cells and
MCF7/Tx400
as determined
by extracellularof
flux
analysis. Mean
± SD providedby
(n ≥MTT
4).
in the
presencecells
of increasing
concentrations
doxorubicin
as determined

assay. (D) Baseline ECAR of MES and MES/Dox cells as determined by
extracellular flux analysis. (E) Viability of MCF7 and MCF7/Tx400 cells in the
presence of increasing concentrations of doxorubicin as determined by MTT assay.
(F) Baseline ECAR of MCF7 and MCF7/Tx400 cells as determined by extracellular
flux analysis. Mean ± SD provided (n ≥ 4).

207

Supplementary Figure 3-2. NCI/ADR-RES cells have increased
rates of amino acid and nucleotide metabolism compared to
OVCAR-8 cells
Altered metabolic pathways in NCI/ADR-RES cells relative to OVCAR-8 cells as
determined by mass spectrometry based metabolomics and metabolite sets
enrichment analysis (MSEA). Pathway impact, number of metabolites detected
that support the assignment of a pathway; -log(p), negative log of the p value
determined by unpaired t test (n = 4).
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Supplementary Figure 3-5. MCJ mimetics alter amino acid and
nucleotide metabolism in MCJ-deficient cancer cells
Altered metabolic pathways in NCI/ADR-RES cells treated with MITOx30 for 12
h relative to vehicle treated cells as determined by mass spectrometry based
metabolomics and metabolite sets enrichment analysis (MSEA). Pathway impact,
number of metabolites detected that support the assignment of a pathway; -log(p),
negative log of the p value determined by unpaired t test (n = 4).
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Supplementary Figure 3-6. MCJ mimetics do not increase
doxorubicin toxicity
Representative images from H&E staining of (A) liver and (B) heart sections of
control (untreated) mice or mice treated with doxorubicin (Dox) alone or in
combination with MITOx20 or MITOx30. Treatments were performed every other
day. Mice were sacrificed after 11 d.
Supplementary Figure 6. (A and B) Representative images from H&E staining of (A) liver and
(B) heart sections from control (untreated) mice or mice treated with doxorubicin (Dox) alone or in
combination with MITOx20 or MITOx30. Treatments were performed every other day. Mice were
sacrificed after 11 d.
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6.2. Supplementary Tables
Supplementary Table
NCI/ADR-RES Cells

3-1.

Pathway

Compound

Amino acids

Alanine
Arginine
Asparagine
Aspartate
Cysteine
Glutamate
Glutamine
Glycine
Histidine
Leucine/Isoleucine
Lysine
Methionine
Phenylalanine
Proline
Serine
Threonine
Tryptophan
Tyrosine
Valine
ATP
ADP
AMP
dAMP
Adenosine
Adenine
GDP
GMP
Guanosine
Guanine
CTP
CDP
CMP
Cytidine
Thymidine
Thymine
UTP
UDP
UMP
Uracil
IMP
Inosine

Nucleotides

Metabolome

Analysis

*Peak

OVCAR
2.15E+07
2.02E+07
4.36E+06
3.12E+07
5.21E+06
3.08E+08
5.34E+07
3.64E+06
2.98E+06
9.27E+07
5.04E+06
4.37E+06
3.83E+06
1.55E+08
1.55E+06
5.86E+06
8.57E+06
4.33E+06
4.06E+07
5.44E+05
1.30E+06
8.25E+05
3.19E+05
4.99E+04
1.84E+06
3.78E+05
1.08E+05
5.81E+05
2.12E+06
6.89E+05
7.08E+05
1.48E+05
1.23E+06
2.43E+05
1.22E+05
4.66E+05
6.82E+05
1.35E+05
9.31E+06
2.48E+04
1.77E+07

*Median

of

Area
NCI/ADR-RES
2.45E+07
2.45E+07
5.44E+06
3.73E+07
5.37E+06
2.88E+08
5.12E+07
3.44E+06
4.54E+06
1.22E+08
8.68E+06
5.86E+06
5.51E+06
1.50E+08
2.25E+06
7.69E+06
1.10E+07
6.43E+06
5.24E+07
2.50E+06
5.85E+06
1.86E+07
3.13E+05
5.45E+04
4.75E+06
1.36E+06
2.32E+06
1.03E+05
4.16E+05
4.56E+05
1.08E+06
7.58E+05
2.06E+06
3.04E+05
1.27E+05
1.77E+06
4.68E+06
3.33E+06
6.94E+06
4.98E+05
1.22E+07

OVCAR-8
†Fold

Increase
1.14
1.21
1.25
1.20
1.03
0.94
0.96
0.94
1.53
1.31
1.72
1.34
1.44
0.97
1.45
1.31
1.29
1.49
1.29
4.59
4.50
22.52
0.98
1.09
2.58
3.59
21.52
0.18
0.20
0.66
1.53
5.12
1.67
1.25
1.04
3.79
6.87
24.68
0.75
20.10
0.69

and

‡p-value

0.010
0.002
0.013
0.017
0.615
0.196
0.510
0.509
0.000
0.004
0.000
0.027
0.004
0.137
0.006
0.012
0.033
0.005
0.000
0.000
0.000
0.000
0.986
0.489
0.000
0.000
0.000
0.002
0.000
0.037
0.002
0.000
0.001
0.014
0.927
0.000
0.000
0.000
0.006
0.000
0.026

value. †Fold increase of peak area calculated as ADR-RES/OVCAR-8. ‡Determined by
unpaired t test (n = 4).
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Supplementary Table 3-1 (continued)
Nucleotides

Phosphates
Glycolysis

Other sugars

TCA cycle

Pentose Phosphate
Pathway
GSH homeostasis

Gamma-glutamyls
Ser & 1C metabolism

Urea cycle

Hypoxanthine
Xanthine
Allantoin
5-Hydroxyisourate
Urate
N-Formyl-GAR
5,6-Dihydrothymine
Nicotinamide
Adenylosuccinic acid
UDP-glucose
NADPH
NAD+
NADH
Diphosphate
Glucose
Glucose-6-phosphate
Fructose-1,6-bisphosphate
Glyceraldehyde-3-phosphate
2/3-Phosphoglycerate
Pyruvate
Lactate
Maltose
Mannitol
Arabitol
Citrate
α-Ketoglutarate
2-Oxoglutaramate
Succinate
Fumarate
Malate
2-Hydroxyglutarate
Erythrose-4-phosphate
Sedoheptulose-1-phosphate
α-Ribose-1-phosphate
Glutathione
Glutathione disulfide
5-Oxoproline
S-Glutathionylcysteine
Cys-Gly
Ascorbate
Dehydroascorbate
γ-Glutamylcysteine
γ-Glutamylglutamine
Homocysteine
Cystathionine
Dimethylglycine
Phosphoserine
S-Adenosylhomocysteine
S-Adenosylmethionine
Ornithine
Citrulline
Argininosuccinate

5.30E+07
1.33E+07
1.28E+05
1.16E+07
2.41E+04
2.32E+05
1.96E+06
1.60E+07
1.87E+04
1.85E+06
2.93E+04
2.42E+06
2.15E+05
1.84E+07
1.16E+07
7.60E+05
5.43E+05
9.18E+04
3.72E+05
3.74E+05
2.87E+07
7.44E+04
2.21E+05
1.26E+05
4.79E+06
1.37E+05
8.97E+04
3.09E+06
2.72E+06
2.15E+07
1.56E+05
7.01E+04
3.36E+05
1.74E+06
3.06E+08
4.85E+05
2.59E+07
1.43E+05
4.65E+06
5.03E+04
1.56E+05
2.00E+06
1.37E+06
2.65E+04
1.08E+06
1.12E+06
3.05E+06
1.98E+05
5.53E+05
3.92E+04
1.82E+06
1.21E+06
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4.10E+07
7.54E+06
1.46E+05
6.64E+06
3.49E+04
3.88E+05
1.77E+06
3.28E+07
4.50E+05
2.85E+06
4.61E+04
4.09E+06
1.64E+05
1.42E+07
1.50E+07
9.38E+05
6.36E+05
8.85E+04
3.31E+05
2.99E+05
2.17E+07
9.78E+04
2.90E+05
3.47E+05
6.35E+06
7.73E+04
8.09E+04
4.66E+06
2.11E+06
1.47E+07
1.06E+05
6.25E+04
3.94E+05
1.51E+06
3.24E+08
6.21E+05
1.88E+07
1.64E+05
5.61E+06
1.29E+05
1.30E+05
2.89E+06
3.71E+05
6.23E+04
3.14E+06
9.88E+05
1.49E+06
1.94E+05
8.05E+05
7.40E+05
4.87E+06
1.03E+06

0.77
0.57
1.14
0.57
1.45
1.67
0.90
2.05
24.05
1.54
1.57
1.69
0.76
0.77
1.29
1.23
1.17
0.96
0.89
0.80
0.75
1.31
1.31
2.75
1.33
0.56
0.90
1.51
0.78
0.68
0.68
0.89
1.17
0.87
1.06
1.28
0.73
1.15
1.21
2.57
0.83
1.44
0.27
2.35
2.91
0.88
0.49
0.98
1.46
18.85
2.67
0.85

0.012
0.002
0.074
0.000
0.005
0.002
0.054
0.000
0.000
0.000
0.044
0.001
0.001
0.001
0.022
0.024
0.009
0.736
0.014
0.017
0.018
0.029
0.003
0.000
0.003
0.000
0.557
0.000
0.000
0.000
0.003
0.163
0.009
0.075
0.484
0.022
0.000
0.604
0.063
0.000
0.043
0.002
0.000
0.000
0.000
0.002
0.001
0.725
0.019
0.002
0.000
0.190

Supplementary Table 3-1 (continued)
Polyamines

Aminosugars

Arg & Pro
metabolism

Panthothenate

Sulfur metabolism

Indole & Tryptophan

Glycerophospholipid
biosynthesis

Sphingolipids
Carnitine & fatty acid
metabolism

Saturated Fatty acids

Monounsaturated
Fatty Acids

Putrescine
Spermidine
Spermine
N-Acetylneuraminate
UDP-N-Acetylglucosamine
CMP-N-Acetylneuraminate
Carnosine
Phosphocreatine
Creatine
Creatinine
N-Succinylcitrulline
trans-4-Hydroxyproline
Pantothenol
5,6-Dihydrouracil
4'--Phosphopantothenate
Taurine
Hypotaurine
Thiocysteine
5-Hydroxyindoleacetate
Indole
Indole-3-acetate
Quinolinic acid
Glycerol-3-phosphate
Ethanolamine phosphate
Sphingosine
Acetylcholine
CDP-choline
Choline
Sphinganine-1-phosphate
Carnitine
Acetylcarnitine
Propionylcarnitine
Butanoylcarnitine
Hexanoylcarnitine
Tetradecanoylcarnitine
Hexadecenoylcarnitine
Octadecenoylcarnitine
Linoleoyl-CoA
Pentanoate
Hexanoic acid
Heptanoic acid
Octanoic acid
Nonanoic acid
Decanoic acid
Dodecanoic acid
Tetradecanoic acid
Hexadecanoic acid
Octadecanoic acid
Tetradecenoic acid
Hexadecenoic acid
Octadecenoic acid

2.45E+06
4.37E+06
1.17E+06
2.59E+05
4.02E+06
2.20E+05
3.12E+04
1.63E+05
1.18E+09
7.22E+06
2.52E+05
3.15E+06
1.75E+06
6.44E+05
2.09E+05
3.86E+07
3.38E+05
1.46E+06
8.34E+05
1.57E+04
1.05E+05
9.82E+04
9.08E+05
2.32E+05
1.66E+06
2.55E+06
7.74E+05
3.74E+08
3.09E+04
1.11E+07
4.51E+06
1.81E+06
2.00E+06
1.72E+05
1.07E+06
3.56E+05
6.93E+05
1.23E+06
5.24E+04
3.07E+05
1.52E+05
5.07E+05
1.54E+06
4.93E+05
3.15E+05
2.86E+06
3.09E+07
3.24E+07
1.66E+05
1.94E+06
2.40E+07
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2.51E+06
2.61E+06
6.06E+05
3.54E+05
5.93E+06
2.32E+05
3.57E+04
5.42E+04
1.42E+09
9.53E+06
6.33E+04
4.05E+06
8.90E+05
7.73E+05
3.00E+05
1.75E+07
2.07E+05
1.33E+06
1.77E+06
1.87E+04
1.35E+05
4.56E+04
8.83E+05
9.83E+04
7.64E+05
1.85E+06
1.44E+06
3.69E+08
3.22E+04
1.09E+07
2.54E+06
5.03E+05
4.95E+05
1.71E+05
5.08E+05
9.85E+04
1.95E+05
1.40E+05
4.11E+04
3.09E+05
1.20E+05
4.45E+05
2.33E+06
8.00E+05
5.47E+05
5.03E+06
4.07E+07
3.55E+07
3.05E+05
3.98E+06
3.16E+07

1.02
0.60
0.52
1.37
1.47
1.06
1.15
0.33
1.20
1.32
0.25
1.29
0.51
1.20
1.43
0.45
0.61
0.91
2.13
1.19
1.28
0.46
0.97
0.42
0.46
0.73
1.87
0.99
1.04
0.98
0.56
0.28
0.25
0.99
0.48
0.28
0.28
0.11
0.78
1.01
0.79
0.88
1.51
1.62
1.74
1.76
1.32
1.10
1.83
2.05
1.32

0.767
0.002
0.062
0.067
0.000
0.592
0.644
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.003
0.000
0.000
0.102
0.000
0.182
0.001
0.001
0.889
0.000
0.012
0.001
0.003
0.730
0.409
0.220
0.001
0.000
0.000
0.516
0.003
0.006
0.012
0.003
0.063
0.438
0.005
0.015
0.017
0.006
0.007
0.029
0.161
0.017
0.006
0.061
0.246

Supplementary Table 3-1 (continued)
Poly-unsaturated
Fatty Acids

Essential fatty acids
Lipids
Bile acids
Arachidonate
metabolism

Sterols
Other

Octadecadienoic acid
Octadecatrienoic acid
Arachidonic acid
Stearidonic acid
Docosahexaenoic acid
Adrenic acid
Eicosapentaenoic acid
Dihomo-γ-linolenic acid
Docosapentaenoic acid
Undecanoic acid
Glycochenodeoxycholate
Taurodeoxycholate
13-Hydroxyoctadecadienoic acid
Prostaglandin A2
Prostaglandin D2
Leukotriene A4
Cholesterol sulfate
2-Methyleneglutarate
Leucocyanidin
Methylenediurea
3-Oxalomalate
2-Deoxy-α-glucoside
N-Acylmannosaminolactone
N6-Methyllysine
Shikimate-3-phosphate
Glucono-1,5-lactone
Catechin
Riboflavin
Glucosinolate
Ribose-5-diphosphate
S-Acylglutathione
9-Oxononanoic acid
Noradrenaline
N-Acetylmethionine
2-Oxo-7-methylthioheptanoate
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1.03E+07
4.28E+05
4.62E+06
2.13E+04
2.00E+06
3.38E+06
1.86E+05
9.16E+05
1.23E+06
1.02E+05
6.42E+04
3.79E+04
1.04E+05
1.01E+04
3.01E+05
1.30E+04
1.90E+05
3.25E+04
2.34E+05
1.14E+07
6.14E+06
1.36E+06
1.65E+05
3.92E+05
1.20E+05
3.11E+04
1.43E+06
6.52E+04
1.44E+05
1.49E+05
3.96E+05
1.14E+05
6.04E+05
8.34E+05
2.46E+05

1.81E+07
6.65E+05
5.85E+06
1.55E+04
2.22E+06
1.42E+06
1.78E+05
1.27E+06
5.14E+05
1.50E+05
5.15E+04
3.51E+04
1.20E+05
1.12E+04
4.29E+05
2.32E+04
1.24E+05
9.57E+04
3.51E+05
1.35E+07
4.67E+06
3.06E+06
3.70E+05
3.59E+05
1.21E+05
3.70E+04
5.52E+05
4.37E+04
2.36E+05
1.45E+05
4.82E+05
1.28E+05
7.30E+05
1.77E+06
1.92E+05

1.76
1.55
1.27
0.73
1.11
0.42
0.96
1.39
0.42
1.47
0.80
0.93
1.15
1.12
1.42
1.79
0.65
2.94
1.50
1.19
0.76
2.25
2.24
0.92
1.01
1.19
0.39
0.67
1.64
0.97
1.22
1.12
1.21
2.13
0.78

0.089
0.254
0.226
0.225
0.808
0.008
0.854
0.219
0.016
0.004
0.267
0.489
0.385
0.284
0.011
0.001
0.001
0.045
0.052
0.002
0.007
0.000
0.001
0.238
0.730
0.282
0.000
0.025
0.001
0.539
0.107
0.156
0.033
0.000
0.038

Supplementary Table 3-2. Metabolome Analysis of NCI/ADR-RES Cells
Treated with MITOx30
Pathway

Compound

Amino acids

Alanine
Arginine
Asparagine
Aspartate
Cysteine
Glutamate
Glutamine
Glycine
Histidine
Leucine
Lysine
Methionine
Phenylalanine
Proline
Serine
Threonine
Tryptophan
Tyrosine
Valine
Cystine
ATP
ADP
AMP
dAMP
Adenosine
Adenine
GTP
GDP
GMP
Guanosine
Guanine
CTP
CDP
CMP
Cytidine
Cytosine
dTMP
UTP
UDP
UMP
Uracil
IMP
Inosine
Hypoxanthine
Xanthine

Nucleotides

*Peak Area
Vehicle
MITOx30
2.55E+06
2.90E+06
1.33E+06
1.78E+06
2.47E+05
2.65E+05
9.31E+06
8.62E+06
3.78E+05
6.75E+05
4.84E+07
5.48E+07
1.68E+05
2.46E+05
1.14E+06
1.52E+06
4.27E+05
4.44E+05
7.59E+06
1.06E+07
7.09E+05
1.00E+06
1.06E+06
1.28E+06
1.52E+06
1.89E+06
1.65E+07
1.63E+07
4.17E+05
4.49E+05
4.42E+05
5.75E+05
3.95E+05
4.70E+05
1.88E+06
2.23E+06
7.00E+06
8.18E+06
1.56E+05
1.94E+05
2.93E+06
2.64E+06
8.98E+05
3.09E+06
3.92E+06
9.75E+06
4.25E+05
4.63E+05
3.27E+04
1.32E+04
6.68E+05
5.16E+05
4.99E+05
3.83E+05
3.96E+05
6.59E+05
1.29E+05
4.06E+05
1.26E+05
7.07E+04
5.94E+04
1.33E+05
3.78E+05
1.83E+05
3.13E+05
2.84E+05
1.07E+05
3.12E+05
1.10E+05
2.11E+05
8.62E+04
9.02E+04
3.36E+04
2.70E+04
1.08E+06
6.94E+05
1.11E+06
1.17E+06
2.97E+05
2.43E+06
5.10E+05
4.44E+05
1.97E+05
2.95E+05
2.78E+06
1.76E+06
6.31E+06
4.16E+06
2.98E+05
3.18E+05

*Median

†Fold
Increase
1.14
1.33
1.07
0.93
1.79
1.13
1.47
1.34
1.04
1.39
1.41
1.21
1.24
0.99
1.08
1.30
1.19
1.19
1.17
1.24
0.90
3.44
2.49
1.09
0.40
0.77
0.77
1.67
3.15
0.56
2.24
0.48
0.91
2.91
1.92
1.05
0.80
0.64
1.06
8.21
0.87
1.50
0.63
0.66
1.07

‡p-value

0.021
0.001
0.530
0.577
0.000
0.318
0.003
0.005
0.317
0.003
0.021
0.053
0.001
0.803
0.187
0.019
0.068
0.052
0.041
0.062
0.804
0.008
0.001
0.486
0.073
0.079
0.223
0.083
0.017
0.011
0.000
0.067
0.171
0.001
0.025
0.884
0.118
0.103
0.883
0.000
0.343
0.000
0.018
0.004
0.605

value. †Fold increase of peak area calculated as MITOx30/Vehicle. ‡Determined by
unpaired t test (n = 4).
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Supplementary Table 3-2 (continued)
Nucleotides

Phosphates
Glycolysis

Other sugars
TCA cycle

Pentose Phosphate
Pathway

GSH homeostasis

Gamma-glutamyls

Ser & 1C metabolism

Urea cycle
Polyamines

Aminosugars

Arg & Pro metabolism

Allantoate
5,6-Dihydrothymine
Nicotinamide
Adenylosuccinic acid
UDP-glucose
NAD+
Phosphate
Diphosphate
Glucose
Fructose-1,6-bisphosphate
2/3-Phosphoglycerate
Phosphoenolpyruvate
Lactate
Mannitol
Citrate
α-Ketoglutarate
Succinate
Fumarate
Malate
Oxaloacetate
2-Hydroxyglutarate
Erythrose-4-phosphate
Sedoheptulose-1-phosphate
α-Ribose-1-phosphate
Phosphoribosylpyrophosphate
Glutathione
Glutathione disulfide
5-Oxoproline
Cys-Gly
Ascorbate
Dehydroascorbate
γ-Glutamylcysteine
γ-Glutamylalanine
γ-Glutamyl-GABA
γ-Glutamylglutamine
Cystathionine
Dimethylglycine
Phosphoserine
S-Adenosylmethionine
Citrulline
Putrescine
Spermidine
Spermine
N-Acetylneuraminate
α-Glucosamine-1-phosphate
UDP-N-acetylglucosamine
CMP-N-acetylneuraminate
Phosphocreatine
Creatine
Creatinine
Hydroxyproline
N-Succinylglutamate
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6.62E+04
2.10E+06
5.89E+06
5.85E+04
8.28E+05
3.17E+06
1.56E+06
2.34E+06
6.60E+05
1.92E+05
2.85E+05
3.24E+04
5.03E+06
4.46E+06
3.78E+06
7.49E+04
1.22E+06
8.86E+05
1.02E+07
3.28E+05
1.52E+05
3.05E+04
9.87E+04
1.54E+06
1.80E+04
7.48E+07
5.15E+04
2.24E+06
1.92E+05
5.69E+04
9.16E+04
4.74E+04
2.84E+05
5.05E+04
1.82E+04
2.43E+05
1.00E+06
4.37E+05
4.03E+05
7.78E+05
2.37E+06
2.69E+06
2.60E+06
2.49E+05
5.94E+04
2.33E+06
1.09E+05
2.70E+05
3.43E+08
9.06E+05
8.56E+05
2.30E+04

8.69E+04
1.48E+06
7.59E+06
1.13E+05
7.54E+05
2.53E+06
3.03E+06
4.85E+06
5.25E+05
1.92E+05
2.04E+05
1.88E+04
4.96E+06
1.55E+05
2.68E+06
5.82E+04
1.80E+06
6.91E+05
7.78E+06
2.86E+05
1.32E+05
2.18E+04
1.24E+05
1.47E+06
2.05E+04
8.09E+07
4.14E+04
2.53E+06
2.13E+05
5.58E+04
1.15E+05
1.70E+05
3.05E+05
3.65E+04
1.68E+04
3.02E+05
7.39E+05
3.52E+05
3.79E+05
9.85E+05
2.75E+06
1.67E+06
1.07E+06
6.31E+05
5.70E+04
2.20E+06
1.13E+05
5.96E+04
3.04E+08
9.50E+05
7.22E+05
1.88E+04

1.31
0.70
1.29
1.93
0.91
0.80
1.95
2.07
0.80
1.00
0.72
0.58
0.99
0.03
0.71
0.78
1.48
0.78
0.77
0.87
0.87
0.72
1.26
0.95
1.14
1.08
0.80
1.13
1.11
0.98
1.26
3.60
1.08
0.72
0.92
1.24
0.74
0.81
0.94
1.27
1.16
0.62
0.41
2.53
0.96
0.95
1.04
0.22
0.89
1.05
0.84
0.82

0.049
0.002
0.001
0.006
0.082
0.025
0.001
0.010
0.001
0.574
0.008
0.002
0.487
0.212
0.002
0.728
0.009
0.041
0.020
0.128
0.717
0.823
0.011
0.814
0.872
0.249
0.023
0.128
0.038
0.840
0.252
0.000
0.571
0.530
0.290
0.205
0.002
0.154
0.953
0.034
0.606
0.082
0.020
0.004
0.947
0.278
0.677
0.003
0.035
0.891
0.222
0.513

Supplementary Table 3-2 (continued)
Panthothenate
Sulfur metabolism

Indole & Tryptophan
Signaling
Inositol
Glycerophospholipid
biosynthesis

Carnitine
Saturated fatty acids
Xenobiotics
Other

Pantothenol
Taurine
Hypotaurine
Methionine-S-oxide
3-Methyleneoxindole
4-Oxalocrotonate
Adrenaline
Inositol-1,2,3,5,6-pentakisphos.
Glycerol-3-phosphate
Ethanolamine phosphate
N-Methylethanolamine phos.
Acetylcholine
CDP-choline
Choline
Carnitine
Octanoic acid
Nonanoic acid
Pentobarbital
Triacanthine
4-Aminobenzoate
Leucocyanidin
Methylenediurea
β-Butoxyethylnicotinate
cis-4-Coumarate
Shikimate-3-phosphate
Poly-γ-glutamate
Catechin
Ribose-5-diphosphate
Thioredoxin disulfide
S-Acylglutathione
N-Acylglutamate
Glycerone sulfate
N-Acylaspartate
2-Oxo-7-methylthioheptanoate
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1.30E+05
2.13E+06
1.90E+05
3.33E+05
7.38E+04
7.60E+06
1.42E+05
1.88E+05
1.63E+05
3.69E+04
4.42E+05
3.16E+06
1.49E+05
2.77E+07
8.87E+06
1.15E+04
2.15E+04
7.15E+04
2.24E+06
1.23E+05
4.73E+04
3.73E+06
1.13E+06
2.47E+05
5.98E+04
8.44E+06
6.62E+05
2.38E+04
1.49E+05
2.53E+05
2.19E+04
6.38E+04
7.41E+04
1.20E+05

1.50E+05
9.74E+05
9.94E+04
3.94E+05
8.78E+04
7.79E+06
2.06E+05
1.25E+05
1.92E+05
6.41E+04
4.04E+05
2.40E+06
1.74E+05
2.87E+07
8.77E+06
3.48E+04
4.69E+04
6.30E+04
1.89E+06
1.45E+05
4.44E+04
3.18E+06
1.48E+06
3.12E+05
8.17E+04
9.79E+06
3.92E+05
1.94E+04
7.03E+04
2.73E+05
1.91E+04
5.44E+04
8.07E+04
1.03E+05

1.15
0.46
0.52
1.18
1.19
1.03
1.45
0.67
1.18
1.74
0.91
0.76
1.17
1.03
0.99
3.03
2.18
0.88
0.84
1.18
0.94
0.85
1.32
1.26
1.37
1.16
0.59
0.82
0.47
1.08
0.87
0.85
1.09
0.86

0.182
0.000
0.014
0.011
0.004
0.521
0.388
0.110
0.059
0.213
0.087
0.001
0.156
0.898
0.545
0.006
0.007
0.795
0.025
0.041
0.875
0.044
0.113
0.051
0.020
0.207
0.009
0.413
0.006
0.306
0.265
0.438
0.969
0.295
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CHAPTER 4. Concluding Remarks
MCJ is a negative regulator of mitochondrial metabolism that functions
through direct interactions with Complex I. MCJ is predicted to bind the NDUFv1
subunit of Complex I (Hatle et al., 2013), however the binding interactions that
facilitate the function of MCJ are currently unknown. Considering that the
NDUFv1 contains the NADH binding site of Complex I (Deng et al., 1990), MCJ
may disrupt the binding of NADH and NDUFv1 in order to regulate Complex I
activity. It is also possible that NADH (or NAD+) may act directly on MCJ, thereby
transiently affecting the regulatory activity of MCJ.
While the crystal structure of MCJ has not been solved, the N-terminus is likely
the domain governing its regulatory function as it has a unique amino acid
sequence compared to all currently known eukaryotic proteins (Hatle et al., 2007;
Shridhar et al., 2001). Additionally, as shown in this dissertation (CHAPTER 3) a
peptide mimetic of the N-terminus is sufficient to regulate mitochondrial
metabolism in MCJ deficient cancer cells. Due to the unique character of the
N-terminus, MCJ may be a druggable target, and there may not be significant offtarget effects on other proteins. Therefore, the development of small molecule
inhibitors or agonists of MCJ function may provide therapeutic benefits.
Inhibitors of MCJ may improve the efficacy of vaccines to viral infections, such
as those for influenza. Currently approved vaccines for influenza elicit a strong
antibody response to surface viral proteins (notably hemagglutinin), however
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genetic drift/shift and strong immune selection of circulating viruses often
renders responses ineffective (Krammer, 2015). In addition, antibody titers wane
over time, which results in a loss of protection. As such, yearly immunizations are
needed to maintain protection. The ultimate goal of influenza vaccine research is
to produce a “universal” vaccine that could eliminate the need for annual
vaccinations (Pica and Palese, 2013).
CD8+ T cell responses are often targeted to internal viral proteins, which
typically undergo less change over time. Therefore, vaccines that elicit stronger
CD8+ T cell memory may provide lasting protection. The polio vaccine is a notable
example that stimulates strong T cell memory and effectively provides protection
for life. As shown previously (CHAPTER 2), loss of MCJ in mouse models is highly
protective to secondary influenza virus infection through the promotion of CD8+
T cell effector functions and memory development. Inhibiting MCJ during
immunization could therefore lead to improved CD8+ T cell memory development
and to enhanced vaccine responses.
In addition, there is ongoing research into the production of vaccines for cancer
(Banchereau and Palucka, 2018; Finn, 2018). As for viral infections, the cytotoxic
effector function of CD8+ T cells is important for the elimination of transformed
cells. While the role of MCJ in cancer immunity has not yet been addressed, it is
likely that an MCJ inhibitor could also promote the efficacy of cancer vaccines.
MCJ deficiency in the liver also has several positive outcomes, therefore
inhibitors may provide therapeutic benefits in liver diseases. Loss of MCJ in the
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liver is highly protective to the development of steatosis (fatty liver) in mouse
models of fasting (Hatle et al., 2013). Steatosis is the first clinical manifestation of
non-alcoholic fatty liver disease (NAFLD) in humans, and it is thought that excess
buildup of fatty acids eventually leads to inflammation, hepatocyte death, and
fibrosis in the liver (although the exact mechanisms are currently unclear). NAFLD
progression can lead to cirrhosis and liver cancer, however there are currently no
specific treatments in the clinic for this disease. Since loss of MCJ function can
effectively prevents steatosis, it is possible that inhibitors of MCJ may improve the
outcomes of NAFLD patients.
MCJ may also represent a target for the treatment of metabolic syndrome. The
most common comorbidity of a number of metabolic diseases is obesity, notably
abdominal fat deposition. A large-scale genome wide association study (GWAS)
identified MCJ as the closest gene to a single nucleotide polymorphism that
strongly correlated with increased waist circumference in humans (Heard-Costa
et al., 2009). While this finding is only a correlation that has not been fully
examined, it implicates MCJ in the maintenance of fat metabolism and storage.
Thus, inhibition of MCJ may provide a therapeutic benefit to metabolic syndrome
patients.
In addition, loss of MCJ has been shown to substantially decrease liver toxicity
after acetaminophen overdose. The only treatment currently available is
administration of N-acetylcysteine (NAC), however the efficacy is substantially
diminished in a relative short amount of time post overdose (< 10 hours). It has
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been shown that downregulation of MCJ expression up to 24 hours after the
overdose substantially protects the liver in mouse models (Barbier-Torres et al.,
2017). In addition, high MCJ expression in the liver of patients experiencing drug
induced liver injury is predictive of poor outcomes (Barbier-Torres et al., 2017),
therefore inhibition of MCJ function may provide a strong benefit to these patients.
Substantial benefits in these systems that occur in the absence of MCJ lead to
an unanswered question: what advantageous trait does MCJ provide when its loss
is apparently positive? For CD8+ T cells, it is possible that while a deficiency in
MCJ is favorable for viral immunity, susceptibility to autoimmune disease is
enhanced. CD8+ T cells are implicated in the pathology of several autoimmune
diseases due – at least in part – to aberrant cytotoxic activity (Blanco et al., 2005;
Gravano and Hoyer, 2013). Since MCJ deficiency enhances the cytotoxic capacity
of CD8+ T cells (CHAPTER 2), the risk of developing autoimmunity may be
increased in the absence of MCJ. While CD4+ T cells are also implicated in
autoimmunity, only a limited number of these cells have been shown to exhibit
cytotoxic function (Takeuchi and Saito, 2017). Therefore within the immune
system, the beneficial function of MCJ may be to limit cytotoxicity by CD8+ T cells
to prevent excessive normal tissue damage and autoimmunity.
While loss of MCJ in the liver is not detrimental under controlled laboratory
conditions (Hatle et al., 2013), survival during prolonged periods of metabolic
stress may require MCJ function. A notable role of the liver is in the regulation of
lipid metabolism (Berg et al., 2002; Voet and Voet, 2011). While mouse models of
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fasting (< 2 days) indicate that loss of MCJ is beneficial as hepatocytes have an
increased capacity to metabolize lipids, the effects of starvation conditions are
unknown (Hatle et al., 2013). There may be a decreased length of time that MCJ
deficient mice can survive without food, thereby leading to an earlier death due to
starvation. Therefore from an evolutionary standpoint, the presence of MCJ in the
liver is an advantageous trait when resources are limited. In line with this, NAFLD
may be a modern negative consequence of this ancestral need in times of food
scarcity as MCJ tips the balance toward lipid storage rather than breakdown.
Similar to starvation conditions, MCJ loss may be detrimental during cold
stress. Metabolic reactions produce significant amounts of heat, which maintains
body temperature in endotherms (Berg et al., 2002; Voet and Voet, 2011). It was
recently shown that mitochondria generate a large amount of heat relative to other
cellular components (Chretien et al., 2018), therefore regulation of mitochondrial
respiration by MCJ may play a role in thermal regulation. Thus, a deficiency in
MCJ may lead to dysregulated body temperatures in times of stress.
MCJ is highly expressed in the heart, however its role in heart function and
cardiovascular health has not been addressed. It is known that production of ROS
by mitochondria promotes tissue damage during ischemia-reperfusion (IR) injury,
which occurs during a myocardial infarction (MI; also known as a heart attack).
The current standard of care for MI patients is to immediately remove the clot,
which rapidly restores blood flow and increases oxygen concentrations in the
ischemic tissue. This results in a burst of mitochondrial ROS production and
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causes IR injury. Complex I produces a significant amount of ROS (Chouchani et
al., 2014; Scialo et al., 2017), but whether MCJ exacerbates or assuages IR injury is
unknown. However, considering that MCJ deficiency has been correlated with
decreased ROS production in CD8+ T cells (Champagne et al., 2016), it is possible
that loss of MCJ in cardiac cells may be protective of IR injury.
While many studies have shown benefits due to the loss of MCJ, deficiency can
be detrimental in the context of cancer. As shown previously (CHAPTER 3), loss
of MCJ in cancer cells supports chemoresistance through the promotion of drug
efflux by ABC transporters. Restoration of MCJ function using peptide mimetics
substantially reverses this mechanism of resistance, therefore activating the
function of MCJ can provide benefits for the treatment of chemoresistant cancer.
The role of MCJ in metastasis is currently unknown. Mitochondria can promote
tumor progression and are likely involved in metastasis (Wallace, 2012; Zong et
al., 2016). In line with this, mitochondria can traffic to the leading edge of the cell
and provide the ATP required to facilitate migration (Cunniff et al., 2016). While a
potential role for MCJ in this process is unknown, it is feasible that loss of MCJ (or
other negative regulators of mitochondrial metabolism) improves migratory
capacity. Thus, promoting MCJ function during cancer treatment may also have
the added benefit of limiting the metastatic potential of tumor cells.
While there is likely a strong benefit in cancer treatment due to limiting ABC
transporter activity, there may also be negative consequences. Active transport of
substrates generally requires ATP, therefore restricting mitochondria respiration
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may have detrimental off-target effects. This is especially true for patients with
disorders associated with ABC transporters and similar proteins as disease
symptoms may be worsened (e.g., cystic fibrosis, adrenoleukodystrophy, Stargardt
disease). Additionally, restriction of TAP (transporter associated with antigen
processing), the ABC transporter required to deliver peptide antigen to MHC
class I molecules in the ER, may have negative consequences for antigen
presentation to T cells and associated immune responses. Therefore, a balance will
need to be maintained between inhibiting ABC transporters that mediate
chemoresistance and those required for critical cell functions.
Overall this dissertation describes how the regulation of mitochondrial
metabolism by MCJ has profound effects on cellular metabolism and how this can
be exploited for therapeutic purposes. Future studies will likely elucidate new
avenues of manipulating MCJ function for the treatment of human disease.
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